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Abstract
There is an increasing need for more efficient generation of transgenic con-
structs. Here we present a universal multi-site Gateway vector to use in re-
combineering reactions. We show its use in the generation of BAC transgenics
as well as the generation of endogenous targeting vectors. The modular nature
of the vector allows for rapid modification of constructs to generate different
versions of the same construct. As such it will help streamline the generation





The Anterior Gradient 2 (AGR2) protein has been implicated in a variety
of biological systems linked to cancer and metastasis, tamoxifen-induced drug
resistance, pro-inflammatory diseases like IBD and asthma, and limb regen-
eration. The molecular mechanisms by which AGR2 mediates these various
phenotypes in disease progression in both cancer and IBD are poorly under-
stood, as is the biological function(s) of AGR2 under non-disease conditions.
Here, we use a combination of biochemical techniques, organ culture, cell bi-
ology and mouse genetics to investigate the biological significance of AGR2
both in cell lines and in vivo. We present data based on phage-peptide inter-
actomics screens suggesting a role for AGR2 in mediating the maturation and
trafficking of a class of membrane and secretory proteins, and investigate a pu-
tative interaction between AGR2 and one member of this class of proteins. We
also describe the construction of a universal vector for use in making a variety
of transgenic animals, and then present data showing its use as a promoter
reporter, and attempt to investigate the temporal and spatial expression of
AGR2 in the developing and adult mouse. Further, we present data describ-
ing the localisation pattern of AGR2 in the developing murine kidney using
xv
a combination of organ culture and antibody staining, and suggest a role for
AGR2 in the developing kidney based on this data that is in agreement with
a chaperone function for membrane and secretory proteins. Together, these
data suggest that AGR2 has an intrinsic consensus docking site for a subset
of its client proteins, that AGR2 plays a role in protein maturation in ciliated
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1.1 Investigating Gene Function
In the 200 years since the “father of genetics,” Gregor Mendel, first discovered
that traits in pea plants could be passed from one generation to another in a
pattern now described as Mendelian Inheritance, the science of genetics has
yielded many insights into the biology of living beings, and disease. Although
Mendel first described genes as traits that could be inherited as discrete enti-
ties, the term gene was not used until much later, and the main composition
of the gene, DNA, was not discovered until the 1940s [Avery et al., 1944] [Wat-
son and Crick, 1953a] [Watson and Crick, 1953b]. Since then, we have gained
insights into the mechanism of genetic inheritance and translation into pro-
teins, and the structure, packaging and complexity of genetic material. More
recently, the complex nature of gene expression has become clearer, with layers
of regulation of a gene such as alternative splicing [McManus and Graveley,
2011], epigenetic changes to the genetic material [Bird, 2007], and small inter-
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fering RNAs being discovered [Fire et al., 1998] [Wianny and Zernicka-Goetz,
2000]. Genetics seeks to determine the biologicial function of a genetic product,
the protein or enzyme, and to investigate its regulation spatially and tempo-
rally, at the level of the chromosome and post-translationally. Identification of
disease genes has been made easier since the advent of high-throughput and
next generation sequencing technologies [Pettersson et al., 2009], and inves-
tigating the characteristics of disease-linked genes can give insights into gene
function. With estimates of between 20,000-25,000 predicted genes having
been identified from the Human Genome Project [Lander et al., 2001] [Pen-
nisi, 2003], the in vivo function of many genes remains to be characterised.
There are a number of approaches that have been employed to investigate
gene function. Transcript expression analysis is a powerful tool for provid-
ing quantitative information about mRNA levels in a given organism, tissue
type or disease tissue [Loven et al., 2012]. Protein expression pattern analy-
sis using antibodies on fixed tissue can provide information about the in vivo
localisation patterns of a protein either in normal or in disease tissues. The ad-
vent of animal transgenics, whereby foreign genetic material is integrated into
the genome of a model animal such as mouse, zebrafish or the fruit fly, has
opened up possibilities for exploring gene function in vivo. New tools in animal
transgenics have also been instrumental in elucidating gene function, for ex-
ample through reporter lines, gene knockouts or knock-ins, and tissue-specific
transgenes. The ability to culture cancerous, transformed non-cancerous or
non-transformed primary cells has further enriched our ability to investigate
gene function, and the discovery of small interfering RNAs and subsequent
use in functional assays has revolutionised the field of genetics. The rise of
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the proteomics and interactomics fields have provided a more global approach
to uncovering gene function, with techniques such as microarray, chromatin
immunoprecipitation chips (ChIP on chip), yeast-two-hybrid (Y2H) screens
and phage display proteomics identifying novel interactions or gene expression
patterns that can help to characterise protein function.
1.1.1 Protein expression pattern analysis using antibody
based methods
The protein expression pattern in a particular cell type and/or at particu-
lar points in development can hint at a specific function in the developing or
adult organism, and co-expression patterns with known or suspected interact-
ing partners can be particularly useful in elucidating biological function [Zhang
et al., 2004]. Antibody-based methods using fixed and sectioned tissues or us-
ing organ culture followed by tissue fixing, are one method of determining the
protein expression pattern of a gene. Normal or diseased tissues such as tu-
mours can be analysed for the expression of particular proteins using fixed (for
example, with paraformaldehyde), processed and wax-embedded samples that
are cut into sections 4-10µm thick. Often, the efficacy of antibody binding
requires antigen retrieval, a process whereby the proteins in a given sectioned
tissue sample are treated to reveal their epitopes. The process by which various
methods of antigen retrieval work are not clear, but it is thought that breaking
the intermolecular cross-linkages that are formed during fixation may be one
mechanism [Leong and Leong, 2007]. Organ culture is now a possibility for
some embryonic organs such as the mouse kidney, and these organs can be
fixed, permeabilised and stained with antibodies to reveal spatial protein ex-
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pression patterns in vivo. This technique will be discussed further in chapters
2 and 6.
Although useful, there are limitations to antibody-based methods. Fixed
tissue can only give information on the protein expression pattern of a gene at
a given point in time. In addition, tissue penetration by antibodies can be a
problem for fixed whole organs, and background staining in immunohistochem-
istry can also be a problem. The process of antigen retrieval described above
is not always successful in unmasking an epitope made unavailable by fixing
techniques. Availability of suitable antibodies for use in these applications can
also be problematic, with many antibodies effective for immunofluorescence
studies on cell culture monolayer not suitable on fixed and sectioned tissue.
Nevertheless, in some cases there is no alternative to antibody-based tech-
niques. For many proteins and antibodies the challenges listed above can be
surmounted, and valuable data can be obtained. For example, comparisons
between a particular protein expression pattern or level in normal versus can-
cerous tissue from a particular tissue type can be useful in highlighting proteins
involved in onset or progression of cancer [Como et al., 2002] [Armes et al.,
2013]. Although protein expression analysis with antibodies tends to be less
quantitative than transcript analysis, new advances such as proximity ligation
assays, using antibody based detection systems in fixed tissue and cell culture,
may prove useful for providing valuable quantitative protein expression data
in the future [Recupero et al., 2013] [Camilo et al., 2012].
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1.1.2 Promoter reporters and lineage tracing
Another effective way to investigate expression patterns is to use a marker
for a given gene’s expression in a model animal (Figure 1.1). It is possible to
tag a protein in vivo with a marker such as green fluorescent protein (GFP),
making a fusion protein, either at the endogenous locus (affecting one or both
alleles of the gene), or at another locus using BAC transgenics (see section 3.2).
Tagged cDNA constructs with a gene specific short promoter, or enhancer with
minimal promoter sequences, have also been described, however, these are less
reproducible or predictable than endogenous constructs or those based on BAC
transgenics. For promoter reporters, the marker is expressed from the gene’s
own promoter, leading to temporally-accurate and tissue-specific expression
of the marker. In the case of a fusion protein at the endogenous locus, the
total amount of protein is not affected but the product of at least one of the
alleles might not retain its biological function due to the tag, and in the case
of a fusion protein based on BAC transgenics and inserted elsewhere in the
genome, there may be an excess of protein that may lead to off-target biological
effects. It is also possible to design a promoter reporter to simply express the
marker without being tagged to the protein, thus removing the possibility that
the tag may influence the function of the protein, although this will no longer
provide intracellular information. This can be achieved in the same ways as
described above, either by insertion of the marker at the endogenous locus or
elsewhere in the genome. Integration at the start codon (replacing it) of the
endogenous locus is useful as the location of the foreign transgene is known,
however, there may be issues of haplo-insufficiency that need to be considered
as the endogenous gene will not be expressed.
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Figure 1.1: Promoter Reporters
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Another option is to insert the marker at the C-terminus of the en-
dogenous gene, using an internal ribosomal entry site (IRES) [Pelletier and
Sonenberg, 1988] or 2A peptide from viruses such as enteroviruses [Szymczak
et al., 2004] to link the expression of the reporter to the gene of interest. This
ensures that the endogenous expression pattern is maintained without losing
the allele, thus removing the issue of haploinsufficiency. This method however,
also has its disadvantages, since IRES sequences that allow the polymerase to
dock back onto the DNA can be unreliable [Hennecke et al., 2001], and 2A
peptides are not thought to be reliable for membrane proteins due to extra
amino acids left at the N-terminus during the process, although some studies
do show efficiency for membrane proteins with modified 2A peptides [Trichas
et al., 2008] [Tang et al., 2009] [Kim et al., 2011]. Conversely, insertion at
a random location is not likely to affect the native protein, although it is
possible for the transgene to integrate randomly into a deleterious genomic
location, again leading to off-target effects. Additionally, random integration
can also lead to the transgene being located at a region that is sub-optimal
for expression such as telomeres, or silenced loci. For this reason, transgenes
are sometimes harboured at loci that are known to be “safe” and yet retain
widespread tissue expression such as Rosa26 in mouse, which also has been
shown to be conducive to a high rate of integration events through homolo-
gous recombination [Irion et al., 2007] [Soriano, 1999]. All of these types of
transgenic models have advantages and disadvantages as discussed, and these
need to be taken into consideration when analysing the data from transgenic
models.
Despite the considerations for all of these types of promoter reporters,
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they can provide an effective means of investigating the expression pattern of
a gene in that the markers are expressed only from the promoter linked to
the gene in question. This means that the marker will be expressed not only
in the same place and at the same time as the gene of interest, but also at
the same levels, providing subtle information that it is not necessarily easily
possible to gain using antibodies (although the long half-life of markers such
as lacZ and, to some extent GFP, must be kept in mind when analysing data).
Furthermore, promoter reporters can be adapted to provide lineage tracing
using recombination enzymes such as Cre-recombinase, in which all daughter
cells that express a gene of interest will be labelled, even when they no longer
express the original gene. This can provide data about the contribution of a
gene’s expression to the maturation of a particular cell type.
Lineage tracing is a powerful method of following the progeny from a
single cell in vivo. Essentially, a cell is labelled in such a way that the marker
is permanently passed down to all daughter cells, providing information about
the number, location and differentiation status of the progeny [Kretzschmar
and Watt, 2012]. It has been used as a technique in developmental biology,
for example to follow the lineage of stem cells [Snippert et al., 2010], and in
cancer to follow the clonal expansion of cancerous cells [Wang et al., 2007].
Fundamental to the concept of lineage tracing is the notion of conditional or
inducible genetic systems that can introduce genetic mutations somatically,
in a temporally and spatially controllable manner [Nagy, 2000]. The most
common systems used to achieve this are the Cre-loxP system, the inducible
CreERT2 system and the FLP/FRT-recombinase system [Kretzschmar and
Watt, 2012]. Cre recombinase is a recombinase enzyme from the P1 bacte-
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riophage. It specifically recognises a sequence of DNA known as loxP that
is 34 base pairs long, and catalyses a recombination event between two loxP
sites [Sternberg and Hamilton, 1981] [Hamilton and Abremski, 1984]. The
enzyme was subsequently found to be active in eukaryotic cells [Lakso et al.,
1992], and was quickly used by ES cell and transgenic technologies as a valuable
tool in mediating site-specific changes to the mouse genome [Gu et al., 1993].
The CreERT2 system was designed to provide temporally inducible expression
of Cre in vivo. In this system, Cre is fused to the estrogen receptor (ER) ligand
binding domain, which has been mutated. Upon ligand (tamoxifen) binding,
the ER-Cre fusion protein is translocated to the nucleus where the Cre moeity
can effect recombination between two loxP sites [Feil et al., 1997]. In this
way, recombination to allow expression of a given transgene can be temporally
controlled by the administration of tamoxifen. The flippase system works in a
similar way to the Cre-loxP system, with the enzyme Flp recoginising identi-
cal FRT sites on the DNA [Zhu and Sadowski, 1995]. These systems can be
employed to label the progeny of a cell by using activation of a recombinase
in a founder cell specifically. In a simple example (Figure 1.2), a mouse line
with Cre expressed in specific cells only (for example, under the control of a
gene-specific or tissue-specific promoter), is then crossed to a separate mouse
line in which a marker such as GFP or lacZ is harboured. In the genome at a
specific locus, several stop codons and polyA signals flanked by loxP sites are
placed between the marker cDNA and its promoter, preventing functional ex-
pression of the marker. Crossing this line to a Cre-expressing line in which Cre
is expressed in a specific cell type or tissue type brings about excision of the
loxP -flanked stop codon, and therefore expression of the transgenic marker.
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Figure 1.2: Lineage Tracing
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In this way, only cells that express Cre or descendants of these cells will
be labelled. An elegant example of the CreERT2 system was carried out using
intestinal stem-cell specific expression of CreERT2 in a mouse line, crossed
with a mouse line harbouring a loxP-flanked Neomycin resistance cassette that
effectively stopped transcription of four fluorescent markers. In this model,
the choice of which of the four reporters to be activated was random in each
activated cell. Expression of Cre-ERT2 only in the intestinal stem cells allowed
lineage tracing and clonal analysis of single stem cells, and determination of
their fate in the intestinal crypt, leading to a new model of stem cell division
and fate [Snippert et al., 2010]. Other more complex lineage tracing systems
have also been described for lineage tracing of cancerous cells, such as the
MADM system in which interchromosomal recombination can be followed in
vivo [Zong et al., 2005] [Luo, 2007].
1.1.3 Interactomics
Whilst antibody expression data and animal transgenics can provide infor-
mation about a gene’s biological function, proteomics screens and functional
protein-based assays have also added to our toolkit for investing gene function.
Using biochemical and imaging techniques such as co-immunprecipitation, en-
zymatic assays, immunofluoresence and mass spectrometry, many questions
relating to protein interactions or activity can be answered. More recently,
larger-scale approaches to identifying gene function such as mass-spectrometry
based identification of organelle compostion [Ishikawa et al., 2012], transcrip-
tomics screens in healthy versus diseased tissues [Strausberg et al., 2004],
phenotypic screens using siRNA-mediated depletion [Boutros and Ahringer,
11
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2008] and discovery of interacting proteins or peptides with yeast-two-hybrid
(Y2H) [Rual et al., 2005] [Bruckner et al., 2009] or phage peptide display
screens [Murray et al., 2007] have been employed. The growing field of in-
teractomics uses these techniques to identify protein networks, defining the
“interactome” of proteins to help give a more global picture of protein function
in certain environments and cellular compartments.
Linear Peptide motifs
Both transient and more robust protein-protein interactions have classically
been thought to occur through the effect of hydrophobic patches between large
globular domains, but many examples of short linear peptides binding to glob-
ular domains have now been described [Neduva and Russell, 2006] (Figure
1.3). For example, the C-terminal KDEL ER-retrieval motif has been shown
to bind a receptor that mediates retrograde transport and retrieval from the
golgi, [Raykhel et al., 2007], and a consensus motif ψ-K-x-D/E (where ψ is a
hydrophobic residue) is found on proteins that are sumoylated and is recog-
nised by the SUMO transferase Ubc9 [Teng et al., 2012]. These motifs may
lie on the surface of a protein or within a disordered, accessible loop [Dyson
and Wright, 2005] and some motifs are specific to regions on proteins that are
post-translationally modified such as phosphorylation or glycosylation [Huang
et al., 2008]. For proteins capable of binding a linear peptide motif in vivo,
identifying those motifs is key to defining a group or class of proteins with
which they interact, and thus determining their interactomes [Neduva and
Russell, 2005].
Bioinformatics advances and the sequencing of the human genome (and
12
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Figure 1.3: Linear Peptides Mediating Interactions
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other species) have allowed genome-scale interaction studies to identify previously-
unknown linear motifs [Neduva et al., 2005]. Defining interactomes may be
particularly important for “hub” proteins such as p53 [Vogelstein et al., 2000]
or the ATM kinase [Matsuoka et al., 2007], that interact with many differ-
ent proteins either in a common pathway or at a particular cellular location.
In addition, identifying peptide-globular domain interactions may be impor-
tant for disrupting medically-relevant interactions with small molecules, since
very few examples of small molecules disrupting large interfaces have been
described [He et al., 2005], [Neduva and Russell, 2006]. Screening for linear
peptide motifs that provide docking sites for a given protein can be achieved
using various techniques, and one technique that has been employed is phage
peptide display [Smith, 1985] [Rossenu et al., 1997].
Phage peptide display proteomics
Phage display is a technique that was developed to screen for protein-protein,
protein-peptide and protein-DNA interactions [Smith and Petrenko, 1997].
First described in 1985, phage display involves the use of a bacteriophage
as a host system for expression of polypeptides on one of the coat proteins on
the surface of the phage virion (normally M13 filamentous phage) [Smith and
Petrenko, 1997]. In this way, large combinatorial phage peptide libraries with
a random peptide expressed on the virion coat protein of each virion can be
built up [Noren and Noren, 2001]. The phage library, containing many differ-
ent presented peptides, is washed over immobilised target protein or DNA in
a microtitre plate, and non-binding phage is washed away. The bound phages
are then harvested and used to infect bacteria, and the phage DNA can then
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be sequenced to identify the unique cDNA, and thus peptide or polypeptide,
that binds the target protein or DNA. The technique was first used in the
application of phage antibody libraries for making custom antibodies to tar-
get proteins [McCafferty et al., 1990] [Hoogenboom et al., 1998], with the
immunoglobulin variable region displayed on the virion surface to screen for
binding affinity. The process was improved by developing a system of se-
lective enrichment, in which phage virions that bind the target protein are
enriched through successive rounds of infection and selection, allowing rare
binding peptides to be identified out of a large pool (as much as one in a mil-
lion) [Crameri and Walter, 1999] (Figure 1.4). Later, the technique has been
used for identification of receptor-ligand interactions [Hartley, 2002], and lin-
ear peptide-protein interactions [Smothers and Henikoff, 2001]. For example,
phage peptide display was able to identify linear motifs that bound to the p53
co-activator p300 (PxxP, PxP, PRLP), and this motif was found to be present
in p53 and validated as a p300 docking site [Dornan et al., 2003]. The pro-
line repeat motif has since been shown to be important in transcription factor
signalling [Neduva and Russell, 2007].
More recently, some criticism of phage display as a technique for identify-
ing peptide-protein interactions has been put forward, with a suggestion that
the technique may be biased toward hydrophobic interactions [Luck and Trave,
2011], and that this bias may exclude important interactions based on linear
peptides such as those incorporating electrostatic interactions or Van der Waals
interactions. Nevertheless, it is clear that phage peptide display proteomics,
when paired with bioinformatics resources and annotated genomes, is a very
powerful technique for interrogating protein-protein interaction networks and
15
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Figure 1.4: Phage Peptide Display
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providing leads for validation in vivo.
1.2 Anterior Gradient 2
1.2.1 AGR2 expression patterns in vertebrates
The Anterior Gradient-2 (AGR2) family was first described in 1998 as a se-
creted protein in Xenopus laevis eggs [Aberger et al., 1998]. The secreted
protein in X. laevis was found to be involved in anterior specification of the
embryo, and expression was reported in the forebrain and mucous-secreting
cement gland of the developing Xenopus embryo. Expression of AGR2 ho-
mologues have also been reported in other vertebrates. In zebrafish (Danio
rerio), zAgr2 is widely expressed in many tissues including epidermis, oesoph-
agus, olfactory bulbs, pharynx, gills and goblet cells of the intestine, as verified
by qRT-PCR and whole-mount in situ hybridisation [Shih et al., 2007] [Chen
et al., 2012]. Another study found that an AGR2 homologue was upregulated
in infected tissues of Atlantic salmon with amoebic gill disease, and expression
in healthy salmon was mainly found in epithelial tissue of the gill, intestine and
brain [Morrison et al., 2006]. In the gibel carp (Carassius auratus gibelio), an
AGR2 homologue was shown to be expressed in the mucus-secreting hatching
gland, and later the pharynx, swim bladder and pronephric duct. In the adult
carp, AGR2 mainly localised to the kidney epithelia, and was found at lower
levels in the intestine, ovary and gills [Xia et al., 2009].
Expression of the AGR2 homologue nAG was also described in the adult
salamander in a study investigating newt limb regeneration [Kumar et al.,
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2007]. Newt limbs regenerate by de-differentiating limb cell types (skeletal,
bone and non-neuronal cells of the nervous system) into earlier stem-cell like
precursors, followed by proliferation of these stem-cell like cells mediated by
various developmental genes into a mass called the blastema [Stocum, 2007].
Re-differentiation, however, into specified cell types to re-grow a limb is poorly
understood. In this study, the newt (salamander) AGR2 homologue nAG was
found to promote limb regeneration after amputation and to interact directly
with the protein Prod-1 in Y2H and co-immunoprecipitation assays. Prod-1 is
a GPI-anchored cell-surface protein that is expressed in a proximal-distal gradi-
ent in the limb blastema, and is essential for limb regeneration. The proximal-
distal gradient of Prod-1 exists in both regenerating and normal limbs, and
Prod-1 is regulated by retinoic acid [da Silva et al., 2002]. nAG was expressed
in the nerve sheath of the amputated limb, and in glands in the blastema of
the regenerating limb. Surprisingly, introduction of nAG by electroporation
directly into the blastema of the amputated limb was able to restore regener-
ation of distal structures (digits), but without promoting nerve regeneration
in the the limb. As a secreted ligand for Prod-1, nAG represents a novel fac-
tor in the process of limb regeneration in amphibians and may also represent
an important factor in regenerative medicine in humans. Human AGR2 has
been reported to interact with another GPI-anchored protein, metastasis pro-
tein C4.4, which shares some domain architechture with Prod-1 (cysteine-rich
domains and Ly6-type domains) [Fletcher et al., 2003], suggesting that there
might be a conserved, functional interaction pathway.
In mice, transcript analysis initially revealed expression of the AGR2
homologue (mAgr2, Gob4 ) in the intestines, colon and stomach of the adult
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mouse [Komiya et al., 1999], and in situ hybridization determined that mAgr2
was localised to the mucus-secreting cells (goblet cells) of these tissues. Ex-
pression of AGR2 in the goblet cells of the intestine in mice was also reported
in a more recent study [Park et al., 2009]. Goblet cells are specialised cells of
the intestinal epithelium, and their main function is to secrete mucins. Mouse
Agr2 and Xenopus laevis Agr2 share significant homology (46%), and both
contain a putuative cleavable leader sequence required for targeting proteins
to the secretory pathway [Komiya et al., 1999]. This finding in mice, combined
with the conserved expression of the AGR2 homologue in X. laevis in mucus-
secreting cement gland, was the first suggestion that AGR2 might be involved
in the secretory pathway.
The Anterior Gradient family in humans consists of two closely related
genes, AGR2 and AGR3, located close to each other (60 kilobases apart)
on Chromosome 7p21.1 [Petek et al., 2000] (Figure 1.5A) and sharing 71%
identity [Fletcher et al., 2003]. Another homologue, AGR1 (also known as
Erp18/19, or TXNDC12, is located on Chromosome 1 in humans and is less
closely related to AGR2 and AGR3 [Rowe et al., 2009]. The human AGR2
gene spans 8 exons over 11 kilobases (Figure 1.5B), with the start codon in the
second exon. The AGR2 protein shares close homology with the oxidoreductase
family of protein disulphide isomerases (PDIs) [Persson et al., 2005]. The
active motif of the PDI family is CXXC, which is also found in thioredoxins
and is therefore also referred to as Tx-domain motifs [Ferrari and Soling, 1999].
Although both AGR2 and AGR3 share homology with thioredoxin, in humans
they lack the disulphide active site, with a serine in place of the second cysteine
(Figure 1.5C).
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Figure 1.5: Human Anterior Gradient Homologues
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This CXXS motif has been identified in another ERp protein, albeit with
lower PDI activity than members containing the CXXC motif [Anelli et al.,
2002]. Sequence alignment of AGR2 homologues from Xenopus laevis AG-1
and AG-2, Xenopus laevis Agr2, Pufferfish (Tetraodon nigris) agr2, Atlantic
salmon (Salmo salar) agr2, Atlantic salmon Agr3, Zebrafish (Danio rerio)
Agr2, Zebrafish Agr1, Mouse (Mus musculus) Agr2, Human (Homo sapiens)
AGR2, Mouse Agr3, Human AGR3 and Human AGR1 shows that the least
conserved regions of these genes is in the N-terminal region (Figure 1.6A, B).
Phylogenetic analysis of Agr homologues in fish, amphibians, reptiles, birds
and mammals determined that there were three subfamilies of Agrs; Ag1,
Agr2 and Agr3 [Ivanova et al., 2013]. Agr2 and Agr3 subfamily members
are present only in amphibians and higher vertebrates, and are located on
the same syntenic fragment, whilst the Ag1 subfamily members are located
on a different syntenic fragment and are only present in fishes and amphib-
ians. These Ag1 subfamily members are lost in reptiles, birds and mammals,
suggesting that loss of this subfamily member may correspond to loss of re-
generative ability associated with fish and amphibians [Ivanova et al., 2013].
It has been suggested that human Agr2 and Agr3 are the result of tandem
duplication [Fletcher et al., 2003], and this may also be the case for mouse
anterior gradient 2 family genes.
1.2.2 Animal Models and Biology of AGR2
The human Anterior Gradient 2 gene (hAGR2, HAG2, GOB4 ) encodes a
19,878 Da protein that is regulated by the proteasome [Pohler et al., 2004],
and which has been proposed as a member of the PDI family of molecular
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Figure 1.6: Human Anterior Gradient 2
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chaperones [Persson et al., 2005]. Recent work has shown that it is capable of
dimerising via a cysteine bridge allowing it to mediate ER-stress responses [Ryu
et al., 2012], and it has also been shown to function as a PDI in vivo, interact-
ing with target protein MUC2 in the ER in part through this cysteine [Park
et al., 2009]. hAGR2 is 175 amino acids long and contains a putative N-
terminal cleavable leader sequence (also known as a signal peptide) [Pohler
et al., 2004] that targets proteins to the ER membrane and secretory path-
way (Figure 1.6C). A predicted cleavage site would yield a mature, processed
form, after cleavage of the N-terminal residues by signal peptidase in the ER
lumen. Biochemical studies into the localisation of these two forms of AGR2
using transfected full-length or mature forms have suggested differential locali-
sation [Fourtouna et al., 2009], with the full length protein localising predomi-
nantly to the ER and the shorter, mature protein lacking the N-terminal leader
sequence localising primarily to the nucleus. While the mature protein does
contain a potential nuclear localisation signal, the presence of such a consensus
site has not been shown experimentally. The leader sequence targets nascent
proteins to the ER membrane and is then cleaved, with membrane domains
remaining in the ER membrane or, in the case of soluble proteins, localising
to the ER lumen (discussed further in section 1.3). Co-translational cleavage
by signal peptidase is thought to be essential for correct folding of the nascent
protein [Vitale and Denecke, 1999], and it is presumed that the transfected,
full-length form would be targeted, upon translation by the ribosome, to the
ER membrane by the signal peptide and be processed into a soluble, mature
form resident in the ER lumen. The transfected form of mature AGR2 lacks
this leader sequence and would therefore not be targeted to the ER membrane,
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but would rather remain soluble within the cell and outside the ER lumen. It
is not clear whether the differential localisation of transfected, mature and
transfected, full length AGR2 is due simply to the lack of the leader sequence
in the mature form, however, studies have shown that AGR2 can function as
a p53 inhibitor in the cytoplasm, promoting nuclear exclusion [Pohler et al.,
2004], that endogenous AGR2 localises to the nucleus as well as the ER in
fractionation assays [Fourtouna et al., 2009], and that it forms a complex with
reptin, a predominantly nuclear protein [Maslon et al., 2010], suggesting dis-
tinct nuclear functions for AGR2, or possibly an unidentified isoform lacking
the N-terminal leader sequence and allowing a pool of cytoplasmic and nuclear
AGR2 to exist.
In addition to the N-terminal leader sequence, AGR2 also shares a C-
terminal ER-retrieval sequence with other members of the molecular chaperone
families. The classical 4-amino acid motif consists of H/KDEL, and has been
shown to act as an ER retrieval sequence to return ER-resident proteins once
they have left the ER for the secretory pathway [Munro and Pelham, 1987].
Early studies determined that the motif is recognised by the golgi-resident
KDEL receptor in mammalian cells, which binds to the protein and triggers
retrograde transport back to the ER lumen [Yamamoto et al., 2003]. Variations
on the sequence have been identified [Persson et al., 2005], including KTEL,
the terminal 4-amino acid sequence at the C-terminus of AGR2, and differing
affinities for the KDEL receptor are associated with these variations [Raykhel
et al., 2007] [Alanen et al., 2011]. Other mechanisms exist for ER-retention
of proteins; ER-membrane resident proteins often have a di-lysine motif in
their C-terminal region [Teasdale and Jackson, 1996], and ER-membrane or
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luminal associated chaperone proteins such as BiP (Grp78) are retained in
the ER in large complexes mediated by their membrane or luminal domains
[Nilsson and Warren, 1994]. Although the H/KDEL motif has been shown
to function as an ER-retention motif, examples of proteins with this motif at
their C-terminal that have functions and localisations outside the ER have
been described [Inohara et al., 1989] [Akasofu et al., 1989]. It is not known if
this is a result of the error rate of the KDEL motif as an ER-retrieval sequence,
or whether escape from retrieval is mediated by an unknown factor [Vitale and
Denecke, 1999]. More recently, Dong et al. have shown that deletion of the
KTEL motif at the C-terminus of AGR2 in human cancer cells led to secretion
of AGR2, and that it is essential for the induction of AREG (amphiregulin,
an EGF-receptor ligand) by AGR2 [Dong et al., 2011] in esophageal and lung
adenocarcinomas. However, achieving ER-retention using the classical KDEL
motif did not rescue function [Gupta et al., 2012a], suggesting that the C-
terminal motif in AGR2 confers specificity for the function of AGR2 and is
not simply an ER-retrieval sequence.
Other studies have found secreted extracellular AGR2 in the serum of
lung adenocarcinoma patients [Chung et al., 2011], the serum of prostate can-
cer patients [Kani et al., 2013] and at the extracellular cell surface of circulating
pancratic cancer cells [Dumartin et al., 2011]. In this last study, AGR2 was
also found to increase the level of secretion of the precursor of cathepsin D,
a secreted lysosomal protein. Furthermore, immunohistochemical analysis of
AGR2 expression in prostate cancer tissues demonstrated a strong expression
pattern in secretory epithelial cells [Zhang et al., 2005], and in the chicken
oviduct, enriched with secretory cells secreting proteins such as ovalbumin,
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AGR-2 was identified as being highly expressed [Kim et al., 2007], further sup-
porting a role for AGR2 in the secretory pathway. Another study found that
AGR2 localised to the ER lumen, and was found to be bound to cargo proteins
in the secretory pathway as well as nascent polypeptide chains as they translo-
cated through the ER membrane [Higa et al., 2011]. In this study AGR2 was
found to be involved in maintenance of ER homeostasis, and that its expression
was controlled by the unfolded protein response (UPR), implicating AGR2 not
only in folding and trafficking of membrane or secreted proteins, but also in the
ER stress response. In a separate study of pancreatic cancer cells, induction
of AGR2 regulated expression of ubiquitin-proteasome degradation pathways,
ER chaperones such as PDI, and lysosomal proteases such as cathepsins B and
D, suggesting association with the ER-stress response in these cells [Dumartin
et al., 2011].
The first studies characterising the human AGR2 gene and protein iden-
tified similarities with members of the molecular chaperone families, such as
the classical PDI/thioredoxin structural fold and strong ER association [Pers-
son et al., 2005] [Higa et al., 2011]. This has provided some suggestions as to
the biological function of AGR2. Animal models implicate AGR2 in intestinal
goblet cell function [Park et al., 2009] and gastric cell differentiation [Gupta
et al., 2012b], and it has also been suggested to play a role in other devel-
opmental processes such as limb regeneration in amphibians [Kumar et al.,
2007]. In the first mouse knockout paper, the authors provide a link with
a potential substrate protein, MUC2, demonstrating an interaction between
these two proteins involving the single cysteine in the AGR2 PDI-like motif
and demonstrating that AGR2 is required for the production of MUC2 [Park
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et al., 2009]. MUC2 is a mucin, one of the secreted mucin proteins manufac-
tured by goblet cells in the intestine. Other mucins are present in other tissues
as well, and AGR2 has also been shown to be sufficient and required for the
production of the cancer-associated mucin MUC1 in pancreatic ductal ade-
nocarcinoma cells [Norris et al., 2012]. Furthermore, a zebrafish knockdown
of AGR2 using morpholinos confirmed a role for AGR2 in goblet cell mucin
production, as seen by a reduction in alcian blue staining of mucins (unpub-
lished, personal communication, E Patton), and a more recent study has found
that zebrafish Agr2 is essential for mucin production and terminal differentia-
tion of intestinal goblet cells [Chen et al., 2012]. Although the authors of the
first mouse knockout paper did not report any other noticeable phenotypes,
a more recent AGR2 mouse knockout study has implicated AGR2 in gastric
cell differentiation [Gupta et al., 2012a]. In this paper, the authors identify
AGR2 as essential for differentiation of several stomach cell types including
chief cells, parietal cells, enteroendocrine cells and mucus-secreting pit cells.
Loss of Agr2 in these mice resulted in an increase of stem-cell like stomach
precursors expressing Sox9, and a decrease in terminally differentiated cells,
suggesting a role for Agr2 in mediating the stem-cell - differentiated cell switch
required for terminal differentiation. There may be an important link between
the findings of this study and the nAG (newt homolog) involvement in newt
limb regeneration discussed in section 1.2.1, where cells in the amputated limb
revert to a more stem-cell like state before differentiating into the appropriate
cell types in an nAG-dependent manner.
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1.2.3 Disease association of hAGR2
AGR2 in cancer
Cancer type Mechanism of Involvement Source
Breast adenocarcinoma Upregulation/Overexpression [Duran et al., 2008] [Fletcher et al., 2003]
Associated with ERBB2+ tumours [Duran et al., 2008]
Poor prognosis [Barraclough et al., 2009] [Hrstka et al., 2010]
Metastasis [Liu et al., 2005] [Barraclough et al., 2009]
[Fletcher et al., 2003]
Mucoid Ovarian Upregulation [Park et al., 2011]
Overexpression [Gray et al., 2012]
High plasma concentration [Edgell et al., 2010]
Other Ovarian Poor prognosis [Darb-Esfahani et al., 2012]
Upregulation/Overexpression [Armes et al., 2013]
Prostate Overexpression in blood serum [Kani et al., 2013]
Upregulation/Overexpression [Kristiansen et al., 2005] [Bu et al., 2011]
Metastasis [Hu et al., 2012]
Poor prognosis [Zhang et al., 2007]
Pancreatic Upregulation/Overexpression [Barry et al., 2012] [Ramachandran et al., 2008]
Secreted in pre-malignant neoplas-
tic juice
[Chen et al., 2010] [Makawita et al., 2011]
Promotes initiation/progression of
pancreatic epithelial neoplasia
[Norris et al., 2012]
Gastric Metastasis [Lee et al., 2011]
Colorectal Poor prognosis [Valladares-Ayerbes et al., 2012]
Pre-malignant Barrett’s
epithelial
Overexpression [Pohler et al., 2004]
Lung Overexpression [Chung et al., 2012] [Fritzsche et al., 2007]
Table 1.1: AGR2 in Cancer
Although the biological function of AGR2 has not been fully elucidated,
links with disease, and particularly cancer, have been well documented. AGR2
and its close homologue AGR3 have been shown to be involved in both onset
and disease progression of cancer. AGR2 has in particular been highlighted
in numerous screens for genes differentially expressed or regulated in various
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Resistance Involvement of AGR2 Source
Tamoxifen Induced by tamoxifen, overexpressed in tamoxifen-
resistant tumours
[Hrstka et al., 2010]
Cisplatin Mediates resistance in xenograft models [Gray et al., 2012]
Doxorubicin Overexpressed in doxorubicin-resistant tumours [Hrstka et al., 2010]
Docetaxel Reduced expression in docetaxel-resistant tumours [Zhao et al., 2009]
Anti-estrogen therapy AGR2 and Cathepsin D mRNA upregulated in resis-
tant cell line
[Huber et al., 2004]
Table 1.2: AGR2 in Cancer Drug Resistance
types of cancer including breast [Duran et al., 2008] [Fletcher et al., 2003],
pancreatic [Barry et al., 2012], prostate [Kani et al., 2013] [Kristiansen et al.,
2005] [Bu et al., 2011], and lung [Chung et al., 2012] [Fritzsche et al., 2007].
AGR2 is a survival factor that has been shown to contribute to inhibition of
the tumour suppressor p53 [Pohler et al., 2004] and to promote nuclear exclu-
sion of p53 in cultured cells subjected to DNA damage [Fourtouna et al., 2009].
In a screen of premalignant lesions from Barrett’s epithelium, a pre-neoplastic
oesophageal disease caused by damage from bile reflux, AGR2 was found to
be strikingly overexpressed [Pohler et al., 2004], suggesting that it contributes
to cellular transformation. AGR2 has also been shown to be co-expressed
with the estrogen receptor in breast cancer cell lines [Thompson and Weigel,
1998], and the gene has been shown to be estrogen responsive, containing up to
four putative estrogen response elements (EREs) in its promoter region [Kim
et al., 2007] [Hrstka et al., 2010]. In fact, AGR2 is overexpressed in many
hormone-responsive cancers. In breast carcinomas, high AGR2 expression was
associated with ERBB2 positive tumours [Duran et al., 2008], a member of
the epidermal growth factor receptor family involved in pathogenesis of ag-
gressive breast cancers. In breast carcinomas it is also associated with poor
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prognosis [Barraclough et al., 2009] [Hrstka et al., 2010], and with a malignant
metastatic phenotype [Barraclough et al., 2010]. In ovarian cancers, AGR2
is associated particularly with mucinous tumours [Park et al., 2011] [Gray
et al., 2012], but also with endometrioid tumours [Armes et al., 2013] and
serous tumours [Darb-Esfahani et al., 2012]. A high blood plasma concen-
tration of AGR2 has also been associated with both serous and non-serous
ovarian cancers [Edgell et al., 2010]. Increased levels of AGR2 are also associ-
ated with many prostate carcinomas [Kristiansen et al., 2005] [Kovalev et al.,
2006]. AGR2 transcripts have been detected in the urinary sediments of both
healthy and cancerous patients, with increased levels in the urinary sediments
of patients suffering from prostate cancer [Bu et al., 2011]. AGR2 has also
been detected at higher levels in the serum of prostate cancer patients, leading
some to propose AGR2 as a blood-based biomoarker for prostate cancer [Kani
et al., 2013]. Knockdown of AGR2 in a prostate cancer cell line induced cellu-
lar sensescence, linking AGR2 not only to horomone-related tumours but also
metastasis in prostate cancer [Hu et al., 2012]. In addition, AGR2 is associated
with poor survival in prostate cancer patients [Zhang et al., 2007].
AGR2 has also been studied in non-hormone related cancers. Elevated
levels of AGR2 have been found in the pancreatic juices of pre-malignant neo-
plasia of the pancreas [Chen et al., 2010] [Makawita et al., 2011]. It has been
found to promote initiation and progression of pancreatic epithelial neopla-
sia [Norris et al., 2012], and was found to be highly differentially expressed
in pancreatic cancers (14-fold increase of mRNA levels) compared to normal
pancreatic tissue in one study [Ramachandran et al., 2008]. AGR2 is impli-
cated in gastric cancer cells that have a high metastatic potential [Lee et al.,
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2011], and more recently has also been implicated in colorectal cancer and is
associated with poor prognosis [Valladares-Ayerbes et al., 2012]. Furthermore,
AGR2 was found to be present at higher levels in the serum of lung adeno-
carcinoma patients [Chung et al., 2011], and in one study to be elevated in
94% of lung adenocarcinomas [Chung et al., 2012] athough in this last study
AGR2 was not found to be associated with worse prognosis. Other groups
have also found elevated expression of AGR2 in non-small cell lung adeno-
carcinomas [Fritzsche et al., 2007] [Pizzi et al., 2012], and again the elevated
expression was not found to be prognostic of poor outcome. In addition, AGR2
has been implicated in renal Wilms tumours, where a locus including AGR2
was identified as a as a loss of heterozygosity site associated with some of these
tumours [Sossey-Alaoui et al., 2003], although the region contains several other
candidate genes as well and this association has not yet been validated.
There is evidence suggesting that AGR2 can mediate cytotoxic drug re-
sistance in tamoxifen and doxorubicin-resistant tumours, that it is induced by
tamoxifen [Hengel et al., 2011] [Hrstka et al., 2010], and that both AGR2 and
AGR3 can mediate cisplastin resistance in xenograft models [Gray et al., 2012].
AGR2 is overexpressed in tamoxifen and doxorubicin-resistant breast cancers,
is associated with poor prognosis in tamoxifen-treated tumours [Hrstka et al.,
2010], and has been shown to play a role in Docetaxel resistance (although in
this model AGR2 downregulation is associated with resistance) [Zhao et al.,
2009]. In a study involving anti-estrogen therapy-resistant cancer cell line
T47Dr, AGR2 and cathepsin D were found to be among those genes whose
mRNA was upregulated in the resistant cell line compared with the non-
resistant control [Huber et al., 2004].
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Links between AGR2 and metastasis have also been found, with one
study finding that AGR2 interacts with metastasis protein C4.4 [Fletcher et al.,
2003]. It has also been shown to mediate metastasis in animal models [Liu
et al., 2005], with overexpression of AGR2 in this study shown to induce non-
metastatic breast cancer cells to metastasise to the lung. In another study,
AGR2 was shown to mediate tumour growth, cellular transformation and cell
migration both in vivo and in vitro [Wang et al., 2008]. Other studies also
demonstrate the ability of AGR2 to promote cell proliferation, cell cycle pro-
gression and induced cell death [Park et al., 2011] [Vanderlaag et al., 2010]. In
pancreatic cancer cells, AGR2 is positively correlated with invasiveness poten-
tial of the cells, and the precursor of the secreted lysosomal protease cathepsin
D is a functional downstream target of this pro-invasive activity [Dumartin
et al., 2011], suggesting a link between the secretory pathway, AGR2 and
invasiveness of tumours. This was supported by a metastasis screen compar-
ing pancreatic ductal carcinoma tumour tissue and liver hepatocarcinomas, in
which the invasiveness potential of AGR2 was reported [Barry et al., 2012].
Furthermore, in androgen-responsive prostate cell lines, increased AGR2 ex-
pression was also found to be correlated with increased migratory and inva-
siveness potential in these cell lines [Bu et al., 2011].
It is clear that AGR2 is involved in the onset and progression of many
cancers, and that it has a role to play in metastasis, resistance and aggressive-
ness of many of these cancers. It is likely that there are different mechanisms
and pathways by which AGR2 mediates these effects from cancer type to can-
cer type, and possibly from subtype to subtype. Whether AGR2’s involvement
in most of these cancers is related to its functions as a molecular chaperone, or
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whether there are other modes of action, for example, mediating cytoplasmic
p53 inhibition in the cytoplasm or nucleus, remains to be shown.
Inflammatory Bowel Disease
As well as the association with cancer, AGR2 has been linked to inflamma-
tory bowel disease (IBD). In 1996, a genome-wide association study identified
a susceptibility locus at chromosome 7p21.1, a region of the genome that en-
codes both AGR2 and AGR3 [Satsangi et al., 1996]. Supporting the findings
of the 1996 genome-wide association study, a study of single nucleotide poly-
morphisms (SNPs) in humans found that SNPs in the 5-prime region of AGR2
were associated with increased susceptibility to ulcerative colitis [Zheng et al.,
2006]. The study also found that the AGR2 promoter could be regulated by
the goblet-cell specific transcription factors FOXA1 and FOXA2. As described
above, recent findings have highlighted the importance of AGR2 in goblet cell
function and development and in two murine gene knockouts of Agr2 the mice
were found to be susceptible to ulcerative colitis, further cementing the link
between AGR2 and IBD [Park et al., 2009] [Zhao et al., 2010]. In the second
mouse knockout study AGR2 was found to be important for ER homeosta-
sis [Zhao et al., 2010], and a different ER-stress related gene, XBP1, has also
been demonstrated to be a genetic risk factor for inflammatory bowel dis-
ease [Adolph et al., 2012]. The intestines of patients suffering from some forms
of IBD often display marked ER stress [Bogaert et al., 2011] [Niederreiter and
Kaser, 2011], suggesting that dysregulation of the ER stress response associ-
ated with low levels of AGR2 may pose a secondary pathway for increased
susceptibility to IBD.
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Asthma
AGR2 has more recently been implicated in the pathophysiology of asthma.
The first study to highlight a link between AGR2 and asthma involved a
screen for genes overexpressed upon allergen exposure in a mouse model of
asthma [Valentin et al., 2009]. In these mice, genome-wide microarray analysis
demonstrated that Agr2, along with other mucous-secretion associated genes,
was overexpressed, in mice exposed to an allergen (ovalbumin). A further study
using the Agr2 mouse knockout line described previously [Park et al., 2009]
demonstrated that AGR2 was induced in asthma following allergen exposure,
and that mucin overproduction was observed [Schroeder et al., 2012]. In their
model, immature lung mucin Muc5AC forms a complex with AGR2, and the
knockout mice exhibit a 50% reduction in Muc5AC and Muc5B, togther with
an increase in mucins retained in the ER as shown by alcian blue staining.
In a separate study in human lung epithelial cells, MUC5AC was found to be
induced by interleukin-13 (IL-13), and a reduction in IL-13 was found to lead
to a decrease in both AGR2 and MUC5AC levels [Yu et al., 2012], suggesting
that IL-13 may be upstream of AGR2 in a particular pathway. This data fur-
ther confirms the importance of AGR2 in maturation of mucins, and proposes
a novel disease model of mucin dysfunction involving AGR2.
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1.3 Secretory pathway and trafficking transmem-
brane proteins to cellular compartments
AGR2 has been shown to be secreted in several types of cancer as discussed
above, and studies on homologues in other species also associate AGR2 with
the secretory pathway (such as in the chicken oviduct, as a secreted protein
in Xenopus laevis, and in the regenerating newt limb blastema). The find-
ings that AGR2 is required for maturation of at least two mucins, a class
of secretory proteins that mature and are trafficked through the secretory
pathway, further implicate AGR2 in this pathway. The secretory pathway
is the principal mechanism by which soluble, secreted proteins are trafficked
to the cell plasma membrane for exocytosis. From the endoplasmic reticu-
lum (ER) lumen, soluble proteins are first exported from the ER in vesicles,
and these vesicles are then trafficked through the golgi network by successive
fusion through the golgi compartments. This process is mediated by many
proteins, enzymes and co-factors. Likewise, the principal mechanism by which
integral, transmembrane proteins mature and arrive at their resident location
is also through the secretory pathway (Figure 1.7). Hydrophobic patches are
shielded from the aqueous intracellular environment through association with
chaperone proteins and vesicular transport through the cytosol by way of the
golgi network. Nascent integral membrane proteins that are being synthesized
by ribosomes in the ER must be inserted into the ER membrane. For mul-
tipass membrane proteins, insertion into the ER membrane occurs either via
signal peptides at the N-terminus, or more commonly, the first alpha-helix in
the growing peptide that acts as signal-anchor sequence [Lodish et al., 2000].
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Figure 1.7: Targeting Proteins to the ER Membrane and Secretory Pathway
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In the case of the N-terminal signal peptide (also referred to as a leader
sequence), a cleavage site allows this hydrophobic, ER-targeting sequence to
be removed, and evidence suggests that proper removal of this peptide may
be necessary for correct processing and folding of the N-terminal domain of
the protein [Gillikin et al., 1997] [Huang et al., 2010]. The signal peptide at
the N-terminus is recognised the signal recognition particle (SRP) complex
in the ER membrane, which then targets the transmembrane protein to an
ER component known as a translocon. The function of the translocon is to
allow the hydrophilic portion of the transmembrane protein to pass through
the ER membrane into the ER lumen. The lumenal side of the ER mem-
brane maintains its integrity through the action of the BiP chaperone on the
lumenal side, which associates with the translocon, moving away when the ri-
bosome that is synthesising the nascent protein associates with the cytoplasmic
side of the translocon [Vitale and Denecke, 1999]. Chaperone proteins some-
times assist in the process of transport through the secretory network, aiding
in folding and/or assembly of subunits whilst preventing unwanted protein
aggregation due to exposure of hydrophobic patches to the aqueous environ-
ment [Ellis, 1999] [Ellis, 2006]. In this way, the hydrophobic portions of the
nascent polypeptide are shielded from the aqueous environment, whist allow-
ing the hydrophilic portions destined for the cytoplasm or the extracellular
environment to pass through to the ER lumen or cytoplasm.
In the first step towards entering the secretory pathway, membrane pro-
teins in the ER membrane or secretory proteins in the ER lumen are packaged
into vesicles that are exported to the cis-Golgi network (Figure 1.8).
The cargo-loaded vesicles pass through the trans-Golgi network, shut-
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Figure 1.8: The Secretory Pathway
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tling vesicle-loaded proteins to their destined location at the plasma membrane
or extracellular environment. The cargo-loaded secretory vesicles eventually
fuse with the plasma membrane, either discharging their cargo into the ex-
tracellular environment in the case of soluble secretory proteins, or siting the
integral membrane proteins into the plasma membrane with the portion lo-
cated on the internal side of the vesicle being placed into the extracellular
environment [Lodish et al., 2000]. This process is mediated by at least three
specialised proteins known as SNARE proteins [Sutton et al., 1998], although
the mechanisms of this process are not currently clear, mainly because imaging
these processes is extremely difficult due to the rapid nature of the interaction




Although the link between AGR2 and disease has been well established, little is
known about the mechanistic roles of AGR2 in either disease or development.
In order to understand how AGR2 contributes to the formation of tumours,
mediates metastasis and cytotoxic drug resistance, and how polymorphisms
in the gene contribute to IBD, it is important to identify protein networks
involving AGR2 (its interactome).
The overall aims of the PhD project are to identify and validate putative
interacting proteins for AGR2 from phage peptide display data, and to inves-
tigate the biological role of AGR2 in normal tissue and development. These will
be achieved using (i) biochemical techniques including co-immunoprecipitation,
colocalisation by confocal microscopy and imaging techniques such as total in-
ternal reflection microscopy (TIRF-M), (ii) generation and characterisation of
antibodies against putative AGR2 binding proteins, (iii) creation of a trans-
genic mouse line that expresses a GFP-Cre fusion protein from the Agr2 pro-
moter to analyse expression patterns in developing and mature mice and pro-
vide a Cre-driver mouse for lineage tracing or cell-type specific co-expression
and (iv) characterisation of AGR2 expression in embryonic mouse tissue using
antibody-based techniques. Taken together, this in vivo and in vitro data will
begin to define the tissue-specific interactome of AGR2 and help determine








2.1.1 Cell lines and culture conditions
Cell lines were cultured in humidified incubators equipped with CO2 gas cylin-
ders. Antibiotics were used to maintain cell lines, however, media without
antibiotics were used for cells to be transfected. Media were obtained from
Invitrogen (GIBCO) and supplemented with fetal calf serum as detailed, and
stored at 4◦C. Trypsin-EDTA (Invitrogen) was used to suspend cells for split-
ting and was also stored at 4◦C.
The cell lines used are detailed below:
Cell lines




5% CO2, 37◦C DMEM, 10% FCS, 1% Penicillin-






5% CO2, 37◦C DMEM, 10% FCS, 1% Penicillin-






5% CO2, 37◦C DMEM, 10% FCS, 1% Penicillin-
Streptomycin when not transfecting
n+15
IMCD3 Mouse SV-40 trans-
formed renal epithelial















5% CO2, 37◦C DMEM-F12, 10% FCS, 0.25%
sodium bicarbonate, 1% Penicillin-
Streptomycin when not transfecting
n+2
NIH-3T3 Mouse immortalised fi-
broblast
5% CO2, 37◦C DMEM, 10% FCS, 1% Penicillin-
Streptomycin when not transfecting
n+2
Table 2.1: Cell Lines - Description and growth conditions, *kindly provided




DMEM: Dulbecco’s Minimal Essential Medium containing
sodium pyruvate, L-glutamine, 4500mg/L glucose
and phenol red
DMEM-F12: Dulbecco’s Minimal Essential Medium in a 1:1 ratio
with Ham’s F12 medium containing 15mM HEPES,
sodium pyruvate, L-glutamine, 4500mg/L glucose
and phenol red
MEM: Minimal Essential Medium containing L-glutamine
and phenol red
2.1.2 Subculturing, storage and recovery of cells
Subculturing
Cell lines were subcultured every 3 days (A375, IMCD3, hTERT-RPE, NIH-
3T3), or 5 days (MCF7) in either 10cm dishes or 75cm2 flasks (Corning) in ster-
ile tissue culture hoods. Cells were washed once in sterile PBS and trypsinised
with Trypsin-EDTA (Invitrogen) before incubating at 37◦C for 3 min (MCF7,
A375 cells) or 5-10 minutes (IMCD3, hTERT-RPE, NIH-3T3 cells). Cells were
then resuspended in warm media before splitting into fresh dishes or flasks and
incubating as described in Table 2.1 and at a splitting dilution dependent on
cell type and experimental requirements. Final volume for subculturing was
10ml (10cm dish) or 25 ml (75cm2 flask). For experiments in 6 well plates final




Cell lines were grown to 95% confluence in 10cm dishes and trypsinised as
described above before diluting trypsinised cells in a final volume of 10ml. Cells
were pelleted by centrifuging at 1000rpm (Sorvall Legend X1R) for 5 minutes
in sterile 15ml falcon tubes and resuspended in fetal calf serum supplemented
with 10% DMSO. Cells were aliquoted in 1ml aliquots into cryotubes (Nunc)
and placed in gradient freezing containers (Nalgene) for 24 hours at -80◦C,
before transferring to liquid nitrogen containers for long-term storage.
Recovery
Cells in cryotubes in liquid nitrogen were placed into a water bath at 37◦C
for 5 minutes to thaw before being transferred into a 25cm2 flask containing
5ml media (constituents dependent on cell line as described in Table 2.1) at
37◦C. Media was replaced after 12-24 hours to remove DMSO and cells were
grown to 80-95% confluence before transferring to 75cm2 flask for culturing as
described above.
2.1.3 Transient Transfection
Cells were grown as described above to 80-95% confluence before plating ac-
cording to cell type and experimental conditions. IMCD3 cells were split 1:4
- 1:6 and incubated for 24 hours at 37◦C before transfection. MCF7 cells
(American and European) and A375 cells were split 1:3 and incubated for 24
hours at 37◦C before transfection. Transfections were carried out with either
Attractene Transfection Reagent (Qiagen) or Lipofectamine 2000 (Life Tech-
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nologies) as per manufacturers instructions. For MCF7 cells and A375 cells,
transfections with Lipofectamine were carried out using Optimem (GIBCO)
again as per manufacturers instructions. IMCD3 cells were transfected with
Lipofectamine 2000 as follows: Per 6 well plate, 1.6µg DNA combined with
800µl Optimem in one tube, 8µl Lipofectamine combined with 800µl Optimem
in another, incubation for 5 minutes at room temperature before combining
solutions and incubating for 20 minutes at room temperature. Media in wells
was replaced with 2ml fresh media, and transfection complexes added to wells
before swirling and incubating at 37◦C for 24-48 hours or as stated.
2.2 Microbiological Techniques
All procedures using bacteria were carried out under aseptic condtions. Cloning
was carried out in competent DH5α cells or competent Stbl2 DH5α cells.
Recombineering was carried out in recombineering-ready SW102 cells (sec-
tion 2.4.6). Luria-Bertani broth (Table 2.2) was sterilised by autoclaving at
121◦C for 20 minutes, selective antibiotics (Table 2.2) were sterilised by filter-
sterilising (0.22µm filter). For cultures requiring zeocin as selective antibiotic
low-salt LB broth was used containing 0.5% (w/v) NaCl.
2.2.1 Bacterial culture and reagents
For small DNA preparation extraction from bacterial cell culture (minipreps)
5-10 ml LB medium containing the appropriate antibiotic was inoculated with
a bacterial colony grown on agar or from glycerol stock and incubated overnight
at 37◦C with shaking at 225rpm. For larger DNA preparations (maxipreps)
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LB broth Selective Antibiotics
1% Tryptone Ampicillin (Sigma), 50-100µg/ml
0.5% (w/v) Yeast extract Kanamycin (Sigma), 10-50µg/ml
1% (w/v) NaCl Chloramphenicol (Sigma), 25µg/ml
Spectinomycin (Sigma), 50-100µg/ml
Zeocin (Invitrogen), 25-50µg/ml *low salt LB
Table 2.2: Bacterial culture medium and antibiotics
5 ml LB medium containing the appropriate antibiotic was inoculated with
a bacterial colony grown on agar or from glycerol stock and incubated for 8
hrs or overnight at 37◦C with shaking at 225rpm, before transferring 1-2 ml
of starter culture to 250ml LB broth containing appropriate antibiotic and
incubating at 37◦C with shaking at 225rpm for 20-24 hours. Culture flasks
were a minimum of 4 times the volume of culture for proper aeration. Glycerol
stocks were taken as appropriate by transferring 0.7ml of culture to 0.3ml of
glycerol (0.5%) (total glycerol concentration 0.15%) in a sterile cryovial (Nunc)




0.5% (w/v) Yeast extract
1% (w/v) NaCl
1.5% (w/v) agar powder
LB agar was melted by heating to greater than 60◦C and allowed to cool
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to lower than 50◦C before addition of appropriate antibiotic as described in
section 2.2.1. Liquefied agar containing antibiotic was poured into 100mm petri
dishes and left in a sterile hood to solidify. Plates were sealed with Parafilm R©
and stored at 4◦C. Prior to use plates were left at room temperature with
Parafilm R© removed for up to 4 hours.
2.2.2 Preparation of competent E. coli cells and trans-
formation
Where competent cells were not bought commercially (Subcloning Efficiency
DH5αTMCompetent Cells, Invitrogen; MAX Efficiency R© Stbl2 TMCompetent
Cells), DH5α cells were made chemically competent as follows:
Competent Cell Buffer 1 Competent Cell Buffer 2
100mM RbCl 10mM MOPS buffer pH 6.8
50mM MgCl2 10mM RbCl
30mM potassium acetate 75mM CaCl2
10mM CaCl2 15% glycerol (v/v)
15% glycerol (v/v)
pH adjusted to 5.8 with dilute acetic acid pH adjusted to 6.8 with sodium hydroxide
filter sterilised filter sterilised
Table 2.3: Buffers for making chemically competent cells
LB broth (5 ml) was inoculated with glycerol stock of DH5α cells and
shaken overnight at 37◦C. 250 µl of starter culture was used to inoculate 50ml
of LB broth in a 250 ml flask and shaken at 37◦C until the culture reached
an OD (600nm) of 0.4 (log phase of bacterial growth). Cells were pelleted by
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centrifuging at 2737xg (4000rpm) (Sorvall Legend X1R) for 15 minutes at 4◦C
and gently resuspended in ice-cold Competent Cell Buffer 1 (16 ml buffer/50
ml culture) and left on ice for 10 minutes. Cells were pelleted as before and
gently resuspended in ice-cold Competent Cell Buffer 2 (2 ml/50 ml culture)
and left on ice for a further 10 minutes. Competent cells were aliquoted in
the cold room into 50 µl aliquots in pre-chilled tubes and snap-frozen in liquid
nitrogen before storage at -80◦C. These cells were used for transformation with
DNA using the heat shock method (see below).
Transformation of bacterial cells with plasmid DNA
Bacterial cells (commercially bought Subcloning Efficiency DH5α TMCompetent
Cells, commercially bought MAX Efficiency R© Stbl2 TMCompetent Cells, or
DH5α cells made chemically competent as described above) were transformed
using the heat shock method. 50-100µl competent cells were thawed on ice and
mixed with 0.1-1.0µg of plasmid DNA in microcentrifuge tubes, and incubated
on ice for 10 minutes. Competent cells mixed with DNA were placed in a wa-
ter bath at 42◦C for 1-3 minutes and incubated on ice for a further 5 minutes.
800µl LB broth was added to the transformed competent cells and mixture
placed at 37◦C for 1h with shaking at 225rpm. Cells were pelleted by cen-
trifuging at 3000rpm for 10 minutes and cells were resuspended in 120µl fresh
LB before plating onto LB agar plates with appropriate selective antibiotic,
and growing at 37◦C overnight in an incubator.
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2.3 Plasmid and BAC DNA
2.3.1 Purification of plasmid DNA
LB broth was inoculated with DH5α cells transformed with desired plasmid
DNA from a colony on an agar plate or from glycerol stock and grown at
37◦ overnight or as described in section 2.2.1, depending on the size of the
DNA plasmid preparation. Bacterial cultures were pelleted by centrifuging
at 6000xg in a Sorvall RC6+ Centrifuge (maxiprep) or a Sorvall legend X1R
table top centrifuge (miniprep). Plasmid DNA was retrieved and purified from
pelleted cells using maxiprep or miniprep kits (Qiagen Plasmid Plus Maxi Kit,
or Qiaprep Spin Miniprep Kit) as per manufacturers instructions. DNA was
resuspended in distilled, sterile water (sterilised by autoclaving at 121◦C for 20
minutes). Plasmid DNA was stored at -20◦C, and quantified using a NanoDrop
spectrometer.
2.3.2 Propagation and preparation of BAC DNA
An 85 kilobase BAC containing the mouse Agr2 gene and flanking regions
(bMQ251g14) was obtained from the 129S7/AB2.2 clone library, shipped in E.
coli in agar. A toothpick was used to streak the bacteria containing the BAC
onto an agar plate containing 25µg/ml chloramphenicol (the selective antibiotic
on the BAC backbone) and grown at 37◦C overnight. Colonies were picked
from the agar plate into 3 ml LB broth containing 25µg/ml chloramphenicol
and placed at 37◦C overnight with shaking at 225rpm. After making glycerol
stock as described above, the remaining 1.6 ml of culture was used to isolate
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and purify the BAC DNA.
Commerical buffers from the Qiagen Plasmid Plus Maxi Kit were used
for the first stage (Buffer P1 resuspension buffer, Buffer P2 lysis buffer, Buffer
P3 neutralisation buffer). For each preparation, 1.6 ml of bacterial culture con-
taining the Agr2 BAC was pelleted in an Eppendorf 5417R microcentrifuge at
5000xg, and the pellet resuspended in 100µl of Buffer P1 before incubating on
ice for 5 minutes. 200µl of Buffer P2 was added followed by a further 5 minutes
on ice. 200µl of Buffer P3 was added and preparations were again incubated
on ice for 5 minutes. Preparations were centrifuged at 10,000xg for 5 minutes,
and supernatant containing BAC DNA was transferred to a fresh tube. BAC
DNA was precipitated by adding 900µl of ethanol (95%) and incubating on ice
for 30 minutes. DNA was pelleted by centrifuging at 10,000xg for 5 minutes,
and the glassy pellet was washed with 200µl ethanol (70%). Preparations were
centrifuged again at 10,000xg for 5 minutes and pellets were air-dried on the
bench for 1 hour. DNA was redissolved in 50µl endotoxin-free TE buffer (Qi-
agen kit) and DNA concentrations were determined by NanoDrop. Purity of
BAC DNA was assessed by NanoDrop (A260/A280 ratio at or greater than
1.8) and by endonuclease test digest with HindIII (20µg BAC DNA, 3µl re-
striction enzyme, enzyme-specific buffer, total volume 50µl) for 3h at 37◦C and
then analysing the digest pattern on an agarose gel (0.8%).
2.3.3 Agarose gel electrophoresis for DNA analysis
50XTAE Buffer was diluted in distilled water prior to use to make a 1x solu-
tion. Ultrapure agarose (weight as appropriate for percentage of agarose gel)
was added to 1x TAE buffer and the solution was boiled in a microwave until
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the agarose had dissolved. The solution was allowed to cool until just warm
to the touch and ethidium bromide was added (5µl/150 ml). The solution was
poured into an electrophoresis gel tank with appropriate comb size and left to
solidify. Combs were removed and gel was submerged in 1x TAE buffer. 6x
DNA loading buffer was added to samples (1:6 ratio) and samples were loaded
into the gel wells. Electrophoresis was carried out at 140V until DNA was
adequately separated, followed by visualisation under a u.v. lamp (Biodoc-It
Imaging System, UVP) with built-in camera (Fluor Cam 210). For samples
requiring recovery of DNA, appropriate bands were excised and recovered us-
ing the QIAquick Gel Extraction Kit (Qiagen) according to manufacturer’s
instructions.
50x TAE (Tris-Acetate EDTA) Running Buffer* 6x DNA Loading Buffer
2M Tris pH 6.8 15% Ficoll 400 (w/v)
0.1M Na2EDTA.2H20 0.25% Bromophenol blue (w/v)
4% Acetic acid (v/v) 0.25% Xylene cyanol (w/v)
pH adjusted to pH 8.5
*obtained from Shared Services, MRC HGU













































Table 2.6: Primers II
2.4.1 Gateway cloning
Gateway cloning is a system from Invitrogen which enables quick and effi-
cient cassette exchange without the need for restriction endonucleases. The
principle of Gateway cloning makes use of bacteriophage λ recombinase en-
zymes to mediate the exchange of DNA cassettes between recognition sites
in E. coli [Hartley et al., 2000]. Recombination between specific sites is one-
directional, so that an attB site on one DNA segment and an attP site on
another are recombined to yield new sites, attL and attR. Conversely, recom-
bination between attL and attR sites yield attB and attP sites. The direc-
tionality is recognised by two different recombinase enzymes now marketed by
Invitrogen, known as BP Clonase and LR Clonase enzymes. DNA fragments,
usually from PCR products, are amplified containing attB sites flanking the
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DNA sequence to be cloned, and a BP reaction using BP clonase causes recom-
bination into attP sites in a pDONR vector. For selection, the E.coli lethal
ccdB gene is used. Correct recombination of the PCR fragment into the ccdB
site removes the lethal gene and allows positive clone selection. Once the de-
sired DNA fragment has been successfully recombined into the pDONR vector,
the vector, now termed pENTR and with attL and attR sites, is combined with
a destination vector containing attB and attP sites (pDEST) in a reverse re-
combination event using LR Clonase enzyme. Correct clones are selected for
with antibiotic.
Like single-fragment Gateway recombination, Multisite Gateway R© re-
combination can be carried out in two recombinase-mediated steps, however,
it allows specific cassette exchange for up to 4 different fragments. Multisite
Gateway pDONR vectors contain unique attP sites which confer substrate
specificity for the BP clonase enzyme. By using the unique sites only the frag-
ments with correct flanking sites can recombine (see Figure 3.1). Thus, these
sites are not interchangeable [Cheo et al., 2004]. This method will be discussed
further in section 2.4.4 and in Chapter 3.
2.4.2 Cloning of V5-tagged wild type MKS3
The human Meckelin (MKS3) DNA sequence (longest known isoform, 995
amino acids) was amplified from pCMV-HA-MKS3 (generously donated by
Prof C Johnson, Leeds University) with Gateway-compatible primers MKS3wt-




Amplification of wild type Meckelin
Component Final Concentration
10x Platinum Taq buffer 1x
10mM dNTP 0.2mM
50mM MgCl 1.5mM
10µM Forward primer 0.4µM
10µM Reverse primer 0.4µM
Platimum Taq 4U/µl 2U
pCMV-HA-MKS3 (800ng/µl) 800ng
Total volume 50µl
PCR protocol to amplify wild type Meckelin
step 1: 95◦C 2:00 min
step 2: 95◦C 30 sec
step 3: 60◦C 45 sec
step 4: 72◦C 3:00 min
step 5: go to step 1 34x
step 6: 72◦C 5:00 min
step 7: 4◦C for ever
PCR products were loaded onto a 1% agarose gel and DNA was sepa-
rated by electrophoresis. The appropriate band corresponding to Meckelin was
excised and gel purified using the Gel Extraction Kit from Qiagen described
previously and eluted in 30µl. 7µl of the PCR products were incubated with
pDONR221 (215ng) and 2µl of BP Clonase enzyme mix at room temperature
for 1h. Proteinase K was added to inhibit the enzyme (10 minutes at 37◦C),
and mixture was transformed into DH5α cells as described above before plating
on agar containing kanamycin (50µg/ml). Clones were picked off agar plates




In the second step, pENTR-MKS3 DNA (300ng) was incubated with
pcDNATM3.1/nV5-DEST (100ng) and 2µl of LR Clonase enzyme mix for 1h at
room temperature. Proteinase K was added to inhibit the enzyme (10 minutes
at 37◦C), and the mixture was transformed into DH5α cells as described in
section 2.2.2 before plating on agar containing ampicillin (100µg/ml). Clones
were picked off agar plates into LB broth containing ampicillin, grown to make
minipreps and verified by sequencing.
2.4.3 Site-directed Mutagenesis
Mutants of the wild-type V5-tagged MKS3 vector described above were made
using the QuikChange TMsite-directed mutagenesis kit from Stratagene
(www.chem.agilent.com). The reason for choosing these mutations will be fur-
ther discussed in subsequent chapters. Primers used to generate mutations are
listed in Table 2.5; MKS3-Y385A-F, MKS3-Y385A-R, MKS3-P382T-F384Y-
F, MKS3-P382T-F384Y-R. In the first step, the forward and reverse primers
containing desired mutation(s) are annealed to the two denatured strands of
parental (vector) wild type DNA. A PCR cycle with a long elongation phase
allows the entire vector sequence to be amplified with the desired mutation(s).
Repeating the cycles enriches for the mutated DNA. DpnI digest then removes
parental DNA by recognising E coli DNA methylation on the parental strands.
The mixture is then transformed into bacteria and plated on agar containing
appropriate antibiotic, and clones are picked off the agar plates into LB broth
with antibiotic for growth and DNA miniprep as described previously. Us-




Amplification of mutant Meckelin isoforms
Component Final Concentration
10x Stratagene Pfu Turbo buffer 1x
10mM dNTP 0.5mM
10µM Forward primer 0.4µM
10µM Reverse primer 0.4µM
Pfu Turbo Polymerase 2.5U/µl 2.5U
pENTR-MKS3 (50ng/µl) 50ng
Total volume 50µl
PCR protocol for site-directed mutagenesis
step 1: 95◦C 30 sec
step 2: 95◦C 30 sec
step 3: 55◦C 1 min
step 4: 68◦C 7:30 min
step 5: go to step 1 15x
step 6: 4◦C for ever
PCR reactions were then DpnI-digested (10U/reaction) for 2h at 37◦C
before transforming into chemically competent DH5α cells as previously de-
scribed, and plating onto agar containing kanamycin (50µg/ml). Colonies were
picked into LB broth with antibiotic and minipreps were made also as previ-
ously described. Correct pENTR clones were identified by sequencing. These
pENTR clones were recombined into pcDNATM3.1/nV5-DEST by Gateway
cloning as described in section 2.4.2 and sequence verified.
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2.4.4 Construction of universal expression construct pMUL-
TIrec
Fragments for four different cDNA sequences (GFP-Cre, IRES, puromycin,
polyA) were amplified by PCR using primers as shown in Table 2.6. Each frag-
ment was amplified with specific multi-site Gateway recombinase sites (attB)
at the 5’ and 3’ ends. These fragments were purified by gel extraction as de-
scribed in section 2.3.3 before recombining into pDONR vectors to generate
Multisite-Gateway specific pENTR clones as described above. Clones were
sequence verified and are listed in Table 2.7. Using these unique entry clones,
an LR reaction was performed to bring all four fragments together, in order,
in a single reaction. The conditions for 4-fragment Multisite Gateway R© are
summarised below. The reaction mixture was incubated at room temperature
for 18h before addition of Proteinase K for 10 minutes at 37◦C to inactivate the
enzyme. Mixtures were then transformed into MachI E. coli cells supplied with
Multisite Gateway Pro kit according to manufacturers instructions and plated
onto agar plates containing ampicillin (50µg/ml). Colonies were picked and
grown for DNA miniprep and analysed by analytical restriction endonuclease
digests. The correct clone was termed pcDNA6.2-eGFPCre-IRES-puroR-pA.
Because the antibiotic resistance of both vector pcDNA6.2-eGFPCre-
IRES-puroR-pA and our final destination vector loxP-F3-neo-F3-DEST were
kanamycin, we needed to shuttle the eGFPCre-IRES-puroR-pA cassette through
a series of BP reactions and LR reactions to enable positive selection. The four-
fragment cassette in pcDNA6.2 (117.5ng) was incubated with pDONR/Zeo
from Invitrogen (100ng) and BP Clonase mix (2µl) for 1h at room tempera-
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LRClonase II Plus 2µl
Total volume 50µl
ture in a standard Gateway reaction as described above. Because of the enzyme
specificity and location of attB sites the entire 4-cassette block was recombined
into pDONR/Zeo, yielding pENTR/Zeo-eGFPCre-IRES-puroR-pA. Reaction
mixtures were transformed into DH5α cells and selected on low-salt agar con-
taining zeocin (50µg/ml). Clones were picked into LB broth with zeocin for
DNA miniprep, and correct clones were identified by analytical restriction en-
donuclease digest.
The final LR reaction into the destination vector could now be carried
out by performing an LR reaction between the pENTR/Zeo-eGFPCre-IRES-
puroR-pA vector (with attL sites now flanking the entire 4-cassette block)
and the final destination vector loxP-F3-neo-F3-DEST (with attR sites) with
kanamycin resistance. 150ng of pENTR/Zeo-eGFPCre-IRES-puroR-pA was
incubated with 150ng loxP-F3-new-F3-DEST and 2µl of LR Clonase II for 2h
at room temperature, before addition of Proteinase K for 10 minutes at 37◦C
to inactivate the enzyme. Mixtures were transformed into DH5α and plated on
agar containing kanamycin (50µg/ml). Clones were picked into LB broth with
kanamycin and grown for DNA miniprep as described. Correct clones were
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identified by analytical restriction endonuclease digest and sequence verified.












Table 2.7: Vectors used in construction of pMULTIrec
Recombineering into a BAC uses homologous arms, regions of 50-400
nucleotides flanking the sequence to be recombineered. In order to make this
construct easy to adapt to any BAC, multiple cloning sites were inserted at the
5’ and 3’ ends of the 4-cassette expression and neomycin resistance cassettes.
A multiple cloning site comprising PacI, SwaI, AscI was inserted into the NotI
site at the 3’ side of the expression cassettes. Oligonucleotides (Table 2.5)
corresponding to these sites were annealed by combining 50µl of each oligo
(at 100µM) and incubating for 10 minutes at 95◦C. Oligos were then allowed
to cool gently to room temperature to form double-stranded DNA segments
with overhangs for ligation. These were diluted 1:10. The GFPCre-IRES-
puroR-loxP-F3-neo-F3-DEST vector was digested with NotI as shown below
60
2.4. CLONING METHODS
and incubated for 1h at 37◦C before inactivating the enzyme at 65◦C for 10
minutes.





10x NEB Buffer 3 1x
1000x BSA 1x
Total volume 10µl
The annealed oligonucleotides with 3’ overhangs were ligated into the
the vector as shown below and incubated overnight at 16◦C. Ligation reac-
tions were purified using the QIAquick PCR purification kit (Qiagen) and then
redigested with NotI as shown in the table above to remove any self-ligated
vectors. After inactivating the enzyme the reactions were transformed into
DH5α cells and plated on kanamycin. Correctly ligated clones (in the correct
orientation) were identified by sequencing.
Ligation reaction - annealed oligonucleotides
Component Final Concentration
T4 ligase 1.5U




The process was repeated at the 5’ end exactly as described for the 3’
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multiple cloning site insertion. The XhoI site at the 5’ side of the expression
cassettes was used for insertion of the new multiple cloning site. Oligonu-
cleotides used for annealing and ligation are listed in Table 2.5. The new
multiple cloning site at the 5’ end consisted of BglII-NdeI-PmeI-MluI-NheI.
Clones with correct insertion of the new multiple cloning site were sequence
verified. The insertion of this site, however, caused the entire vector to become
unstable and undergo spontaneous rearrangements (the reason for this is not
known, although high sequence similiarity with a region of the backbone may
have been responsible). For this reason two of the sites were swapped by Dr K
Singh-Dolt to give the following 5’ multiple cloning site sequence: NdeI-BglII-
PmeI-MluI-NheI. We named this universal expression construct, with multiple
cloning sites for ligation of BAC homologous arms, pMULTIrec. A list of all
the vectors used to make the universal expression construct can be found in
Table 2.7.
In addition, various versions of pMULTIrec with different expression cas-
settes were made, including replacing the eGFPCre cassette with mCherry.
The method is explained in Chapter 3. The first of the four expression cassettes
was replaced with the ccdB E. coli lethal gene by carrying out a Gateway BP
reaction with pMULTIrec and pDONR-P1-P5r (this was done by Dr K Singh-
Dolt) to make pDEST-IRES-puroR-pA MULTIrec. In parallel, the mCherry
sequence was amplified from vector pCAGGs-fucci using the Gateway primers
listed in Table 2.6, and the PCR product was placed into pDONR-P1-P5r by
a Gateway BP reaction to make pENTR-mCherry-L1-R5. Combining the two
vectors pDEST-IRES-puroR-pA-MULTIrec with pENTR-mCherry-L1-R5 in




2.4.5 Creation of pMULTIrec-Agr2
Homologous arms corresponding to the 242bp immediately upstream of the
mouse Agr2 start codon and 250bp immediately downstream of the mouse
Agr2 start codon were amplified by PCR using the primers listed in Table 2.5
and using the conditions and PCR protocol shown below.
Amplification of Agr2 3’ and 5’ homologous arms
Component Final Concentration
10x Platinum Taq buffer 1x
10mM dNTP 0.2mM
50mM MgCl 1.5mM
10µM Forward primer 0.4µM
10µM Reverse primer 0.4µM
Platimum Taq 4U/µl 2U
Agr2 BAC miniprep 5µg
Total volume 100µl
PCR protocol to amplify Agr2 homologous arms
step 1: 95◦C 2:00 min
step 2: 95◦C 1 minute
step 3: 58◦C 30 sec
step 4: 72◦C 30 sec
step 5: go to step 1 34x
step 6: 72◦C 5:00 min
step 7: 4◦C for ever
For the 5’ homologous arm the pMULTIrec vector was digested with NdeI
and SalI before ligating the amplified homologous arm. For the 3’ homologous
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arm pMULTIrec (with 5’ Agr2 homologous arm inserted) was digested with
PacI and AscI before ligating the amplified homologous arm. All double di-
gests were carried out using enzymes from NEB (New England Biolabs) and
according to standard protocols. These were then ligated as previously de-
scribed using T4 ligase and buffer, 10ng of digested vector and a range of
dilutions of amplified homologous arms. Correct insertion of homologous arms
was verified by analytical PCR (see Figure 3.7).
In addition, homologous arms corresponding the 400bp immediately up-
stream of the mouse Meckelin start codon and 400bp immediately downstream
of the mouse Meckelin start codon were amplified by PCR and cloned into
the same restriction sites on pMULTI-rec-mCherry, and verified by analytical
PCR, however, this targeting expression construct has not yet been recombi-
neered into a Meckelin BAC to create a Meckelin mCherry promoter reporter.
2.4.6 Recombineering
SW102 cells are bacterial cells with the recombination machinery integrated
into their genome. This machinery consists of three temperature sensitive λ
Red genes: exo, bet and gam. These genes encode an exonuclease (exo), a
pairing protein that mediates homologous recombination with complementary
DNA (bet), and an inhibitor of E. coli exonuclease RecBCD to protect the DNA
targeting cassette from degradation (gam). In this system, the recombineering
genes are not expressed when the bacteria are kept at 32◦C, but when the
bacteria are incubated for 15 minutes at 42◦C, the genes are induced and
homologous recombination can occur [Warming et al., 2005].
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Introducing BAC into SW102 cells by electroporation
SW102 cells were grown in 5 ml LB broth at 32◦C overnight. This starter
culture was used to inoculate 40 ml of fresh LB broth in a 250 ml flask and
grown at 32◦C for one hour. Cells were pelleted by centrifuging (in a 50 ml
falcon tube) for 10 minutes at 2737xg (4000rpm) in a Sorvall Legend X1R
centrifuge. The pellet was washed in 20 ml ice-cold water and centrifuged at
2737xg (4000rpm) for a further 10 minutes, at 4◦C. The pellet was resuspended
in 1 ml ice-cold water, transferred to a microcentrifuge tube and centrifuged
at 10,000xg for 30 seconds at 4◦C. This last step was repeated once more and
pellet was resuspended in ice-cold water to a final volume of 200µl. This was
divided into 50µl aliquots and 100ng of BAC DNA (Agr2, bMQ251g14) was
added to each electrocompetent SW102 aliquot, retaining one without DNA
as a negative control. DNA-SW102 mixtures were left on ice for 5 minutes and
then placed into pre-chilled cuvettes for electroporation (1.8kV, 25µF capaci-
tance, 200ω resistance). After electroporation, cells were placed in 15 ml falcon
tubes with 1 ml LB broth and incubated at 32◦C for one hour with shaking at
225rpm. Cells were then pelleted by centrifuging at 4000xg and resuspended
in 200µl of fresh LB broth before plating onto fresh agar plates containing
chloramphenicol (25µg/ml). Plates were incubated at 32◦C overnight. Intro-
duction of BAC DNA into the recombineering cells was confirmed by culture,
miniprep as described in section 2.3.2 (retaining a portion of the culture for
glycerol stock), and analytical digest as described also in section 2.3.2.
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Recombineering of target DNA into Agr2 BAC
SW102 cells harbouring the Agr2 BAC (bMQ251g14) as described above were
picked from glycerol stock into 10 ml LB broth with chloramphenicol (25µg/ml)
and grown overnight at 32◦C. 1 ml of overnight culture was then added to 50 ml
LB broth with chloramphenicol (25µg/ml) and grown for 1 hour at 32◦C. The
50 ml culture was then divided into 2x 25 ml in conical flasks, and one flask was
placed at 42◦C with swirling for 15 minutes (to induce the Red genes) while
the other flask remained at 32◦C (uninduced control). After induction both
flasks were immediately plunged into an ice-cold water slurry for 10 minutes,
with swirling to cool the cultures. Cultures were transferred to two pre-chilled
50 ml falcon tubes and cells pelleted by centrifuging at 2737 x g (4000rpm) for
10 minutes at 4◦C. The soft pellet was gently resuspended first in 1 ml ice-cold
water and then a further 30 ml ice-cold water was added. Cells were pelleted
as before and soft pellet resuspended in 1 ml ice-cold water before transfer-
ring to fresh microcentrifuge tubes. Cells were centrifuged at 10,000xg for 30
seconds at 4◦C, supernatant removed, and cells resuspended in 1 ml ice-cold
water. Cells were pelleted once more at 10,000xg for 30 seconds at 4◦C before
resuspending in 200µl ice-cold water. On ice, 100ng salt-free targeting cassette
DNA (pMULTIrec-Agr2; section 2.4.5) was combined with 50µl electrocom-
petent induced or uninduced cells (and one induced aliquot without DNA for
negative control) and transferred immediately to the pre-chilled microcuvettes
before electroporating as described above. After electroporation, 1 ml LB was
added and cells were incubated at 32◦C for 2h. Cells were then pelleted at
4000xg and resuspended in 200µl fresh LB before plating on agar containing
kanamycin (10µg/ml; selective antibiotic for targeting DNA cassette). Correct
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clones were identified by picking colonies from the plates, making minipreps as
described in section 2.3.2 (retaining a portion of each culture as glycerol stock
also as described in section 2.2.1), and analysing by (i) HindIII digest pattern
comparison and (ii) PCR analysis. Primers for correct recombineering of the
DNA targeting cassette at the correct location (start codon) on the Agr2 BAC
are listed in Table 2.5 (5prime-F-Agr2BAC, 5prime-R-Agr2GCIP; 3prime-F-
Agr2GCIP; 3prime-R-Agr2BAC). The primers were chosen to amplify 5’ and
3’ regions at the cassette integration site, and each primer pair was designed
to amplify a product that spanned the integration site (from BAC backbone
and from DNA targeting cassette). Analytical gels are shown in Chapter 3,
Figure 3.7.
Removal of loxP site
A loxP site in the backbone of the Agr2 BAC required removal in order not to
interfere with the targeting cassette that also contains a loxP site (for futher
discussion see Chapter 3). Primers were designed (Dr K Singh Dolt) to amplify
the ampicillin resistance gene (amp-F, amp-R; Table 2.5) from vector pROSA
and with 50bp homologous arms identical to the region directly upstream and
downstream of the loxP site on the backbone of the Agr2 BAC. The condi-
tions and PCR protocol are listed below. The ampicillin resistance gene was
recombineered into the Agr2 BAC-pMULTIrec as described above, replacing
the loxP sequence. After electroporation cells were plated on agar containing
ampicillin (50µg/ml) and kanamycin (10µg/ml) for selection. Correct removal
of the loxP site and replacement with the ampicillin gene was confirmed by
PCR analysis using primers that amplified the region from outside the ampi-
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cillin cassette. Amplification of the loxP site yielded a 200bp product whilst
amplification of the ampicillin sequence yielded a 1200bp site (see Chapter 3
Figure 3.7 for analytical PCRs).
Amplification of ampicillin resistance
cassette
Component Final Concentration
10x Platinum Taq buffer 1x
10mM dNTP 0.2mM
50mM MgCl 1.5mM
10µM Forward primer 0.4µM
10µM Reverse primer 0.4µM
Platimum Taq 4U/µl 2U
pROSA (100ng/µl) 100ng
Total volume 50µl
PCR protocol to amplify ampicillin resistance cassette
step 1: 95◦C 2:00 min
step 2: 95◦C 30 sec
step 3: 56◦C 30 sec
step 4: 72◦C 1:00 min
step 5: go to step 1 34x
step 6: 72◦C 5:00 min




2.5.1 SDS-PAGE and Immunoblotting
Preparation of cell lysate
Cell lysates were prepared by harvesting cells into an appropriate volume of
PBS (generally 1 ml) and centrifuging for 10 minutes at 4000xg. Pellets were
resuspended in an appropriate volume of lysis buffer (0.2 - 1.0 ml) and incu-
bated on ice for 30-40 minutes. Lysis buffers used are listed in table 2.8.
Cell Lysis Buffers
Urea Lysis Buffer NP40 Lysis Buffer
7M Urea
0.1M DTT 10mMDTT
0.05% TritonX100 0.1%NP40 (Igepal)
25mM NaCl 40mM KCl
20mM HEPES.KOHpH7.6 25mM HEPES.KOHpH7.6
1x protease inhibitor mix (Roche) 1x protease inhibitor mix (Roche)
Table 2.8: Cell Lysis Buffers
After incubation in lysis buffer, lysate was centrifuged at 13,000rpm in
a table top centrifuge for 30 minutes at 4◦C to pellet cellular debris. The
supernatant was collected and either used for analysis or assay, or snap-frozen
in liquid nitrogen before storing at -80◦C. Prior to analysis, protein content
of the lysates was quantified either by Bradford assay or using NanoDrop
spectroscopic quantification.
Bradford assays were carried out using Bradford Reagent from Biorad.
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The reagent was diluted 1:5 in distilled water and filtered (0.25µm filter). 200µl
of diluted, filtered Bradford reagent was added in transparent 96-well plates to
2µl of sample lysate or standard preparations of bovine serum albumin (BSA)
in a range of concentrations. There is a linear relationship between protein
concentration and the absorbance of a sample with Bradford reagent at 595nm.
Samples were mixed well and absorbance of each sample was measured with a
spectrophotometer at 595nm (Powerwave XS Microplate spectrophotometer,
Biotek). Concentrations were determined by comparison to a standard curve
provided by the BSA samples.
Polyacrylamide gel preparation
Pre-cast polyacrylamide gels were used for one assay only (co-immunoprecipitation
of AGR2 and MKS3 in MCF7 (American) cells, Figure 4.8. For all other ex-
periments polyacrylamide gels were prepared in the laboratory. For analysis of
proteins of high molecular weight 10% polyacrylamide gels were used, whilst for
lower molecular weight proteins 12-15% gels were used (Table 2.9). Separating
gels were either poured between 1.0mm-gap glass plates or between 1.5mm-
gap glass plates dependent on the volume required for loading and allowed
to polymerise at room temperature, and stacking gels were added afterwards
together with either 10-well or 15 well combs dependent on assay and number
of samples. After polymerisation, combs were removed and glass plates con-
taining gels were placed into tanks (Biorad) filled with SDS-Running buffer
(Table 2.10). SDS sample buffer was added to the samples to be loaded onto
the gel and boiled at 95◦C for 3-5 minutes before loading onto the gels. 5µl of
pre-stained protein standards were loaded as marker (Fermentas, broad range
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prestained protein marker), and proteins were separated by electrophoresis at
140V for 45-90 minutes.
10% Separating Gel 12% Separating Gel 15% Separating Gel Stacking Gel
10% acrylamide 12% acrylamide 15% acrylamide 5% acrylamide
375mM Tris pH 8.8 375mM Tris pH 8.8 375mM Tris pH 8.8 125mM Tris pH 6.8
0.1% SDS (w/v) 0.1% SDS (w/v) 0.1% SDS (w/v) 0.1% SDS (w/v)
0.1% APS (w/v) 0.1% APS (w/v) 0.1% APS 0.1% APS (w/v)
0.04%TEMED (v/v) 0.04%TEMED (v/v) 0.04%TEMED (v/v) 0.1%TEMED (w/v)
Table 2.9: Composition of Polyacrylamide Gels
SDS-Running Buffer 5x SDS Sample Buffer
192mM Glycine 250mM Tris pH 6.8
25mM Tris 50% glycerol (v/v)
0.1% SDS (w/v) 5% SDS (w/v)
0.025% bromophenol blue
200mM DTT (added prior to use)
Table 2.10: SDS-Running Buffer and Sample Buffer
Immunoblotting
After separating proteins by electrophoresis as described above, proteins were
transferred to Hybond-C nitrocellulose membranes (Amersham) in tanks filled
with transfer buffer (tanks and equipment, Biorad). Briefly, nitrocellulose
membranes were soaked in methanol for 1 minute, washed for 10 minutes in
distilled water, and soaked in transfer buffer to equilibrate for at least 10 min-
utes. Gels were removed from glass plates and placed over the pre-soaked
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nitrocellulose membrane, and this was placed between 2x 2 card papers also
soaked in transfer buffer (Table 2.12). This was then placed in tank holders
filled with 1x transfer buffer and transfer was carried out at 300mA for 1 hour
on ice, or 30mA overnight. Transferred membranes were removed and rinsed
in TBS buffer once, before staining with either ink or Ponceau stain to con-
firm adequate transfer of protein. Membranes were then washed on an orbital
shaker in TBS-Tween-20 (0.1%) (Table 2.12) unless otherwise stated (3x5 min-
utes) and blocked for 1h in TBS-Tween 0.1% with 5% milk (dried skimmed,
Marvel) again unless otherwise stated (Table 2.12). Primary antibodies were
diluted in blocking buffer as required (dilution dependent on antibody, Ta-
ble 2.12), and incubated overnight at 4◦C. Blots were then washed as above
(3x 5 minutes) and incubated with appropriate secondary antibody diluted in
blocking buffer for 1h at room temperature. Blots were washed again (3x 5
minutes) in wash buffer. Blots were then visualised by ECL (enhanced chemi-
luminescence) using the buffers listed below mixed prior to use in a 1:1 ratio
and poured onto the membranes for 1 minute. ECL solution was removed us-




List of Primary Antibodies for Protein Biochemistry
Name Raised in Dilution Company Product
number
Anti-AGR2 polyclonal Rabbit 1:500-1:1000 Moravian Biotech K47
Anti-AGR2 monoclonal Mouse 1:1000 Abnova H00010551-
M03
Anti-β-tubulin Rabbit 1:1000 Cell Signalling Technologies 2128P
Anti-Fibrillarin Rabbit 1:1000 Cell Signalling Technologies 2639P
Anti-GFP monoclonal Mouse 1:1000 Abcam ab1218
Anti-HA monoclonal Mouse 1:1000 Abcam ab18181
Anti-MKS3 polyclonal Rabbit 1:1000 Abcam ab76786
Anti-MKS3 polyclonal Rabbit 1:500 Santa-Cruz Biotechnology sc-87298
Anti-MKS3 (C-terminal) poly-
clonal
Rabbit 1:100 C Johnson, University of Leeds N/A
Anti-MKS3 (N-terminal) poly-
clonal
Rabbit 1:100 C Johnson, University of Leeds N/A
Anti-V5 epitope monoclonal Mouse 1:1000 Abcam ab27672
Table 2.11: List of Primary Antibodies for Protein Biochemistry
Transfer Buffer TBS-Tween20 wash buffer Blocking Buffer
192mM glycine 1xTBS 1xTBS
25mM Tris 0.1% Tween20 (v/v) 0.1% Tween20 (v/v)
20% Methanol (v/v) 5% milk powder (w/v)
Table 2.12: Immunoblotting Buffers
2.5.2 Co-immunoprecipitation
Transfection and lysis
Human A375 metastatic melanoma cells grown in 10cm dishes were transfected
using Attractene as described in section 2.1.3 with HA-tagged MKS3 and either
GFP-AGR2 or GFP vector, before incubating for 24h. Transfected cells were
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ECL solution I ECL solution II
100mM Tris pH 8.5 100mM Tris pH 8.5
2.5mM Luminol 0.02% (v/v) hydrogen peroxide
0.4mM coumaric acid
ECL solution for chemiluminescence - mixed 1:1
subjected to u.v. at 50J/cm2, or not treated as indicated and incubated at
37◦C for a further 24h. Human MCF7 (American) breast adenocarcinoma cells
grown in 10cm dishes were transfected with HA-MKS3, and GFP-tagged full
length AGR2, RFP-tagged mature AGR2 or GFP vector, before incubating
for 48h.
Cells were harvested into 1ml PBS and pelleted by centrifuging at 4000xg
for 10 minutes at 4◦C. Pellets were resuspended in 1 ml NP40 lysis buffer and
incubated on ice for 30 minutes before centrifuging at 13,000xg for 30 minutes
at 4◦C. Lysates were transferred to fresh tubes. After removing an aliquot
as a pre-immunoprecipitation sample, lysates were first pre-cleared to reduce
unspecific binding. 100µl of sephadex CL 4B resin was washed 3x in ice-cold
lysis buffer (1 ml, 5000xg, 4◦C), and added to 1 ml of lysate. Mixtures were
incubated for 40 minutes on a rotator at 4◦C before centrifuging for 2 minutes
at 13,000xg at 4◦C. Supernatants were transferred to fresh tubes and protein
concentrations were determined by Bradford assay.
Pre-cleared lysates (200-800µg) were then incubated with anti-GFP an-
tibody (2µg, abcam, 1218) on a rotator overnight at 4◦C to pull down GFP
or RFP-tagged AGR2. Protein G-Sepharose beads were washed 3x in ice-
cold lysis buffer (1 ml, 5000xg, 4◦C), and antibody-antigen complexes were
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then incubated with 20µl of Protein G-Sepharose beads for one hour at room
temperature. Beads with bound antibody-antigen complexes were collected
by centrifuging at 5000xg for 2 minutes at 4◦C. Unbound proteins were re-
moved by washing 4x in 0.5 ml ice-cold lysis buffer (5000xg, 2 minutes, 4◦C).
Antibody-antigen-binding protein complexes were eluted from the beads by
adding 50µl sample buffer with 0.2M DTT and boiling at 95◦C for 3 minutes
before centrifuging at 5000xg for 5 minutes at 4◦C. Immunoprecipitated pro-
teins were analysed by denaturing SDS-PAGE followed by immunoblotting.
Where immunoprecipitated fractions were not immediately loaded onto a gel
they were snap-frozen in liquid nitrogen and stored at -80◦C.
2.5.3 Subcellular Fractionation
Cells were fractionated into subcellular components using the ProteoExtract R©
Subcellular Proteome Extraction Kit (Calbiochem). MCF7 cells were grown in
6-well plates (Corning) and transfected as described in section 2.1.3, and incu-
bated at 37◦C for 24h. Cells were harvested into 1 ml PBS and centrifuged at
4000xg for 10 minutes at 4◦C. Pelleted cells were then fractionated according to
manufacturer’s instructions to provide fractionation of the cells into cytosolic,
membrane and organelle, nuclear and cytoskeletal protein fractions. Protease
inhibitors (provided with the kit) were added to each fractionation buffer im-
mediately before use. Fractionated lysates were snap-frozen and stored at
-80◦C before analysing by SDS-PAGE and immunoblotting.
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2.5.4 RNA interference - AGR2
MCF7 (American) cells were grown in 6-well plates or 10 cm dishes (Corn-
ing) and transfected with siRNA, control siRNA, or were not transfected. The
siRNA to AGR2 used was siGenome Smart Pool M-003626-00-0005, and con-
trol siRNA used was from the siGENOME Non-Targeting siRNA Pool (Dhar-
macon/ThermoScientificBio). Transfections were carried out using Dharma-
fect transfection reagent according to manufacturer’s instructions. siRNA was
diluted to 20µM and 5µl of this was used per well for transfection in a to-
tal volume of 2 ml of media (final concentration 50nM). Cells were incubated
for 72h at 37◦C before analysing by SDS-PAGE and immunoblotting or by
immunofluorescence.
2.6 Immunofluorescence
Cells were plated on coverslips (generally at 5x103 - 1x104 cells per well) in the
bottom of 12-well dishes (Corning) and incubated for 24h at 37◦C. If trans-
fection was required, adherent cells were transfected with 0.8µg/well of DNA
using Attractene transfection reagent as described in section 2.1.3. Cells were
then incubated for a further 24h at 37◦C. Cells were fixed by first rinsing in
cold PBS, followed by fixing in Standard Formaldehyde Buffer (Table 2.13) for
10 minutes at room temperature. Cells were then washed 3x 5 minutes in PBS-
TritonX100 (0.1%) before blocking in PBS-TritonX100 (0.1%) with 2% BSA
(w/v) for 1 hour at room temperature. Cells were incubated overnight at 4◦C
with primary antibodies as described in Table 2.14 and in the Results sections.
Coverslips with fixed cells were then washed 3x5 minutes in PBS-TritonX100
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Fixing and Permeabilisation Buffers for Immunofluorescence






10 minutes room temp
Formaldehyde Buffer fixation,
methanol permeabilisation





Fix in Standard Formaldehyde Buffer Fix in Standard Formaldehyde Buffer 15 min Fix in Standard Formaldehyde Buffer
Wash 3x100mM glycine-PBS Wash 2xPBS
Additional incubation in ice-cold
Methanol for 2 min at -20◦C
Permeabilise 100mM glycine, 5%(v/v) saponin
for 20 min room temp
Permeabilise 0.5% (v/v) Triton X100,
BSA 1% (w/v) for 15 min room temp
Table 2.13: Fixing and Permeabilisation Buffers for Immunofluorescence
(0.1%), and incubated with appropriate secondary antibodies (Table 2.15) for
30 minutes at room temperature in the dark. Cells were then washed again
3x5 minutes and either mounted onto glass slides with mounting medium con-
taining DAPI nuclear stain (Vectashield with DAPI hard-set mounting fluid),
or were incubated for 15 minutes at 37◦C in the dark with 50µl TOPRO-3
nuclear stain diluted to 1:1000 in PBS. For TOPRO-3 treated cells, these were
washed again 3x5 minutes in PBS-TritonX100 (0.1%) before mounting on glass
slides (Superfrost) with mounting fluid for fluorescent analysis without DAPI
(DakoCytomation). Cells were analysed on a Leica SP-5 confocal microscope
or on a Nikon A1R confocal microscope with NIS elements imaging software.
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List of Antibodies for Immunofluorescence
Name Raised in Dilution Company Product
number
Anti-Acetylated α-tubulin Mouse 1:1000 Sigma Clone 6-11B-
1 T6793
Anti-γ-tubulin Mouse 1:1000 Sigma Clone GTU-
88, T6557
Anti-AGR2 polyclonal Rabbit 1:500-1:1000 Moravian Biotech K47
Anti-AGR2 monoclonal Mouse 1:1000 Abnova H00010551-
M01
Anti-HA monoclonal Mouse 1:1000 Abcam ab18181
Anti-MKS3 (C-terminal) polyclonal Rabbit 1:100 C Johnson, Leeds University N/A
Anti-V5 epitope monoclonal Mouse 1:1000 Abcam 27672
Table 2.14: List of Antibodies for Immnofluorescence
List of Secondary Antibodies for Immunofluorescence
Name Dilution
Alexa Fluorophore conjugated goat anti-mouse 488 1:200-1:1000
Alexa Fluorophore conjugated donkey anti-rabbit 488 1:200-1:1000
Alexa Fluorophore conjugated goat anti-mouse 594 1:200-1:1000
Alexa Fluorophore conjugated donkey anti-rabbit 594 1:200-1:1000
Table 2.15: List of Secondary Antibodies for Immunofluorescence
78
2.6. IMMUNOFLUORESCENCE
2.6.1 mKate2-Arl13B IMCD3 immunofluorescence assays
IMCD3(mKate2-Arl13B) cells were plated at a density of 104 per coverslip and
incubated overnight at 37◦C on coverslips in a 12 well plate. Cells were fixed in
Standard Formaldehyde Buffer (Table 2.13), washed and blocked as described
above, before incubation with anti-AGR2 mouse monoclonal antibody (Ab-
nova) or Anti-AGR2 rabbit polyclonal antibody (Moravian Biotech) overnight
at 4◦C. Coverslips were then washed and incubated with Alexa-fluorophore
conjugated antibody (either goat anti-mouse 488 or donkey anti-rabbit 488)
at a dilution of 1:1000, washed again and mounted using mounting fluid con-
taining DAPI (Vectashield with DAPI hard-set mounting fluid). Mounted
coverslips were analysed by confocal microscopy.
2.6.2 Immunofluorescence for characterising customMKS3
antibodies
IMCD3 cells were plated at a density of 104 per coverslip and incubated
overnight at 37◦C on coverslips in a 12-well plate. Cells were fixed and per-
meabilised as per each of the four fixation protocols (Table 2.13), and then
blocked in PBS containing TritonX100 (0.1%) and 2% bovine serum albumin
(BSA) for one hour. Cells were then incubated overnight at 4◦C with mouse
anti-acetylated α tubulin and one of the four antibody preparations (fractions)
as described in section 5.3 and Figure 5.4. Cells were then washed according to
the various wash protocols, and incubated in secondary antibody (Alexa fluo-
rophore conjugated donkey anti-rabbit 488, Alexa fluorophore conjugated goat
anti-mouse 594) at a dilution of 1:1000 for 1 hour. Cells were then washed and
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coverslips were mounted using DAPI-containing mounting fluid (Vectashield
with DAPI hard-set mounting fluid).
2.6.3 Total Internal Reflection Microscopy
We used TIRF-microscopy to image MKS3 at or just beneath the plasma mem-
brane. MCF7 (American) cells were co-transfected as described in section 2.3.1
(Lipofectamine) with V5-tagged MKS3 wild type, V5-tagged MKS3PTPIFA
mutant, V5-tagged MKS3PTTIY Y double mutant, or V5-empty vector (pcDNA-
nV5-3.1/DEST), all together with pAcGFPN1 empty vector to mark trans-
fected cells, and incubated overnight on coverslips. Cells were then fixed in
Standard Formaldehyde Buffer (Table 2.13), washed and blocked as described
above, before incubating with mouse monoclonal anti-V5 (abcam 27672) and
rabbit anti-Ecadherin primary antibodies overnight at 4◦C. Cells were washed
again as described above before adding fluorophore-conjugated secondary an-
tibodies (Alexa647 anti-mouse, Alexa568 anti-rabbit) at a dilution of 1:1000
for 1h at room temperature. Coverslips were washed 3x5 minutes and then
fixed and stained cells were placed in a chamber filled with buffer (PBS) and
analysed by Total Internal Reflection Fluorescence Microscopy by Prof R Dun-
can, Heriot Watt University (Olympus IX81 fully motorised microscope stand,
equipped with a PLAN APO 150X TIRFM objective, a 4-line motorised TIRF
combiner and 405, 491, 561 and 633 nm lasers). Ecadherin was used as a pos-
itive control to ensure that the cells being visualised were still adherent, and




2.6.4 Proximity Ligation Assay
MCF7 (American) cells were seeded onto coverslips in 12-well plates at 5x104
cells per well and incubated at 37◦C for 24h. Cells were transfected with GFP-
tagged DNA aptamers or HA-tagged reptin (from Dr M Maslon, University of
Edinburgh) as described in section 4.2 (Figure 4.5), using Attractene transfec-
tion reagent according to manufacturer’s instructions. HA-tagged reptin was
used as a positive control for the assay as a published, known binding parter
for AGR2 and with a known nuclear subcellular localisation pattern. Cells
were fixed in Standard Formaldehyde Buffer (Table 2.13), washed and blocked
as described above in section 2.6 before incubating with primary antibodies
overnight at 4◦C (anti-GFP mouse monoclonal, Abcam, 1:1000; anti-AGR2
rabbit polyclonal, Moravian Biotech, 1:1000). After incubation overnight with
primary antibodies, cells were processed according to manufacturer’s instruc-
tions using the Duolink PLS In Situ kit (PLA probe anti-rabbit MINUS, PLA
probe anti-mouse PLUS, Detection Reagents Red). Cells were imaged using
an automated microscope (Olympus BX61), with 60 individual fields imaged
per coverslip and with 7 images per field moving down through the cell from
the top of the cell to the coverslip. These “stacks” were combined to provide
one merged image per field. Images were analysed by an automated program
(Ariol) that counted the number of fluorophores per field and number of cells
counted. Microsoft Windows Excel was used to analyse the data.
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2.7 Embryonic kidney organ culture
2.7.1 Embryonic kidney organ culture and immunofluo-
rescence
Plugged CD1 female mice were euthanised during gestation, at embryonic day
E12.5 (12.5 days post fertilisation) and embryonic kidneys were microdissected
from the embryos using sterile needles and forceps under a light microscope.
Tail ends or limb buds were kept for genotyping (section 2.9). Kidneys were
placed onto permeable culture membranes in 6-well plates (Costar Transwell,
Corning, 24mm diameter inserts, 0.4µm pore size) with 1.5 ml MEM media
in the base of the wells such that membrane is not submerged. Kidneys were
grown for between 24h and 96h at 37◦C in 5% CO2 before fixing and staining.
After culturing for 24-96h, kidneys were removed from culture (still ad-
herent to the porous membrane) and fixed in 4% paraformaldehyde (PFA) in 5
ml PBS (in bijou tubes) for 30 minutes at room temperature. Kidneys adhered
to membranes were then washed (5x30 minutes, 5 ml PBS) and incubated with
primary antibodies (Table 2.16) diluted appropriately in 0.6 ml PBS overnight
at 4◦C. Kidneys were then washed (5x30 minutes, 5 ml PBS), and incubated
with secondary antibodies (Table 2.17) at 1:400 overnight at 4◦C (protected
from the light with foil). Kidneys were washed in PBS (5x15 minutes) and
mounted on glass slides (Superfrost), using glass coverslips as spacers, with
mounting fluid containing DAPI (Vectashield with DAPI mounting fluid - note
NOT hard-set). Fixed, stained and mounted kidneys were analysed by confocal
microscopy with a X60 oil immersion lens.
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List of Antibodies for Kidney Organ Culture Immunofluorescence
Name Raised in Dilution Company Product
number
Anti-AGR2 polyclonal Rabbit 1:500 Moravian Biotech K47
Anti-Acetylated α-tubulin Mouse 1:500 Sigma Clone 6-11B-
1, T6793
Anti-γ-tubulin Mouse 1:500 Sigma Glone GTU-
88, T6557
Anti-JAG1 polyclonal goat 1:100 RandD Systems AF599
Anti-Ecadherin monoclonal mouse 1:100 BD Transduction Labora-
tories
610182




Anti-NCAM monoclonal mouse 1:200 Sigma 9672
Anti-podocalyxin polyclonal mouse 1:200 RandD Systems AF1556
Table 2.16: List of Antibodies for Kidney Organ Culture Immunofluorescence
2.7.2 Embryonic kidney organ culture for analysis of trans-
genic line Agr2PR(GFPCre)
Agr2PR(GFPCre) x CD1 embryonic kidneys were microdissected as above at
embryonic day E12.5 and placed into culture on membranes, also as described
above. Kidneys were cultured for 24h before fixing in 4% paraformaldehyde
for 30 minutes at 4◦C. Kidneys, still adherent to membranes, were washed
in PBS (5x15 minutes) and mounted on glass slides (Superfrost) as described
above using mounting fluid containing DAPI (Vectashield with DAPI mount-
ing fluid). Fixed, stained and mounted kidneys were analysed by confocal
microscopy with a x60 oil immersion lens (Nikon A1R as described above).
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List of Secondary Antibodies for Organ Culture Immunofluorescence
Name Dilution
Alexa Fluorophore conjugated goat anti-mouse 488 1:200-1:1000
Alexa Fluorophore conjugated donkey anti-rabbit 488 1:200-1:1000
Alexa Fluorophore conjugated donkey anti-rabbit 594 1:200-1:1000
Alexa Fluorophore conjugated donkey anti-goat 488 1:200-1:1000
Alexa Fluorophore conjugated donkey anti-rat 488 1:200-1:1000
Table 2.17: List of Secondary Antibodies for Organ Culture Immunofluores-
cence
2.8 Immunohistochemistry
Agr2PR(GFPCre) pups were euthanised at 8 weeks of age by cervical dis-
location (performed by technician in transgenic facility) and intestines were
dissected and made into a gut roll. Intestines were placed into ice-cold PBS be-
fore fixing overnight at 4◦C in 4% paraformaldehyde-PBS. Organs were washed
2x30 minutes in cold PBS on an orbital shaker at 4◦C, and then processed ac-
cording to Table 2.18.
Organs were removed from liquid paraffin and embedded in paraffin
blocks before cutting into 6µm sections using a microtome (Leica RM2235)
and placing on glass slides (Superfrost). Sections were baked at 50◦C for 1h
before placing in xylene overnight. Sections were then washed 3x10 minutes
in 100% ethanol, 2x10 minutes in 96% ethanol, 1x10 minutes in 70% ethanol
and 3x10 minutes in water. Antigen retrieval was carried out using TEG
buffer (10mM Tris, 1mM EGTA, pH9.0) by boiling in the microwave for 10
minutes and sections were then left to cool at room temperature for 1h. Sec-
tions were then washed 1x30 minutes in ammonium chloride buffer (50mM in
PBS, pH7.4). Sections were further washed 3x10minutes in PBS with gelatine
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Protocol for Paraffin-Embedding of Mouse Intestines
Solution Time (min) Temperature (◦C)
25% ethanol 15 25
50% ethanol 15 25
75% ethanol 15 25
Placed into TissueTek VIP 5Jr
IHC machine
70% ethanol 40 35
85% ethanol 40 35
95% ethanol 40 35
100% ethanol 40 35







Table 2.18: Protocol for Paraffin-Embedding of Organs
(0.2%), saponin (0.05%) and BSA 1%, and then incubated with primary anti-
body (rabbit polyclonal anti-GFP, Abcam 6556) at a dilution of 1:500 or 1:1000
in PBS-TritonX100 (0.3%) with BSA (0.1%) overnight at 4◦C. Sections were
then washed 3x10 minutes in PBS with gelatine (0.2%), Saponin (0.05%) and
BSA 0.1%) before incubating with secondary antibodies (Alexa 488 donkey
anti-rabbit, 1:200 in PBS-TritonX100 (0.3%) with BSA (0.1%) for 90 minutes
at room temperature (in the dark). Sections were then washed 3x in PBS
and dried gently before adding mounting fluid (Vectashield with DAPI) and
covering with a coverslip. Nail varnish was used to adhere coverslip to glass
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slide. Immunostained sections were analysed for GFP expression on a Zeiss
axioplan 2 fluorescence microscope equipped with a Hamamatsu ORCA AG
camera.
2.9 Creation of transgenic animals
2.9.1 Microinjection of oocytes
All oocyte microinjections were carried out by Paul Devenney and Emma Mur-
doch, transgenic unit, MRC Human Genetics Unit, Western General Hospital.
DNA for microinjection was prepared as follows: The Agr2 BAC with ex-
pression cassette integrated at Agr2 start codon as described in sections 2.4.5
and 2.4.6 was linearised with PI-SceI restriction endonuclease digest (single
restriction site in backbone of BAC) with the protocol shown below.
Component Final concentration
BAC DNA 2µg
PI-SceI restriction endonuclease (NEB) 5U
PI-SceI Buffer (NEB) 1x
BSA (NEB) 1x
to final volume 30µl
Incubation 37◦C 12h, Enzyme dena-
tured at 65◦C for 20 min
Table 2.19: Linearising Agr2 BAC for microinjection
DNA was ethanol precipitated by adding 3µl of 3M NaOAc to the 30µl
sample, and then adding 75µl of ice-cold ethanol before incubating at -20◦C
for 20 minutes. DNA was pelleted by centrifuging at 10,000xg for 15 minutes
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and pellet was washed with 1 ml of 70% ethanol. DNA was again pelleted in
the same way and pellet was allowed to air-dry. DNA was resuspended in 30µl
of microinjection buffer at 37◦C for 5 minutes with gentle shaking. Concentra-
tions were determined by NanoDrop and diluted to 0.5ng/µl in microinjection
buffer prior to microinjection.
Component Final concentration
Tris-HCl pH 7.5 10mM
EDTA pH8.0 0.1mM
NaCl 100mM
Spermine (Sigma S-1141) 30µM
Spermidine (Sigma S-2501) 70µM
distilled, sterile H2O to appropriate volume
Table 2.20: DNA Microinjection Buffer
2.9.2 Genotyping
Transgenic mice were genotyped using earclip (for pups) or tail or limb bud (for
embryos). DNA was extracted by incubating tissue in 75µl sodium hydroxide
(0.1M) at 95◦C for 30 minutes followed by neutralising by addition of 75µl
Tris-HCl to a final concentration of 20mM. Genotyping was carried out by
PCR for the Cre trangene using the components and protocol below. Primers
for Cre and for internal control Fabpi are also listed below. All genotyping
was carried out by myself unless otherwise stated.
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Genotyping PCR
Amplification of Cre transgene
Component Final Concentration
10x Platinum Taq buffer 1x
10mM dNTP 0.2mM
50mM MgCl 2mM
10µM Forward primer 0.4µM
10µM Reverse primer 0.4µM
Platimum Taq 4U/µl 2U
Template DNA from tissue 5µl
Total volume 25µl
PCR protocol to amplify Cre-recombinase gene
step 1: 95◦C 2:00 min
step 2: 95◦C 30 sec
step 3: 56◦C 30 sec
step 4: 72◦C 1:00 min
step 5: go to step 1 34x
step 6: 72◦C 5:00 min





Table 2.21: Genotyping Primers
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Chapter 3
In Vivo Analysis of Agr2
expression
3.1 Introduction
The involvement of Agr2 in diseases such as cancer and inflammatory bowel dis-
ease has been well established, however, the mechanisms by which it promotes
disease are still unclear. It has been implicated in limb regeneration [Kumar
et al., 2007], at least in amphibians, suggesting a biological role that involves
maintenance of cell growth, and yet other studies implicate Agr2 in terminal
intestinal goblet cell differentiation [Chen et al., 2012] and terminal differentia-
tion of gastric epithelial cells in a mouse knockout model [Gupta et al., 2012b].
Insights have been gained into the biological function of the protein with the
publication of this most recent mouse knockout, however, more subtle phe-
notypes may not have yet come to light, and the mechanism by which Agr2
effects the balance between the stem cell and differentiated cell populations
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are yet to be discovered.
Establishing the expression pattern of a gene through developmental
stages and adult tissues can be useful for establishing its biological role [Alberts
et al., 2002]. There are numerous ways to investigate the expression pattern of
a gene, including antibody-based methods using fixed and sectioned tissues or
using organ culture followed by tissue fixing as described previously. However,
antibody-based techniques can have drawbacks such as antibody specificity
and compatibility with tissue processing, and do not give real-time informa-
tion possible with other types of expression analyses. Alternative methods for
determining the expression pattern of a gene in mice include the use of trans-
genic animals and promoter reporters which, coupled with lineage tracing, may
also provide information about the contribution of a gene to the differentiation
or maintenance of a particular cell type (discussed in sections 1.1.2 and 3.4.4).
In order to fully investigate the global expression pattern of Agr2 in both the
developing mouse embryo and in adult tissues, and to investigate the contri-
bution of Agr2-expressing cells to particuar cell types, we decided to make a
transgenic promoter reporter for the murine Agr2 gene, expressing GFP-Cre
from the Agr2 promoter using BAC transgenics, and with random insertion in
the mouse genome. In addition, expressing Cre recombinase from an ectopic
Agr2 promoter would provide tissue-specific Cre-drivers for tissue-specfic ex-
pression of other transgenes following genetic crosses, making the mouse line
useful for the AGR2 field in general.
Construction of targeting vectors for use in model animal transgenesis
can be lengthy and complex. Rather than making a construct that would only
be useful for our present study into the expression patterns of Agr2, we de-
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3.2. CONSTRUCTION OF THE UNIVERSAL TRANSGENIC
EXPRESSION VECTOR
cided to create a universal, modular expression vector that could be used with
other projects and genes. In this chapter we describe a universal and highly
adaptable construct for gene expression from a BAC or endogenous promoter,
using a BAC cloning platform and multi-site Gateway technology [Sasaki et al.,
2004]. As expression is driven by the promoter available on the BAC, this con-
struct is readily adaptable for the development of transgenic animals used for a
variety of analyses such as gene expression during development, tissue-specific
knockdown and tissue-specific inducible gene expression. The modular nature
of the vector makes it suitable for efficiently making variant BAC constructs
and as such is adaptable to high-throughput generation of BAC transgenes
or targeting vectors using recombineering [Poser et al., 2008] [Skarnes et al.,
2011]. We demonstrate its effectiveness in vivo as a promoter reporter using
the known expression pattern of Six2 as proof-of-concept, and then discuss at-
tempts to use the universal construct as a means of determining the expression
pattern and for lineage tracing of Agr2.
3.2 Construction of the Universal Transgenic Ex-
pression Vector
The generation of highly adaptable constructs for use in transgenic projects
is key to streamlining the production of transgenic lines. In addition, large
genomic contructs such as Bacterial Artificial Chromosomes (BACs) have
been shown to provide high predictability for expression of transgenic con-
structs [Giraldo and Montoliu, 2001]. Commercially available BAC libraries
contain a collection of large genomic constructs from a particular genome,
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such as mouse, and each BAC includes all the genomic components of that
region including introns, exons, and upstream or downstream regions. In some
cases they may include the promoter region of a given gene and, depending
on the size of the BAC, may also include regulatory elements essential for
the expression of the gene. Using a technique termed recombineering, BAC-
based vectors for the creation of transgenic animals can be readily made in E.
Coli [Copeland et al., 2001]. Recombineering is a technique that harnesses the
power of lambda phage recombination enzymes in E. Coli to facilitate homol-
ogous recombination at specific sites. Strains of E. Coli have been engineered
with temperature-sensitive recombination genes from the lambda phage, in
which they are repressed at 32◦C. When the bacteria are placed at 42◦C for a
brief period, the genes become derepressed, and the recombineering machinery
within the bacteria becomes active. A recombineering-ready bacterial strain
harbouring a BAC of interest can be electroporated with a DNA vector that
contains sites of homology (homologous arms) with the BAC, and it will be
recombined into the corresponding region of homology. In this way, DNA con-
taining a transgene can efficiently and effectively be recombineered into a BAC
containing the gene of interest. For the above-mentioned reasons we decided
to base our universal and adaptable expression vector on BAC transgenics.
In order to make this construct adaptable we used the Gateway cloning
platform from Invitrogen which enables quick and efficient cassette exchange
[Hartley et al., 2000]. Like single-fragment Gateway recombination, Gate-
way multisite recombination can be carried out in two recombinase-mediated
steps, however, it allows specific cassette exchange for up to 4 different frag-
ments (Figure 3.1) [Cheo et al., 2004]. To begin with, we set out to create
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Figure 3.1: Universal Expression Construct Cloning Process
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a 4-cassette expression vector containing eGFP-Cre, IRES, puromycin resis-
tance and polyA cassettes. Each fragment was amplified by PCR with specific
multi-site Gateway recombinase sites (attB) at the 5’ and 3’ ends (Figure
3.1A, primers table 2.5). The priniciple of Gateway recombinase cloning uses
the E.coli lethal ccdB gene for positive selection; correct recombination of the
PCR fragment removes the lethal gene and allows positive clone selection. A
“BP reaction” (recombination by the BP clonase enzyme between attB sites
and attP sites on pDONR vectors) is carried out to generate entry clones with
kanamycin resistance. Multisite Gateway pDONR vectors contain unique attP
sites which confer substrate specificity for the BP clonase enzyme. Thus, these
sites are not interchangeable. Using these unique entry clones, an “LR reac-
tion” (recombination by the LR clonase enzyme between attL and attR sites)
was performed to bring all four fragments together, in order, in a single reac-
tion (Figure 3.1B). The destination vector, pcDNA6.2/V5-pL-DEST, is a sim-
ple Gateway-compatible vector with ampicillin resistance for positive selection.
Since we wanted to create an adaptable construct for use in transgenics, a final
expression vector that included a removable neomycin/kanamycin resistance
cassette for ES cell and bacterial selection respectively was required. The ex-
pression vector chosen was a Gateway-compatible loxP-F3-neo-F3-DEST with
such a cassette, flanked by F3 sites for removal (Figure 3.1C). The bacte-
rial kanamycin resistance gene in this vector prevented us from performing
an LR reaction with the entry vectors directly into this expression vector.
Therefore, we first placed the multi-site Gateway cassettes into the first vec-
tor described above (Shuttle Vector A; Figure 3.1B), and then performed a
BP reaction between this vector, containing the multi-site cassettes, and a
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Gateway-compatible vector, pDONR/Zeo, containing zeocin resistance (Fig-
ure 3.1C). Due to the substrate specificity of the attB sites in multisite Gate-
way, the entire 4-cassette block was recombined into pDONR/Zeo, resulting in
pENTR/Zeo-GFPCre-IRES-PuroA-pA Shuttle Vector B (Figure 3.1C). An LR
reaction with the final destination vector containing the neomycin/kanamycin
cassette was performed, again recombining the entire 4-cassette block into the
expression vector in one step (Figure 3.1D).
In this way, we created an expression vector for expression of four cDNAs,
each flanked by substrate-specific attB recombinase sites for specific, efficient
cassette exchange. One, two, three or even four cassettes can be replaced
or removed either individually, in pairs or in a block (Figure 3.2A). How-
ever, we wanted to make this expression construct readily adaptable to a BAC
transgenics platform using recombineering. Recombineering into a BAC uses
homologous arms, regions of 50-400 nucleotides flanking the sequence to be
recombineered. In order to make this construct easy to adapt to any BAC, we
inserted multiple cloning sites at the 5’ and 3’ ends of the expression cassettes
and neomycin resistance cassette (Figure 3.2A). We now had a highly adapt-
able construct comprising readily-exchangeable expression cassettes mediated
by two-step Gateway recombinase activity, flexible multiple cloning sites for
insertion of any homologous arms, and removable neomycin/kanamycin resis-
tance under the control of bacterial (EM7) and mammalian (PGK) promoters
for bacterial and ES cell selection (Figure 3.2A). We named this universal
expression construct pMULTIrec. A list of all the vectors used to make the
universal expression construct can be found in Table 2.7.
In order to replace a cassette, first a PCR product of the new cDNA
95
3.2. CONSTRUCTION OF THE UNIVERSAL TRANSGENIC
EXPRESSION VECTOR
Figure 3.2: Universal Expression Construct schematic and cassette exchange
process
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is amplified with the specific attB sites. Together with the corresponding
pDONR vector (Figure 3.1A and Figure 3.2B), a BP reaction provides the
new entry clone. In parallel, a BP reaction is performed between the existing
expression vector (in this case eGFPCre-IRES-puroR-pA-loxP-F3-neo-F3) and
the pDONR vector corresponding to the entry vector (Figure 3.2B). The result
is a destination vector with one Gateway cassette replaced by the ccdB gene
and flanked by attR/attL sites. A final LR reaction between the new entry
vector containing the specific attL/R sites, and the new destination vector
containing an “empty” cassette provides the vector for use in transgenics with
one or more cassettes exchanged (Figure 3.2B).
To demonstrate the interchangeable nature of this construct, we ex-
changed the first cassette with other cDNAs to create new expression vectors
useful for transgenic analysis. Using the method outlined above, we simply and
efficiently created variations on the promoter reporter, including an mCherry
expression vector (Figure 3.3A). Correct replacement of the eGFP-Cre cassette
with mCherry cDNA was verified by sequencing (not shown) and restriction
endonuclease digest pattern (Figure 3.3B). Other transgenic expression vec-
tors easily adapted from this universal construct include an mKate2 promoter
reporter (Karamjit Singh Dolt) and a promoter-driven eGFP-Cre-ERT2 ex-
pression vector (Eve Miller-Hodges), which have been used to create BAC
mini-targeting vectors and as the basis for endogenous knock-ins. Insertion
of the eGFP-Cre fusion protein allows tissue-specific Cre driver mice for gen-
erating tissue-specific conditional mouse strains and GFP-Cre-ERT2 provides
inducible activation of Cre.
Although we have created these versions of the universal construct, any
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Figure 3.3: Vectors and mCherry expression construct verification
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reporter or other cDNA cassette can in two steps be integrated into any of the
four exchangeable cassettes. Using multi-site Gateway technology combined
with recombineering, the universal nature of the construct makes it a useful
tool for high-throughput genetic analysis, and fast and easy development of
transgenic constructs.
3.3 Testing the universal expression vector sys-
tem in vivo using a known gene expression
pattern
In order to test our system in vivo a gene with a known expression pattern
was required. Six2 expression in the developing kidney provided this known
expression pattern, as it has previously been shown by lineage tracing (us-
ing different targeting constructs for the same gene) to be expressed in the
nephrogenic progenitor cells [Kobayashi et al., 2008]. The developing kidney
involves extension and branching of an epithelial structure termed the ureteric
bud into the metanephric mesenchyme. Communication between these two
cell types leads to a process known as mesenchymal-to-epithelial transition
(MET) in which the mesenchymal cells become epithelialised and form the
basis of the developing nephrons (the filtering units in the adult kidney). The
nephrogenic progenitor cells, or cap mesenchyme, are the mesenchymal cells
that will undergo MET and become nephrons [Costantini and Kopan, 2010].
The expression of Six2 in the developing murine kidney was chosen as a way
to test our expression vector in part because the developing kidney provides
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a useful medium for analysis. Kidneys can be dissected out of mouse embryos
as early as E10.5-E11.5 and grown in culture, where they continue to grow
and develop for up to six days [Saxen and Lehtonen, 1987]. The kidneys are
transparent and are therefore ideal for visualising expressed fluorescent mark-
ers without the need for sectioning, and can be fixed and mounted whole for
confocal imaging or other types of microscopy. Furthermore, the ability to
grow the kidneys in culture makes them applicable for live imaging studies.
3.3.1 Random integration of BAC construct
The making of the transgenic Six2 promoter reporter mice and subsequent
analysis was carried out by Dr Karamjit Singh Dolt in Prof Hastie’s lab at
the IGMM under the supervision of Dr Peter Hohenstein. Briefly, homologous
arms to the Six2 gene were inserted at the 5’ and 3’ multiple cloning sites of
the eGFPCre-IRES-puromycin-pA vector (pMULTIrec) using NdeI and SalI
(5’ end) and PacI and AscI (3’ end). This was then targeted by recombi-
neering into a BAC containing the Six2 locus (Figure 3.4A), replacing the
start codon in exon 1. This recombineered BAC was linearised and microin-
jected into oocytes, and transgenic mice were generated. Analysis of the trans-
genic embryos (Figure 3.4B) and developing, cultured kidneys (Figure 3.4C)
demonstrated GFP expression as expected. Cultured kidneys were fixed and
stained with E-cadherin to highlight structures within the developing kidney,
and analysed by confocal microscopy. GFP positive cells were found in the
cap mesenchyme cells surrounding the ureteric bud (Figure 3.4D) as has been
previously described [Kobayashi et al., 2008]. Thus, the universal expression
vector was effectively able to ectopically express inserts via BAC transgenics.
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Figure 3.4: Ectopic expression of Six2 promoter reporter made from universal
expression construct
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3.3.2 Endogenous targeting of BAC construct
The expression vector can be used for ectopic expression from the BAC in the
model animal genome, or for expression from an endogenous locus, by first
retrieving a fragment of the BAC into a normal targeting vector, followed by
transfection and selection in ES cells. In order to test whether the universal
construct would allow expression from endogenous loci, a targeting construct
with large homologous arms from the Six2 -GCiP BAC was retrieved into a
plasmid backbone by recombineering. A thymidine kinase (TK) negative selec-
tion gene to eliminate non-homologous recombination events was then recom-
bineered into the plasmid backbone (Figure 3.5). The Six2 -GCiP BAC already
contains a neomycin positive selection marker for ES cell selection as part of
the universal construct, thus allowing both positive and negative selection to
screen for correct targeting of the construct at the endogenous locus in ES cells.
The vector was electroporated into mouse ES cells, and was integrated at the
Six2 endogenous locus by homologous recombination. Dr Dolt used long-range
PCR and Southern blotting to identify correctly targeted clones (Figure 3.6A),
which were then used to generate Six2+/GCiP knock-in mice. These mice were
healthy and viable as has been previously shown in other knock-in studies of
this gene [Self et al., 2006], and the GFP expression patterns were identical to
the randomly-integrated Six2-GCiP BAC mentioned above.
The first variant of the universal expression construct, GCiP (with stop
codon), was created for use as a promoter reporter that could also provide
lineage tracing or tissue-specific Cre-driver mice for generating tissue-specific
conditional mouse strains. Expression of Cre recombinase fused to eGFP pro-
vides the possibility of lineage tracing by crossing the transgenic line with a
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Figure 3.5: Method for retrieval of targeting vector with eGFP-Cre (GCiP)
construct as example
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Cre-activated reporter. In order to test the Cre moiety of this variant of the
universal construct, the Six2+/GCiP mouse was crossed to a Rosa26 tdRFP Cre
reporter mouse [Luche et al., 2007]. Expression of Cre drives removal of the
stop codons and polyA signals that prevent expression of the tdRFP marker,
leading to constitutive RFP expression in all cells of this lineage (see section
3.4.4 and 1.1.2 for further discussion of Cre-driven lineage tracing). Dr Dolt
used time-lapse imaging of the brightfield, GFP and tdRFP signals to follow
the dynamics of the lineage trace. As before, cap mesenchyme cells surrounding
the ureteric bud expressed GFP, and these cells rapidly became RFP-positive
while remaining GFP-positive as the Cre moiety activated expression of the
tdRFP reporter allele (Figure 3.6B). As the cells continued to develop and
progressed through MET they lost GFP expression, and post-MET nephrons
on these kidneys were GFP-negative whilst retaining the expression of tdRFP
(Figure 3.6C). The timelapse video can be accessed in Supplementary Data of
the publication listed on page xiii.
The data from the Six2+/GCiP knock-in construct described above con-
firms that the universal recombineering vector can be used for the generation
of endogenous targeting vectors and the generation of transgenic BAC models
as well as randomly integrated BAC expression vectors.
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Figure 3.6: Endogenous targeting of Universal Expression Construct with Six2
as proof of concept
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3.4 Creating the Agr2 promoter reporter
3.4.1 Adapting the universal construct as a promoter re-
porter for Agr2
As mentioned, we wanted to create a promoter reporter for the Agr2 gene that
did not affect the endogenous loci, and which would express Cre recombinase
as part of the reporter to enable lineage tracing. The strategy for ectopic ex-
pression of eGFP-Cre from an Agr2 BAC promoter is summarised in Figure
3.7A. The mouse Agr2 gene spans eight exons (7 coding) over around 11 kilo-
bases on chromosome 12 in the mouse genome, and encoding a protein of 175
amino acids (Figure 1.6). As in human AGR2 (hAGR2 ), the first coding exon
in mouse Agr2 is exon 2, which contains the start codon. We therefore chose
homologous arms of 250bp upstream and downstream of the start codon in
exon 2 to target our universal construct into the BAC by recombineering. We
chose the 85 kilobase Agr2 BAC from the 129S7/AB2.2 clone library which
encompasses the entire Agr2 gene as well as approximately 30 kilobases up-
stream and 43 kilobases downstream of the gene, but does not include the
closely neighbouring Agr3 gene.
The entire Agr2 BAC was electroporated into SW102 bacteria, and se-
lected for with chloramphenicol, the in-built antibiotic resistance gene in the
BAC backbone. SW102 is a strain of recombineering-ready E. Coli bacteria as
described in the introduction to this chapter. Once the BAC was successfully
placed into these bacteria, the pMULTIrec vector with Agr2 homologous arms
was electroporated in and the bacteria were placed at 42◦C for 15 minutes
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Figure 3.7: Agr2 GFP-Cre promoter reporter
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to activate the recombineering genes. Successfully recombineered clones were
selected for on kanamycin and chloramphenicol and then screened for correct
integration events (i.e. at the start codon of the Agr2 gene). Clones were
HindIII digested to reveal a classic BAC pattern, and comparison of pre-and
post-recombineered clones shows a shift in some bands of the digest pattern
(Figure 3.7B) as would be expected with the integration of a piece of DNA
into the BAC, but with most bands remaining the same height indicating that
no unexpected large changes had occured.
Most commercial BACs have a single loxP site built into their back-
bone. Close inspection of the universal vector reveals another, single loxP site
within the transgenic region (just upstream of the F3 site). This is a prob-
lem, since expression of the Cre-recombinase enzyme would lead to excision
of the region between these loxP sites, removing a large portion of the uni-
versal vector (including the section containing the PGK and EM7 promoters
and neomycin/kanamycin resistance genes). For this reason, we needed to re-
move the loxP site in the backbone of the BAC by replacing it with another
selectable marker, ampicillin. Again, we used recombineering to swap the loxP
site DNA with our own cassette containing the ampicillin resistance gene, and
then screened for successful recombinants using PCR. Primers (Materials and
Methods Table 2.5) were designed to the flanking regions of the loxP site.
Before recombineering the amplicon size was 250bp, and after recombineering
it was 1200bp (Figure 3.7C). Finally, to ensure that the integration of the
universal vector GCiP was at the correct locus in the BAC, primers were de-
signed (Materials and Methods section 2.4.6, Table 2.5) for the 5’ and 3’ ends
of the recombination region, with one primer for each from outside the recom-
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bineered vector region, and one from within. Thus, only correctly integrated
clones should be able to amplify the correct size amplicon by PCR (Figure
3.7D). The clone chosen for use in making transgenic mice was tested in each
of the three ways described, and Figures 3.7A,B,C were all made from analysis
of the same clone.
3.4.2 Creation of the Agr2 transgenic line “AGR2PR(GFPCre)”
The recombineered Agr2 BAC clone with start codon in exon 2 replaced with
the GCiP vector was ultra-purified using the large genomic construct maxiprep
kit from Qiagen, and then used for microinjection into fertilised mouse oocytes
(CBA/c57bl/6J F1 x CBA/c57bl/6J F1) at a concentration of 0.5 ng/µl. All
microinjections were carried out by Paul Devenney from the MRC Human Ge-
netics Unit. These fertilised oocytes were then transferred to pseudo-pregnant
females as surrogates (CD1 mice) (summarised in Figure 3.8A). The pups were
weaned and earclipped at around 2 weeks of age, and earclips were used for
genotyping. In total, from 2 micro-injection sessions, there were 64 pups born
to 4 surrogates. Genotyping was carried out using PCR on genomic DNA
from the earclips, with primers (see Materials and Methods) designed to am-
plify the Cre recombinase transgene (400bp), together with an internal control
for ubiquitous housekeeping gene Fabp1 (200bp). Of the 64 pups we identified
8 founder mice; 3 male and 5 female (Figure 3.8B).
The table in Figure 3.8C summarises the breeding of these founders.
To begin with, we tested the male founders. Males 6, 9 and 15 were set
up with female CD1 mice as breeding partners, and offspring were tested for
germline transmission of the transgene using the same genotyping PCR as for
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Figure 3.8: Creation of Agr2 promoter reporter line AGR2PR(GFP-Cre)
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the founders. CD1 mice are often used especially for embryo analysis as they
tend to produce large litter sizes compared to other strains such as C57BL/6.
Male 15 produced average sized litters when bred with a CD1 strain female,
however, none of his offspring yielded transmission of the Cre recombinase
transgene across 3 litters with 3 different CD1 females (see Figure 3.8C). We
thus concluded that the integration event happened after the germline lineage
was established in this oocyte, making this male unsuitable for our purposes.
Breeding of male 9 did produce transgenic offspring, however, the litter sizes
were extremely small (Figure 3.8C), with only 2 or 3 pups per litter. It may be
that the recombineered BAC construct integrated at a site involved in fertility,
or it is possible that this male had a fertility issue unrelated to the transgenic
addition but either way, it made this male less than ideal for transgenic analy-
sis. Founder male 6 was also bred with CD1 females, resulting in average litter
sizes and germline transmission to his offspring. We therefore decided to use
this male for our analyses.
3.4.3 Analysis of transgenic mice for eGFP-Cre expres-
sion
Male 6 was set up with two CD1 females for analysis of embryos and pups.
We first wanted to establish that our BAC transgenic vector was expressing
eGFP-Cre as expected. AGR2 is known to be expressed at clearly detectable
levels in the gut of both humans [Thompson and Weigel, 1998] and mice, and
specifically in the goblet cells of the mouse intestine [Park et al., 2009], so we
looked for expression of GFP in this location to confirm that the promoter
reporter was faithfully expressing as it should. One female was permitted to
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litter down and produced 13 pups, three of which were clearly transgenic based
on PCR-based genotyping (Figure 3.9A, lower panel). The three positive pups
and one negative were euthanised at 6 weeks of age, and the entire intestine
removed and fixed. These were then treated and embedded in paraffin blocks
for sectioning. The sections were processed for immunohistochemical staining
(Materials and Methods section 2.8) and incubated with anti-GFP antibody
overnight (Abcam 6556 rabbit polyclonal), and then incubated with Alexa-
488 donkey anti-rabbit secondary antibody. Sections were then mounted in
DAPI-containing mounting fluid and analysed both by widefield and confocal
fluorescence microscopy. Some fluorescence was observed at the base and along
the length of the villi (Figure 3.9A right panel), in accordance with the known
location of goblet cells [Johnson et al., 2012], however, the signal was very
weak and not clear. In contrast, no signal was seen in a negative control from
the same litter. In parallel, we decided to analyse the embryonic kidney for
expression of GFP in transgenic embryos. The reason for this will be discussed
further in subsequent chapters, but briefly, antibody staining and biochemical
data implied we should find expression of our transgene at the apical side
of the ureteric bud and in the cap mesenchyme of early (E12.5) embryonic
mouse kidneys. Male 6 was set up with a CD1 female mouse and the pregnant
female was euthanised at E12.5. The embryos were dissected out and tails
were kept for genotyping, whilst the kidneys were removed and placed into
culture overnight.
In total, there were 13 embryos from this female, and genotyping con-
firmed that 5 were definitely transgenic (Figure 3.9B, lower panel). After
24 hours in culture, the kidneys from both positive and negative embryos
112
3.4. CREATING THE AGR2 PROMOTER REPORTER
Figure 3.9: Analysis of Agr2 GFP-Cre promoter reporter for GFP expression
in adult gut and cultured embryonic kidneys
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were fixed in 4% paraformaldehyde (PFA), and mounted with DAPI-containing
mounting fluid onto glass slides for analysis by confocal microscopy. Repre-
sentative images taken from positive embryos (Figure 3.9B right panel) again
showed a weak GFP signal, in the region roughly corresponding to the ureteric
bud, and diffuse throughout the cell as expected. However, in order to obtain
detectable fluorescence the gain needed to be increased to higher than normal
levels. Nevertheless, co-excitation of the specimen at a different wavelength
(594 Texas Red) did not produce a red signal indicating that the emission
signal captured from the 488 excitation is not simply autofluorescence from
the tissue, and the negative control did not produce any detectable green sig-
nal when excited at the same levels (Figure 3.9B, left panel), suggesting that
the GFP-Cre may be expressing correctly from the BAC expression vector
although at very low levels.
We decided to take another approach to analyse the tissue, using flow
cytometry. Again, male 6 was set up with a female CD1 mouse, and embryos
were harvested at E12.5. Kidneys were dissected out and treated to make them
into a single-cell suspension, whilst tails were taken from each corresponding
embryo for genotyping (Figure 3.10B). In total, three positive transgenic em-
bryos and one negative embryo were analysed. Flow cytometry was carried out
by E Freyer, a technician at the MRC Human Genetics Unit. The parameters
for exclusion of autofluorescent signal were set using the negative control, and
dead or dying cells were also exlcuded from analysis. Flow cytometric analysis
on the four embryonic kidneys concluded that there was no difference between
the negative (embryo 4) and the positives (embryos 1-3), confirmed by the
number of GFP-postive cells counted as a percentage of the total number of
cells analysed (Figure 3.10 A, C).
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Figure 3.10: Flow cytometry analysis of Agr2 promoter reporter
(AGR2PR(GFP-Cre) X CD1 wt) cultured embryonic kidneys
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3.4.4 Cross to Rosa26YFP Cre reporter mouse for fur-
ther expression analysis
The data above suggested that if there was expression of the GFP-Cre trans-
gene in the Agr2 promoter reporter mouse line from male 6, Agr2PR(GFPCre)(6),
it is very weak expression. Crossing to a Cre-driven reporter mouse strain
should activate constitutive expression of a reporter (such as YFP, or tdRFP
as was used in the Six2 promoter reporter analysis, above). A Cre-driven re-
porter mouse strain is one that contains an ectopic expression cassette for a
reporter such as YFP or lacZ. The reporter expression cassette is not expressed
under normal circumstances as there are several stop codons and polyA sig-
nals between its promoter and the start of the reporter sequence. The stop
codons and polyA signals are flanked by loxP sites (sequences of DNA that
are recognised by the Cre-recombinase enzyme), and expression of the Cre-
recombinase enzyme causes excision of the stop codon, allowing constitutive
expression of the reporter. Thus, only in the presence of Cre-recombinase is
it possible for the reporter to be expressed. One such Cre-driven reporter
mouse strain that we had access to is the Rosa26YFP Cre reporter mouse,
in which a YFP expression cassette is harboured in the Rosa26 locus (Figure
3.11). As previously mentioned, the Rosa26 locus in the mouse is known to
be a safe locus for harbouring ectopic expression constructs [Friedrich and So-
riano, 1991] [Zambrowicz et al., 1997], and does not lead to off-target effects
that could interfere with normal gene function. Stop codons and several polyA
signals between the endogenous Rosa26 promoter and the YFP expression cas-
sette prevent expression of YFP until it is activated by excision of the stop
codon and polyAs, allowing the full YFP cDNA to be transcribed.
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Figure 3.11: Part I - Analysis of Agr2PR(GFP-Cre) X YFP reporter line
Rosa26YFP
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By crossing the Agr2PR(GFPCre)(6) mouse to a homozygous female
Rosa26YFP Cre reporter mouse (Figure 3.11A), any mice transgenic for the
Agr2 promoter reporter construct (Figure 3.11B) will be able to activate ex-
pression of YFP (Figure 3.11C,D) but only in the tissues expressing Cre re-
combinase and crucially, only in cells derived from the original Agr2-expressing
cells with the genomic YFP activated. In this way, expression of Cre should be
enough to drive excision of the STOP codons and polyA signals that prevent
expression of the YFP signal, and harbouring of the YFP expression cassette in
the Rosa26 locus ensures that the genomic envirnonment or location is unlikely
to affect the level of expression of the marker gene.
Agr2PR(GFPCre) founder male 6 was crossed to a Rosa26YFP Cre re-
porter mouse for analysis of embryos. The cross produced 6 embryos for analy-
sis, and genotyping (Figure 3.12D) for presence of the Cre transgene confirmed
that there was one positive embryo and 5 negative. Images were taken using a
fluorescence microscope, first of the whole embryo (Figure 3.12A), and then of
the whole embryo dissected rostro-caudally to reveal the inner tissues (Figure
3.12B brightfield microscopy, Figure 3.12C fluorescence microscopy). There
was no fluorescence seen in any of the embryos, and no observable difference
between the negative embryos (1-5) and the positive embryo (6). Kidneys were
dissected out and placed into culture for 24 hours. Kidneys were then analysed
for YFP expression using a time-lapse microscope for live-cell imaging with
the help of Dr Nils Lindstrőm (Institute of Genetics and Molecular Medicine)
(Figure 3.13A brightfield, 3.13B fluorescence microscopy). Again, there was
no observable difference seen between the negative embryonic kidneys (1-5)
and the positive kidney (6). For comparison, a Six2 promoter reporter trans-
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Figure 3.12: Part II - Analysis of Agr2PR(GFP-Cre) X YFP reporter line
Rosa26YFP - E12.5 whole embryos
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genic kidney from the knock-in described previously in this chapter is shown
in Figure 3.13D (top panel brightfield, lower panel fluorescence microscopy).
This image was taken by Dr Nils Lindstrőm using the same microscope as was
used for the kidneys from Agr2PR(GFPCre) x Rosa26YFP Cre reporter cross
in Figure 3.13.
Due to the disappointing result from the YFP cross embryos, we decided
to test adult tissue for expression of the transgene by western blot and FACS
analysis. As previously mentioned, the mature gut is a known location for
AGR2 expression. We decided to test both the adult gut and adult kidney for
expression of GFP. The anti-GFP monoclonal antibody from Abcam (1218) is
predicted to cross-react with YFP protein, and so we should be able to detect
both GFP and YFP variants if they are being expressed in the transgenic mice.
Agr2PR(GFPCre) founder male 6 was crossed to a new female Rosa26YFP
Cre reporter mouse, and the female was permitted to litter down, producing
a litter of 6 pups. Pups were earclipped and genotyped (Figure 3.14A), again
with one positive transgenic mouse and 5 negative mice. The positive pup
(pup 3) and one negative pup (pup 1) were euthanised at 8 weeks of age and
the entire intestine and both kidneys were dissected out. A 3cm portion of
the upper colon from each mouse was removed for FACS analysis, and the rest
of the intestine and both kidneys were placed in 0.32M sucrose overnight for
subsequent protein extraction. After saturation of the tissue in sucrose buffer,
the tissues were homogenised using a rotor-stator homogeniser, and protein
lysate was isolated by spinning the suspension at high speed. The lysates were
analysed by SDS-PAGE and western blot. Adult gut and kidney lysates from
the positive transgenic littermate (pup 3) were analysed for expression of AGR2
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Figure 3.13: Part III - Analysis of Agr2PR(GFP-Cre) X YFP reporter line
Rosa26YFP - E12.5 embryonic cultured kidneys
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(Figure 3.14B) using anti-AGR2 polyclonal antibody K47 (Moravian Biotech).
As expected, AGR2 protein expression was observed in the adult murine gut
by western blot, as well as the murine kidney. It is not possible to compare
protein levels using this method of protein extraction since the concentration
of protein in the lysate cannot be accurately be determined due to the presence
of other factors such as blood serum. In this case we merely wished to confirm
that AGR2 protein was in fact being expressed in these tissues, before looking
for expression of a transgenic protein under the control of the Agr2 promoter.
Having confirmed the presence of AGR2 protein in both the adult gut and
kidney of the mouse, we tested the lysates from kidney and gut of both the
positive and negative littermates for presence of GFP-Cre or YFP. GFP and
YFP differ in only one amino acid and are thus both predicted to migrate at
around 28 KDa, whereas GFP-Cre is predicted to migrate at approximately
60KDa. We used a positive control for the blot from cell lysate that had been
transfected with eGFP empty vector (Clonetech pAcGFPN1), and loaded the
maximum lysate possible from the positive and negative littermate tissues.
Figure 3.14B (farthest right lane) shows the AGR2 levels detectable from this
amount of lysate. Blots were probed for GFP/GFP-Cre or YFP using abcam
anti-GFP as described above, and a clear band at 28KDa was observed in
the control lane. There were no bands detected at the correct heights (28KDa,
60KDa) in the lanes containing lysate from tissues from the positive littermate,
and the only bands detectable were observed in both positive and negative
littermates, at around 32 or 33 KDa (Figure 3.14C).
In parallel, the intestines dissected for FACS analysis were dissociated
into single-cell suspension. These were analysed for GFP/YFP expression by
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Figure 3.14: Part IV - Analysis of Agr2PR(GFP-Cre) X YFP reporter line
Rosa26YFP - adult gut and kidney
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flow cytometry (Elisabeth Freyer, MRC Human Genetics Unit). Again, the
parameters for exclusion of autofluorescence or dead cells were set according to
the negative littermate, and cell clumps were also excluded. There was almost
no GFP expression detectable, and no observable difference in GFP/YFP ex-
pression between the gut cells from the positive and the negative pups (Figure
3.14D). Taken together, we concluded from this data that there was very little
expression, if any, of the GFP-Cre transgene driven by the ectopic BAC Agr2
promoter at least in the case of founder male 6. Of the female founders, one
died as a result of husbandry error, and the remaining four females were set
up for breeding after male 6 was extensively tested as described above, but all
failed to produce any litters and were eventually culled.
3.5 Discussion
There are several possible reasons that we were unable to detect expression of
the GFP-Cre transgene in these mice. Since we directly microinjected (Paul
Devenney) the BAC expression construct into oocytes rather than endogenous
targeting via ES cells, the integration event into the mouse genome is random.
The mice were viable and seemed healthy, but in the case of male founder
9, there was a problem with fertility. The possibility that the transgene had
integrated at a locus required for male fertility has already been discussed. In
the case of male 6, although the integration event was not deleterious to the
founder male or his offspring (that we are aware of), it is possible that the BAC
vector integrated at a genomic location that is suboptimal for expression. For
example the transgene may have been inserted into a “closed” region of the
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genome that is silenced, and therefore not accessible to initiation of transcrip-
tion machinery. Alternatively, the BAC we chose from the BAC library may
not have contained all the components required for the promoter to activate
transcription. For example, an enhancer region may be absent from the BAC,
which can be anything from a few kilobases away to 1 megabase away [Lettice
et al., 2002].
Rather than try to establish exactly where the transgene had integrated
by plasmid retrieval and sequencing, we felt it was more productive to start
with a new micro-injection session for random integration and also to target
the endogenous locus in ES cells as described for the Six2 knock-in. Work on
this is ongoing, and will form the basis of future expression studies in vivo.
The universal vector itself, however, has been used as a highly adaptable and
flexible cloning and recombineering system for several in-house projects, and
has been made widely available to other research groups via Addgene.
In the following chapter, another approach to investigating the biological
function of Agr2 will be described, using phage-peptide proteomics as the basis
for identifying biologically relevant interacting partners of AGR2.
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Chapter 4
Identification of MKS3 as a
putative novel AGR2 interacting
protein
4.1 Introduction
As previously discussed, the biological function of Agr2 is not fully understood.
It has been shown to be involved in a variety of cancers when upregulated
or overexpressed [Liu et al., 2005] [Maresh et al., 2010] [Vanderlaag et al.,
2010] [Zhang et al., 2005], and to be involved in mucin production [Park et al.,
2009], contributing to inflammatory bowel disease when levels are reduced
[Zheng et al., 2006] . Studies into the association of Agr2 with cancer point
to a nuclear function and interaction with p53 [Pohler et al., 2004] [Maslon
et al., 2010], yet the interaction with MUC2 protein through a disulphide
bond [Park et al., 2009] implicates a role for Agr2 outside the nucleus. Agr2 has
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a putative N-terminal leader sequence with cleavage site that destines AGR2
for the secretory pathway, and previous work has shown that the transfected
"mature" form of Agr2 lacking the N-terminal leader sequence localises to the
nucleus and cytoplasm when transfected into cells [Fourtouna et al., 2009].
Evidence points to dual or multi-faceted roles for Agr2 in vivo, and insights
into its biological functions could help shed light onto the mechanisms by which
Agr2 contributes to disease.
Identifying the interacting partners of a protein can aid in elucidating
its biological function(s). Once an interaction is validated, its function and
mechanisms of interaction can be investigated. Short linear peptide motifs on
the surface of proteins or within disordered loops are known to provide bind-
ing sites for globular proteins [Neduva and Russell, 2005] [Neduva and Russell,
2006]. These linear peptide motifs can be an important tool in proteomics
and the study of interactomes. Screening for linear peptide motifs that pro-
vide docking sites for a given protein can be achieved using various techniques,
including phage peptide display [Smith, 1985] [Rossenu et al., 1997], as dis-
cussed in section 1.1.3. Briefely, phage peptide display involves the expression
of a peptide on the major coat protein of a phage virion (normally M15 or
filamentous phage fd [Smith and Petrenko, 1997]). Large combinatorial phage
peptide display libraries, in which a single random peptide is expressed on the
surface of each virion can be built up, and this library can be used to screen
for potential binding peptides for a given protein or DNA. Using this approach
(Figure 4.1A), a peptide was identified that bound AGR2 (Figure 4.1B), and
was validated by various methods including ELISA based deletion and alanine
scan (Figure 4.1C) [Murray et al., 2007].
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Figure 4.1: Phage display identifies minimal peptide that binds to AGR2 in
vitro
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Further analysis of the identified binding peptide revealed a degree of
degeneracy in the sequence [Fourtouna et al., 2009], with certain amino acids
or families of amino acids tolerated in substitution (discussed further, below).
These data were used as the basis for database mining in the human genome
in an attempt to uncover possible AGR2 binding proteins.
This chapter will focus on the interaction between AGR2 and the linear
peptide identified by phage display, and validation of a potential interaction
between AGR2 and a protein containing the linear peptide motif.
4.2 Linear peptide as basis for identification of
AGR2 interactome
The AGR2-binding linear peptide HLPTTIYYGPPG was identified using a
combinatorial phage peptide library as described above. The essential binding
residues PTTIYY were determined using a series of deletion and alanine mu-
tants (Figure 4.1 C) and the dissociation constant (Kd) was determined to be
in the region of 30µM. AGR2 was previously shown to be highly overexpressed
in Barrett’s epithelium [Pohler et al., 2004], a pre-neoplastic condition that
can lead to adenocarcinoma of the oesophagus. In order to test the ability of
the linear peptide PTTIYY to bind native AGR2, cell lysates from Barrett’s
epithelia were washed over a streptavidin column containing biotinylated pep-
tide. The peptide was able to purify native AGR2 from Barrett’s epithelium
to near homogeneity (Figure 4.1D) [Murray et al., 2007]. In contrast, AGR2
was not purified from normal squamous oesophageal epithelia under the same
conditions, and the peptide did not pull down any other protein in this assay,
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demonstrating specificity.
4.2.1 Expression of AGR2 in cancer cell lines as tools for
investigation
Using this data, the ability of the peptide to bind native AGR2 in cell cul-
ture was evaluated. To investigate this, the cell lines to be used in this and
subsequent experiments were characterised. AGR2 has been shown to be over-
expressed in a variety of cancers, including several hormone-related cancers
such as breast cancer, some ovarian cancer subtypes and prostate cancer, as
well as other hormone-independent cancers [Brychtova et al., 2011]. To study
the biology of AGR2 in cell cuture, we acquired a panel of cancer cells that
express varying levels of AGR2. MCF7s are a human estrogen receptor alpha
(ERα)-positive breast adenocarcinoma cell line that have been used extensively
worldwide for research purposes [Soule et al., 1973] [Lacroix and Leclercq,
2004]. These cells originally had a karyotype of 85 chromosomes, however the
MCF7s in use today have a karyotype of 69 chromosomes, and studies have
shown divergence within MCF7 cell lines from different sources [Villalobos
et al., 1995] [Liscovitch and Ravid, 2007], highlighting that not all cell lines
of a given type are necessarily identical. We acquired two MCF7 lines from
different sources ("American" and "European"), and these were tested for ex-
pression of AGR2 both at the mRNA level (not shown) and by Western blot
using two different antibodies to AGR2; polyclonal anti-AGR2 K47 from Mora-
vian Biotech (Figure 4.2A), and anti-AGR2 monoclonal from Abnova (Figure
4.2B).
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Figure 4.2: Expression of the pro-oncogenic protein AGR2 in two humanMCF7
breast cancer cell lines and human melanoma cell line A375
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The results demonstrate that one MCF7 cell line (American) expresses
AGR2 at very high levels, and in comparison, a second MCF7 breast cancer
cell line (European) expresses much lower levels of the protein. A third cell
line, human malignant melanoma cell line A375, was also tested and found to
be absent for AGR2 expression at both the mRNA (not shown) and protein
levels, making this a useful tool for analyses. The expression of AGR2 was also
analysed in both MCF7 cells lines by immunofluorescence using both the anti-
AGR2 polyclonal and anti-AGR2 monoclonal antibodies (Figure 4.2C, D). The
localisation of endogenous AGR2 is somewhat different in the two MCF7 cells
lines. AGR2 localised to both the endoplasmic reticulum (ER) and cytoplasm
with a small amount in the nucleus in American MCF7 cells. Although co-
localisation with ERmarkers was not shown in these figures, the ER association
of AGR2 has been reported previously using co-localisation with ER markers
by immunofluorescence [Fourtouna et al., 2009]. In addition, the distribution
pattern of AGR2 mainly in the ER and with some localisation to the cytoplasm
and nucleus is also in agreement with previous data [Fourtouna et al., 2009].
In contrast, the localisation of AGR2 in European MCF7 cells appears less
diffusely distributed, and is also at lower levels, in agreement with the protein
blot described above. In order to evaluate the specificity of the anti-AGR2
polyclonal antibody by immunofluorescence, high-Agr2-expressing MCF7 cells
were transfected with siRNA to AGR2 and analysed by immunofluorescence
and western blot after 72h incubation, using anti-AGR2 polyclonal antibody
K47. AGR2 was knocked down in this cell line as seen by western blot and
by immunofluorescence, compared to control siRNA or untransfected controls,
validating the polyclonal antibody for use by immunofluorescence (Figure 4.3).
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Figure 4.3: Knockdown of AGR2 using AGR2-specific siRNA in MCF7 (Amer-
ican) breast cancer cells
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4.2.2 Linear Peptide Motif Interaction with AGR2
In order to evaluate the ability of the hexapeptide PTTIYY to bind native
AGR2 in cell culture, MCF7 (American, high AGR2-expressing cells) were
tranfected with GFP-aptamers (GFP-hexapeptide fusion) as shown in Figure
4.4A. Three cloned GFP-tagged aptamers (gifted by Argyro Fourtouna, Hupp
lab) as shown were tested for their ability to bind AGR2; GFP-PTTIYY rep-
resenting the minimal hexapeptide, GFP-PTTIYA mutant, and GFP-STOP-
PTTIYY in which a stop codon was inserted before the PTTIYY generating
native GFP expression. The PTTIYA mutant peptide had previously been
shown to reduce binding to AGR2 in vitro by ELISA [Murray et al., 2007].
The constructs were transiently transfected into MCF7 (American) cells and
incubated for 24 hours before fixing and analysis by immunofluorescence. A
polyclonal antibody to AGR2 (Moravian Biotech, K47) was used to visualise
endogenous AGR2 in these cells, and colocalisation to expressed GFP was
evaluated by confocal microscopy.
In MCF7 (American) cells transfected with the GFP-stop codon-PTTIYY
aptamer, AGR2 was seen to localise primarily to the endoplasmic reticulum
(ER) as previously reported [Fourtouna et al., 2009] whilst expressed GFP
was seen to accumulate in the nucleus as is commonly seen with untagged,
expressed GFP (Figure 4.4). Cells transfected with GFP-PTTIYA aptamer
were similarly seen to accumulate expressed GFP in the nucleus, with AGR2
localising to the ER as expected. In contrast, in cells transfected with the
GFP-PTTIYY aptamer, GFP was seen to partially co-localise with AGR2 in
the ER, with less GFP accumulation in the nucleus.
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Figure 4.4: Partial co-localisation of GFP-tagged peptides with AGR2 in
MCF7 breast cancer cells
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This differential distribution suggests that AGR2 and the hexapeptide
are bound in these cells either directly or in a complex, retaining expressed
GFP in the ER. Whilst these data suggest that the AGR2-peptide interaction
identified in vitro also holds true in cell culture, colocalisation does not in it-
self demonstrate a direct interaction, nor does it allow accurate quantification
of the interaction compared to controls. A technique that has been devel-
oped recently by outside groups (in collaboration with the Edinburgh Cancer
Research Centre) that can help identify direct protein-protein interactions is
known as proximity ligation assay. This technique involves binding of primary
antibodies to the proteins of interest, followed by ligation of oligonucleotides
(fused to secondary antibodies) that are within very close proximity (less than
40nm), coupled with polymerase rolling circle amplification and fluorescent
probe hybridisation [Gullberg et al., 2003] [Jarvius et al., 2006] (Figure 4.5B).
This results in a binary signal from a particular fluorophore that should only
be visible when the initial ligation event has occurred (ie when the two proteins
of interest are in close enough proximity).
MCF7 (American) cells were transfected with the GFP-PTTIYY ap-
tamer, GFP-PTTIYA aptamer, or GFP-STOP-PTTIYY aptamer, and incu-
bated for 24 hours. In addition, cells were transfected with HA-tagged Reptin,
a known AGR2-binding protein [Maslon et al., 2010] as a positive control.
After fixing and permeabilising, fixed cells were incubated with monoclonal
anti-GFP (Abcam 1218, raised in mouse) and polyclonal anti-AGR2 (Mora-
vian Biotech, K47, raised in rabbit). Oligonucleotide-fused secondary antibod-
ies from O-link Bioscience against either mouse or rabbit were bound to the
primary antibodies and then amplified by rolling circle polymerisation.
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Figure 4.5: Proximity Ligation Assay describes varying degree of co-
localisation of peptides with AGR2
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A red (DsRed) fluorophore-conjugated probe for the amplified oligonu-
cleotide was hybridised and the signals analysed by fluorescence microscopy.
Seven z-stacks were taken for each of 60 individual fields of sight for each con-
dition, and each set of seven stacks was merged to form one image giving a
total of 60 images per condition. This was done to ensure that signals were
not missed due to being out of the focal plane, giving a clear picture of number
of signals throughout the depth of the cell. The signals were analysed using
a proprietary software (Ariol) designed in part by a lab at CRUK (Dr John
Bartlett’s group), in which the software is taught to define cell boundaries,
and count fluorescent signals of a given size per cell and per field of vision.
The results were disappointing, in that there appeared to be a high level
of noise in the system. The Proximity Ligation Assay technique is becoming
more common as a tool to study protein-protein interaction and localisation,
however, inherent in the system is a reliance on specificity of the primary
antibodies due to the quantitative nature of the assay. A single proximity
event can be amplified to produce a fluorescent signal making the assay more
sensitive than standard immunofluorescence. Unspecific binding or insufficient
washing can cause noise in the system, resulting in poor or ambiguous results.
Cells transfected with HA-tagged Reptin and incubated with anti-HA and anti-
AGR2 primary antibodies did yield nuclear DsRed fluorophores as expected
although these were not quantified. In the case of the inital GFP-aptamer -
AGR2 interaction assay, there did appear to be a difference in the number
of cytoplasmic signals between the PTTIYY aptamer and GFP alone, with
the PTTIYA mutant at an intermediate level between the two (Figure 4.5C).
However, a high level of signal was seen even with the GFP-STOP-PTTIYY
138
4.3. IDENTIFICATION AND VALIDATION OF LINEAR
PEPTIDE-CONTAINING HUMAN PROTEIN MECKELIN AS POSSIBLE
AGR2-BINDING PROTEIN
aptamer. This suggests that there may be unspecific binding between GFP
alone and AGR2, or that the GFP antibody or anti-AGR2 antibody is not
specific enough for this assay. Attempts to optimise the AGR2 antibody or
GFP antibody to reduce background signal were unsuccessful and therefore
we did not repeat the assay using this technique. Nevertheless, the initial
proximity ligation assay supports the findings from the immunofluorescence
data and biochemical techniques that the PTTIYY aptamer binds AGR2.
4.3 Identification and validation of linear peptide-
containing human protein Meckelin as pos-
sible AGR2-binding protein
Phage-peptide display as a technique was useful in identifying the AGR2-
binding hexapeptide PTTIYY as discussed above, but the next question was
whether this information could now be used to identify AGR2-binding proteins
in the human proteome. The hexapeptide, or linear motif, was shown in vitro
to be highly specific (Figure 4.1) for binding to AGR2, and the published Kd
for the interaction between the hexapeptide and AGR2 is in the µM range.
This is in agreement with the peptide ligand-protein dissociation constants
of other molecular chaperones that must be able to bind and release their
substrates under physiological conditions [Feifel et al., 1998], unlike ligands
such as pharmacological drugs that often have dissociation constants in the
nanomolar range. We used the results of the alanine-scan and substitutional
mutation scan of the linear peptide motif published by Murray et al. (2007) and
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Fourtouna et al. (2009) to probe the human genome and search for potential
AGR2 interacting proteins.
4.3.1 Database mining the human proteome for linear
peptide motif
The original phage display peptide was a 12-mer with the sequence HLPT-
TIYYGPPG. By truncating the 12-mer from the N-terminal it was shown that
the presence of the first position of the hexapeptide was essential for binding
to AGR2, however, this position was labile in its identity, and the alanine scan
showed that mutation of the proline to an alanine did not significantly affect
binding to AGR2 [Murray et al., 2007]. Similarly, truncation of the 12-mer
from the C-terminal indicated that the final tyrosine residue in position 6 of
the hexapeptide was essential for binding, reducing the core binding motif
to a hexapeptide. A mutational scan of the linear peptide motif determined
which residue substitutions could be tolerated to maintain binding affinity to
AGR2 [Fourtouna et al., 2009]. A competition assay determined which residues
could be substituted in each of the six positions of the hexapeptide, resulting
in a linear peptide motif with the sequence X-[TS]-[AGNQPLMVITS]-I-[YF]-
[YF] (Figure 4.6 A). Positions 2, 4, 5 and 6 in the hexapeptide were found to be
relatively fixed, tolerating only moderate changes to their identity. Threonine
and serine at position 2 are similar in that they are both polar amino acids
bearing an alcohol group, and tyrosine and phenylalanine are also very similar
in that they are both aromatic amino acids bearing a large circular benzene
ring and share similar structure, indicating a possible spacing requirement for
maximal binding of the peptide to the AGR2 protein.
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Figure 4.6: Database mining of human genome for proteins containing linear
doman motif
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The linear peptide and its possible substitutions represented a potential
candidate for an in vivo binding motif for AGR2. To look for proteins in the
human proteome that contain this linear peptide motif, we used a search engine
from the Prosite website called Motifscan. This database search resulted in 225
hits when multiple isoforms of the same gene were excluded (Appendix I). This
list of hits was analysed for both functional and structural/localisation trends.
Among the hits were cilia-associated proteins, protein-folding and transport-
associated proteins, glycosylases, solute transporters and ion channels, and
cancer-associated proteins. Interestingly, a large proportion (74 percent) of the
hits were secreted or transmembrane proteins, suggesting a role for AGR2 in
maturation or chaperoning of this class of protein. In fact, both the 2009 AGR2
mouse knockout paper [Park et al., 2009] and another more recent paper [Norris
et al., 2012] suggest a role for AGR2 as an ER chaperone for MUC2 and MUC1
respectively, as well as another mucin family member, MUC5AC [Schroeder
et al., 2012] with both of these being secreted proteins, in agreement with the
large number of transmembrane and secreted proteins found in the database
search. Furthermore, a large number of all the hits from the search were large,
cysteine-rich proteins that undergo extensive post-translational modifications,
again in agreement with the characteristics of MUC2, MUC1 and MUC5AC.
Using a web-based program (ToppFun, http://toppgene.cchmc.org/ en-
richment.jsp), we input all the gene names that were identified by the Prosite
Motifscan program. Programs for probing enrichment patterns of a given gene
set have been described previously [Subramanian et al., 2005], and this gene set
enrichment program is based on the same concept but with more options avail-
able. The program assesses a user-defined set of genes for enrinchment of var-
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ious parameters compared to the genome as a whole. These include GO (gene
ontology) terms, co-expression analysis, protein class, or disease associations.
The output provides a measure of the enrichment of the gene set compared to
the genome for a particular parameter. The measure is given as a P-value that
represents the statistical significance of the parameter’s over-representation in
the gene set compared to the genome. The results are displayed from highest
over-representation for whichever parameter has been chosen to lowest, with
“top” scorers topping the output list. The results can help give a picture of
the biological function or cellular localisation of a gene set, or provide global
information about gene expression clusters or networks. A complete list of all
the hits can be found in Appendix I, and some sample spreadsheets from the
input of our gene set into the ToppFun program are in Appendix II.
When biological function is used as a parameter for comparison, the
top 8 scores are all related to transport across the plasma membrane. The
top score is transmembrane transport with a P-value of 3.49e−14. In fact, 17
of the top 20 scores are related to transport, the lowest of these still with
a P-value of 2.97e−05. When a different parameter, Molecular Function, is
analysed, the top scores are neurotransmitter symporter/transporter activity
(P=1.44e−21 and P=1.26e−19 respectively). Also of note for this category, is
G-protein coupled receptor activity with a P-value of 4.03e−13. Using Cellular
Component as a parameter, the top score for enrichment is proteins integral to
plasma membrane (P=1.48e−11) and proteins found at the apical surface of the
plasma membrane (P=2.46e−06). These high levels of enrichment further sup-
port a role for AGR2 in the secretory pathway. Another cellular compartment
highly enriched included the cilium (including axoneme), with a P-value of
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4.86e−3. In addition, when the Prosite Motifscan list was analysed for known
gene expression patterns from Gudmap (a consortium of transcript and mi-
croarray data from mouse tissue) [Harding et al., 2011], kidney tissue types
were enriched including renal podocytes (P=2.78e−03), renal proximal tubules
(P=2.19e−03), renal cap mesenchyme (P=2.89e−02) and renal S-shaped bod-
ies (early nephrons) (P=1.89e−03). The possible significance of this will be
discussed further in Chapters 6 and 7.
The high over-representation of the neurotransmitter transporter activity
and G-protein coupled receptors (compared to other membrane transporters or
receptors) suggests that the AGR2-binding linear peptide motif identified by
phage peptide display proteomics is a valid motif and not simply due to a bias
inherent in the phage display process. Furthermore, Cathepsin D was identi-
fied in the list of hits, a lysosomal protease whose secretion has previously been
shown to be promoted by AGR2 in pancreatic cancer cells [Dumartin et al.,
2011], as was a member of the mucin family, MUC16 (also known as CA125),
a glycoprotein that is over-expressed in mucinous ovarian cancers, promotes
tumour invasiveness, and is associated with poor prognosis [Streppel et al.,
2012]. AGR2 has previously been shown to interact with other members of
the mucin family, and to be essential for their maturation and secretion [Park
et al., 2009] [Norris et al., 2012]. In addition, MUC16 has been shown to bind
mesothelin, promoting cell adhesion and metastasis [Rump et al., 2004], and
mesothelin is another protein identified in the Prosite Motifscan list as contain-
ing the AGR2-binding linear peptide motif. As mentioned in the Introduction,
over-expression of AGR2 is highly associated with onset and negative progno-
sis of mucinous ovarian cancers, and the presence of a putative linear peptide
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binding motif in both MUC16 and mesothelin suggests a possible functional
pathway involving AGR2.
Of the numerous proteins identified within the human proteome con-
taining the linear peptide motif, we decided to focus on validating a few in
particular in order to test our system of using phage-peptide interactomics to
identify interactions in vivo. One of these was a human transmembrane protein
called MKS3, or TMEM67 (Meckelin). We chose MKS3 as it fit the criteria of
the largest group identified by the Prosite motifscan data, namely, it is a large
(995 amino acid), glycosylated [Smith et al., 2006], 3-transmembrane protein
(predicted) with numerous cysteines (26 in the N-terminal region) [Flicek et al.,
2012] (Figure 4.7). The protein is evolutionarily conserved, with homologues
in C. elegans and D. melanogaster, but no known paralogues [Dawe et al.,
2007b]. The predicted N-terminal structure of the protein has putative topo-
logical similarities to the Frizzled family of receptors [Dawe et al., 2007b], a
family that has been implicated in Wnt ligand signalling and in differentiation
and development [Bhanot et al., 1996]. It also harbors an N-terminal signal
peptide that may target it to the secretory/membrane pathways [Smith et al.,
2006]. It has been shown to be involved in centriole migration that is essential
for initiation of ciliation in mammalian cells [Dawe et al., 2007b] as well as mi-
tosis, and Meckelin is a gene that, when mutated in humans causes ciliopathies.
Numerous different mutations have been described leading to varying levels of
severity of disease. In the case of Meckel-Gruber syndrome neonatal or in
utero death occurs [Chen, 2007] [Gunay-Aygun et al., 2009], however other
mutations in Meckelin lead to less severe phenotypes [Baala et al., 2007].
MKS3 wild type protein localises to the ER and Golgi, plasma membrane
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Figure 4.7: Human Meckelin (TMEM67, MKS3, meckelin) - Gene and protein
domains
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and primary cilium in ciliated cell lines [Dawe et al., 2007b] as well as to ba-
solateral actin cables [Dawe et al., 2009] [Adams et al., 2012]. In addition, it
is seen to localise to the mitotic spindle in dividing cells (personal communi-
cation, C Johnson, Leeds). In ciliated cell lines depleted of MKS3 protein by
siRNA, migration of the centrioles to the plasma membrane is blocked, leading
to loss of cilia [Dawe et al., 2007b]. Furthermore, epithelial branching morpho-
genesis was also severely impaired, indicating a role for Meckelin in epithelial
morphogenesis, although the mechanisms for this are unclear. In contrast, in a
spontaneous Meckelin mouse knockout a different phenotype is observed, with
abnormally long cilia seen rather than an absence of cilia [Cook et al., 2009].
The primary cilia in mammalian cells act as sensors that play an important
role in signal transduction, differentiation [Satir and Christensen, 2008], and
cell cycle [Plotnikova et al., 2009] and are required for the proper development
of many organs. In addition, cilia are easily visualised in many cell lines using
immunofluorescence microscopy, and thus can provide a readout for phenotypic
changes. One of the symptoms of ciliopathies caused by mutations in Meckelin
is polycystic kidneys. The ToppFun suite analysis of the putative AGR2-
binding linear peptide motif identified that cilia-associated genes and genes
expressed in the developing kidney were strongly over-represented. Taken to-
gether, we felt that Meckelin represented an ideal candidate for demonstrating
proof-of-concept that phage-display proteomics could be used to identify rele-
vant biological interactions in vivo, and if correct, could provide insight into a
biological role for Agr2.
147
4.3. IDENTIFICATION AND VALIDATION OF LINEAR
PEPTIDE-CONTAINING HUMAN PROTEIN MECKELIN AS POSSIBLE
AGR2-BINDING PROTEIN
4.3.2 Validating the AGR2 - MKS3 Interaction
As a starting point, we decided to test a putative interaction between MKS3
and AGR2 using co-immunoprecipitation (CoIp). CoIp involves capturing a
target protein using an antibody against that protein, and then binding the
heavy chain of the antibody indirectly to a solid phase (e.g. Sepharose beads
covalently linked to Protein A or Protein G which bind the heavy chains of most
antibodies). The captured protein may remain bound to another protein or
even complex of proteins, and when the unbound protein pool is washed away,
the remaining bound protein(s) can be identified using standard biochemical
techniques such as western blot or mass spectrometry. It is a technique that
is widely used and can be a powerful means of identifying physiologically rele-
vant protein interactions. As a technique, however, it does have its limitations,
as it will only identify protein-protein interactions that are stable enough to
withstand the process. As a result, more transient interactions may be over-
looked, and the system may be prone to inconsistency. Nevertheless, overex-
pressed, HA-tagged MKS3 (Figure 4.8A) was found to co-immunoprecipitate
with GFP-tagged AGR2 in both MCF7 (American) breast cancer cells and in
human metastatic melanoma cell line A375 (Figure 4.8B,C).
A375 cells were co-transfected with either C-terminally tagged GFP-
AGR2 or GFP vector (Clonetech pAcGFPN1), and wild type HA-tagged MKS3
(Figure 4.8B). AGR2 has been previously shown to bind and inhibit p53 [Pohler
et al., 2004], so we decided to investigate whether induction of p53 with u.v.
light had any effect on Meckelin binding to AGR2. Cells transfected with
GFP-AGR2 were subjected to u.v. at 50J/cm2, or not treated, as shown in
Figure 4.8B, and then incubated overnight.
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Figure 4.8: Overexpressed HA-tagged Meckelin co-immunoprecipitates with
GFP-tagged AGR2 in human breast cancer cell line MC7 and human
melanoma cell line A375
149
4.3. IDENTIFICATION AND VALIDATION OF LINEAR
PEPTIDE-CONTAINING HUMAN PROTEIN MECKELIN AS POSSIBLE
AGR2-BINDING PROTEIN
After lysis, GFP-AGR2 was immunoprecipitated from the lysate with
anti-GFP monoclonal antibody (abcam 1218), and antibody/antigen com-
plexes were pulled down on Protein G-Sepharose beads and analysed by west-
ern blot. The blot was probed using anti-AGR2 polyclonal antibody K47
(described above) to confirm pulldown of GFP-AGR2 (50KDa), and was then
reprobed using anti-HA monoclonal antibody (Abcam 18181). Full length
MKS3 is predicted to migrate at 110KDa [Flicek et al., 2012], however, both
untagged and HA-tagged Meckelin has also been described as migrating at 120-
130KDa [Dawe et al., 2007b] [Dawe et al., 2009], possibly indicating some form
of post-translational modification. The significance of this potential modifica-
tion has not been reported. A western blot of HA-tagged Meckelin indicates
that both the 110 and 130KDa forms can be seen in transfected cells (Figure
4.8A). In addition, lower bands were clearly observed, and similar bands ob-
served in this thesis using anti-V5-tag and anti-MKS3 antibodies (Figures 4.12
and 5.1), as well as anecdotal reports from other groups that observe similar
bands using different antibodies, suggest that these may represent processed
or alternative isoforms that have not yet been characterised.
Overexpressed HA-tagged MKS3 co-immunoprecipitated with GFP-tagged
AGR2 in A375 cells, with the 110KDa band appearing in u.v. treated cells,
and the 130KDa band appearing in both treated and untreated cells, but not
in cells transfected with GFP-vector control, indicating that neither the GFP
itself nor the beads bind MKS3. The significance of the second (predicted)
form of MKS3 at 110KDa in u.v. treated cells but not in untreated cells is
unclear, and may form part of future work on Meckelin. The lack of band of
appropriate size in the input lanes is disappointing, however, it is possible that
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transfection levels were low, with bands appearing in the immunoprecipitated
lanes due to concentration of the protein of interest (in this case MKS3) during
the immunoprecipitation process.
AGR2 contains a putative leader sequence at its N-terminal with cleav-
age site [Pohler et al., 2004] that would target it to the endoplasmic reticu-
lum (ER) membrane and secretory pathway. Previous work has shown that
a mature form of AGR2 lacking the N-terminal leader sequence (mAGR2)
localises to the nucleus and cytoplasm [Fourtouna et al., 2009] and further
studies have shown that AGR2 can bind reptin and p53, both primarily nu-
clear proteins [Maslon et al., 2010]. Furthermore, subcellular fractionation in
MCF7 (American) cells shows that AGR2 is localised mainly to the mem-
branes and organelles, but with a significant pool in the nucleus [Fourtouna
et al., 2009]. For this reason, we tested whether both the full-length (ER
and Golgi localised) and mature (nuclear and cytoplasmic) AGR2 could bind
MKS3 in cells (Figure 4.8C). In order to test both of these we transfected
MCF7 (American) cells with either C-terminally tagged RFP-mature AGR2 or
C-terminally tagged GFP-full length AGR2 together with HA-tagged MKS3.
Anti-GFP monoclonal antibody was used, as before, to pull down GFP-full
length AGR2 or RFP-mature AGR2, and then the antibody-antigen com-
plexes were bound to Sepharose-Protein G beads. Unbound fractions were
washed away and the bound antigen-antibody-interacting protein complexes
were eluted from the beads as described above. Only full-length AGR2 was
seen to co-immunoprecipitate with HA-tagged MKS3 in these cells, and not
mature AGR2. This is consistent with the cellular localisation of MKS3 in
the ER, Golgi and plasma membrane [Dawe et al., 2007b]. Interestingly, in
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these cells only the 110KDa-migrating band is seen despite not being treated
with u.v., and possibly indicating a cell-specific difference in dominant MKS3
isoforms. In addition, MKS3 was not seen to co-immunoprecipitate with the
mature form of AGR2 (lacking the N-terminal leader sequence) even when
the C-terminal ER-localisation motif was mutated to a strong ER-retention
sequence previously shown to restrict the mature form of AGR2 to the ER
rather than the nucleus (data not shown) [Fourtouna et al., 2009]. This sug-
gests that the N-terminal leader sequence may have an intrinsic quality that
is required for binding of AGR2 to MKS3.
We next wanted to investigate whether AGR2 and MKS3 could co-
localise in cell lines by immunofluorescence. To do this, we started with
MCF7 (American) breast cancer cells since they express high levels of endoge-
nous AGR2. MCF7 cells were transfected with HA-tagged wild type MKS3
and incubated for 24h. Cells were fixed and incubated overnight with anti-
AGR2 polyclonal antibody together with anti-HA monoclonal antibody, both
as described above. Cells were subsequently incubated with Alexa-fluorophore-
conjugated secondary antibodies (anti-mouse 488, anti-rabbit 594) and Topro-
3 nuclear stain, and analysed by confocal microscopy. The results show that
HA-tagged Meckelin partially colocalises with endogenous AGR2 in MCF7
cells in a perinuclear staining pattern (Figure 4.9A), in agreement with pre-
vious work showing that AGR2 colocalises with the ER and Golgi network
in these cells [Fourtouna et al., 2009]. Untransfected (Figure 4.9B) and no
primary (Figure 4.9C) controls indicate that there is no unspecific binding of
the HA antibody or of the secondary antibodies.
Further analysis in A375 cells co-transfected with GFP-tagged (full-
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Figure 4.9: Overexpressed HA-Meckelin and endogenous AGR2 partially co-
localise in human breast cancer cell line MCF7 (American)
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length) AGR2 and HA-MKS3 (Figure 4.10A) confirmed that the partial colo-
calisation of AGR2 and MKS3 is seen in a separate cell type, although in
this case using GFP-AGR2 rather than an antibody to the endogenous pro-
tein due to the lack of endogenous AGR2 in the human A375 melanoma cell
line. Controls for unspecific binding of the anti-HA antibody (Figure 4.10B)
and unspecific binding of the secondary antibody (Figure 4.10C) in these cells
showed that the antibody binding was specific and that untransfected cells did
not express GFP or have detectable auto-fluorescence in the GFP range.
In order to assess the expression and localisation of endogenous MKS3
by immunofluorescence in MCF7 cells, we used a polyclonal antibody to a
C-terminal peptide of MKS3 (kindly donated by C Johnson, Leeds). MCF7
cells were either transfected with HA-MKS3, or not transfected, then fixed
and incubated overnight with anti-AGR2 monoclonal antibody, and affinity
purifed anti-MKS3 C-terminal antibody. Cells transfected with HA-MKS3
demonstrated partial co-localisation with AGR2 in a very defined peri-nuclear
localisation as well as more diffuse colocalisation in what is likely to be the ER
(Figure 4.11A). This is similar to the localisation of the overexpressed MKS3
and AGR2 as described above. Interestingly, however, endogenous MKS3 was
only seen at the spindle poles during anaphase in dividing cells (Figure 4.11B),
whilst AGR2 was localised diffusely in the cytoplasm of these cells. MCF7 cells
in culture are not normally ciliated [Yuan et al., 2010], and therefore it is pos-
sible that the expression of Meckelin in these cells is cell cycle related, and
is temporally restricted to migration of the centrioles and initiation of cell
division. In contrast, HA-tagged MKS3 was not seen at the spindle poles,
suggesting that the tagged, transfected and overexpressed version of MKS3
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Figure 4.10: Overexpressed HA-MKS3 and GFP-tagged AGR2 partially co-
localise in human melanoma cell line A375
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Figure 4.11: Expression patterns of overexpressed HA-MKS3 and endogenous
MKS3 in MCF7 (American) breast cancer cells
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may not behave the same way as endogenous MKS3 in vivo, or that differ-
ent isoforms may be localised to different compartments. The differences seen
between endogenous MKS3 and overexpressed, HA-tagged MKS3 must be con-
sidered when assessing a putative interaction with AGR2 in cell lines.
4.3.3 Assessing the effect of mutations in the linear pep-
tide motif
The putative interaction between AGR2 and MKS3 was identified based on
a linear peptide motif as described in section 4.3.1. In order to test whether
this was in fact a site of interaction, mutants of MKS3 were cloned with mu-
tations in the linear peptide motif. The wild type sequence of the motif in
MKS3 is PTPIFY (note similarity to the linear peptide identified by phage
display of PTTIYY). As previously described, mutation of the final residue in
the hexapeptide motif to an alanine restricted binding of AGR2 by ELISA,
therefore, we made two N-terminally V5-tagged mutants; one double mutant
where the linear peptide motif was mutated to the optimal PTTIYY, and one
single mutant with the final tyrosine residue mutated to an alanine. MCF7
(American) cells were transfected with wild type or mutant V5-tagged MKS3,
or an irrelevant 14kDa V5-tagged protein, and V5-tagged isoforms were tested
for expression in mammalian cells (Figure 4.12A). We then looked for differ-
ences in co-localisation by immunofluorescence of the mutants compared to
the wild type sequence.
We found that mutating the final tyrosine residue in the linear peptide
motif of MKS3 restricted co-localisation with endogenous AGR2, although
157
4.3. IDENTIFICATION AND VALIDATION OF LINEAR
PEPTIDE-CONTAINING HUMAN PROTEIN MECKELIN AS POSSIBLE
AGR2-BINDING PROTEIN
Figure 4.12: Effect of mutations in the putative AGR2-binding linear domain
motif of V5-MKS3 in human breast cancer cell lines - Part I
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it did not completely abolish it (Figures 4.12B, Figure 4.13). In contrast,
mutating the wild type motif to the optimal motif PTTIYY enhanced co-
localisation compared to the PTPIFA mutant. This is in agreement with
the biochemical findings that mutation of the final tyrosine in position 6 to
anything other than tyrosine or phenylalanine restricted the ability of AGR2
to bind the peptide. The differences in colocalisation between AGR2 and wild
type or mutant MKS3 was also seen in cell line A375 (data not shown).
We next wanted to assess the effect of transfecting either wild type or
mutant MKS3 on endogenous AGR2 localisation in MCF7 cells. Cells were
transfected with V5-tagged wild type, PTTIYY mutant or PTPIFA mutant
MKS3 and incubated overnight. Cells were fractionated into four fractions;
cytosolic proteins, membrane and organellar proteins, nuclear proteins and cy-
toskeletal proteins. Lysates were analysed by western blot and probed using
anti-AGR2 polyclonal antibody. We found that overexpression of any of the
V5-tagged versions of MKS3 led to concentration of AGR2 in the membrane
and organellar fraction and a reduction of AGR2 in the nuclear and cytoplas-
mic fractions (Figure 4.12C). This suggests that there may be more than one
site of interaction, or that a binding-independent signalling pathway may be
responsible for accumulation of AGR2 in the membranes and organelles when
one of its target substrates is overexpressed, such as through the unfolded
protein response (UPR).
Although the contrast between the PTPIFA mutant and the wild type
or double mutant was noted qualitatively, we wanted to assess the differences
between the motif mutants and wild type in a quantifiable manner. One of
the resident locations for the transmembrane protein MKS3 is the plasma
159
4.3. IDENTIFICATION AND VALIDATION OF LINEAR
PEPTIDE-CONTAINING HUMAN PROTEIN MECKELIN AS POSSIBLE
AGR2-BINDING PROTEIN
Figure 4.13: Effect of mutations in the putative AGR2-binding linear domain
motif of V5-MKS3 in human breast cancer cell line MCF7 (American): Part
II
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membrane [Dawe et al., 2007b]. We hypothesized that a reduction in the
affinity of binding to AGR2 caused by a mutation in the linear peptide motif
PTPIFY might alter the dynamics of localisation of MKS3 at this cellular
compartment.
The mechanism by which integral, transmembrane proteins mature and
arrive at their resident location is through the secretory pathway. Hydropho-
bic patches are shielded from the aqueous intracellular environment through
vesicular transport, and by association with chaperone proteins [Lodish et al.,
2000]. Integral membrane proteins first insert into the ER membrane co-
translationally, before moving into the trans-Golgi network and secretory path-
way. Secretory, or ER-lumen bound proteins must pass through the ER mem-
brane into the ER lumen, and this includes resident chaperone proteins such
as BiP (Grp78) [Vitale and Denecke, 1999] (Figure 4.14A). For many trans-
membrane proteins this process in the ER is mediated by an N-terminal leader
sequence (signal peptide), although most multi-spanning transmembrane pro-
teins also insert into the ER membrane thanks to the secondary structure of
their transmembrane domains (termed signal anchor sequence) that resembles
a signal peptide but is not cleaved [Lodish et al., 2000]. Both AGR2 and
MKS3 contain putative N-terminal signal peptides (Figure 4.14B) [Petersen
et al., 2011] with putative cleavage sites, although N-terminally tagged HA-
MKS3 does not lose either the HA-tag or correct localisation [Dawe et al.,
2007b], indicating that the signal peptide is not cleaved at least in the tagged
form. Once integral or trans-membrane proteins are trafficked to the plasma
membrane through the trans-Golgi network, the cargo vesicles fuse with the
plasma membrane in a poorly understood process, inserting the protein into
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Figure 4.14: Both AGR2 and MKS3 contain putative signal peptides at their
N-terminus
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the membrane in the correct orientation [Lodish et al., 2000].
In order to look for changes to the localisation of MKS3 at the plasma
membrane, we needed a technique that allowed us to visualise secretory or
membrane protein-loaded vesicles at high resolution, at the plasma membrane
or just beneath it. Visualising vesicles at the plasma membrane by microscopy
can be challenging due to fluroescence signal from outside the field of interest,
and the small depth of the area being investigated. A technique termed Total
Internal Reflection Fluorecence Microscopy (TIRF-M) is a very powerful way
of imaging the precise location of the plasma membrane and any associated
vesicles [Loder et al., 2013] [Mattheyses et al., 2010]. The principle of TIRF
microscopy (Figure 4.15) uses the difference in the refractive indices of two
media, in the case of TIRF-M, the glass coverslip on which cells are grown and
aqueous medium above it containing the specimen. To achieve total internal
reflection, the refractive index of the specimen must be lower than the coverslip.
By shining a laser beam at the sample through a prism, the reflective quality
of the laser beam as it passes through the glass and then the aqueous medium
causes an evanescent wave to be emitted at the interface between the glass and
the aqueous medium before it is reflected away from the specimen. This means
that only the fluorophores within the evanescent wave are excited, producing
images clear of background noise and allowing fluorescence imaging down to
single-molecule resolution when combined with other imaging techniques such
as Fluorescence resonance energy transfer (FRET) [Holden et al., 2010]. The
excitation wave (produced by the laser beam as it hits the differing refractive
indeces of the interface) decays exponentially as the distance increases away
from the coverslip.
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Figure 4.15: Total Internal Reflection Microscopy
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The depth can be altered by changing the angle of the laser beam, producing
a larger or smaller volume for the excitation wave. In principle, the highest
resolution is restricted to a depth of approximately 100nm.
We used TIRF-microscopy to image MKS3 at or just beneath the plasma
membrane. TIRF microscopy and quantification analysis was carried out
with the help of Prof R Duncan, Heriot Watt University. MCF7 (American)
cells were co-transfected with GFP empty vector (pAcGFPN1) and either V5-
tagged MKS3 wild type (human 995 residue isoform), V5-tagged MKS3 (PT-
PIFA) mutant, or V5-tagged MKS3 (PTTIYY) double mutant and incubated
overnight on coverslips. Cells were then fixed, permeabilised and incubated
with mouse monoclonal anti-V5 (Abcam 27672) and rabbit anti-E-cadherin
primary antibody, before adding fluorophore-conjugated secondary antibod-
ies. Coverslips with fixed and stained cells were then placed in a chamber
filled with aqueous solution (PBS) and analysed by Total Internal Reflection
Fluorescence Microscopy. E-cadherin was used as a positive control to ensure
that the cell membrane was being accurately visualised and to control for de-
tachment of the cells from the coverslip, and expressed GFP was used to locate
and define the boundaries of transfected cells (data not shown). V5-vector and
secondary antibody-only controls were also imaged for unspecific primary or
secondary antibody binding (previously shown in these MCF7 cells in Figure
4.13 and Figure 4.2C), and only a negligible signal was detected (data not
shown).
V5-tagged MKS3 was clearly visualised in transport vesicles at or just
beneath the plasma membrane. TIRF microscopy allows visualisation of the
adherent plasma membrane as described above, suggesting that MKS3 may
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localise to the basolateral plasma membrane (although MCF7 cells do not
normally thought to be polarised). MKS3 has not been described at the baso-
lateral membrane previously, and therefore this may represent a novel cellular
localisation for the protein. A representative image of vesicles of wild type V5-
MKS3 can be seen in the large image, with representative images of vesicles
for each of the V5-tagged MKS3 forms shown in the inset boxes, as labelled
(Figure 4.16A). Of note is that the V5-MKS3-containing vesicles seen at the
plasma membrane for the PTPIFA mutant are not absent (although the sig-
nals were of much lower intensity, gain on representative image shown here is
increased to allow visualisation). When the data were examined for number
of vesicles (or vesicle-sized signals) at the plasma membrane, the number of
signals seen for the PTPIFA mutant was increased compared to the wild type
or the PTTIYY double mutant (vesicle counting was automated) as shown in
Figure 4.16B. Closer inspection of the vesicles seen in Figure 4.16A reveals
that the "vesicles" are much larger than in either the PTTIYY or wild type-
transfected forms of V5-MKS3, and that they appear as diffuse, aggregated
bundles rather than the clear, discrete vesicles seen for the PTTIYY or wild
type. Widefield images for each of the isoforms were also taken immediately af-
ter acquiring the TIRF-M images and then deconvolved to produce 3D images
of the cell (Figure 4.16C). The distribution pattern of V5-MKS3 (PTPIFA) in
these cells is clearly different than wild type MKS3, with evidence of a diffuse
localisation pattern compared to the distinct vesicular and ER/Golgi-like lo-
calisation pattern of the wild type. This suggests that the PTPIFA V5-MKS3
mutant, whilst still able to reach at least one of its target destinations, may
be improperly folded leading to aggregates of misfolded protein.
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Figure 4.16: Differential localisation of MKS3 wt and linear-peptide mutant
in MCF7 breast cancer cells by TIRF-M (Total internal reflection microscopy)
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This is supported by the migration pattern of V5-MKS3 from transfected
lysates (Figure 4.12), which shows more aggregated protein at the top of the
wells in the PTPIFA mutant compared to the wild type or the PTTIYY mu-
tant. What is more difficult to assess, even using TIRF-M, is whether or
not the PTPIFA mutant is able to insert into the plasma membrane - this
would require correct insertion of the nascent protein into the ER membrane
as described above.
We also wanted to assess whether AGR2 was localised in vesicles at
or beneath the plamsa membrane, in a similar compartment to V5-MKS3
as seen by TIRF-M. Cells were transfected with C-terminally tagged GFP-
AGR2 or GFP vector only and incubated overnight. Cells were then fixed
and permeabilised as described above and visualised using TIRF-M also as
described. GFP-tagged AGR2 was seen to localise to the plasma membrane
in vesicles (Figure 4.16D, bottom panel). Similarly, endogenous AGR2 was
also seen to localise to vesicles at the plasma membrane. In this case, fixed
and stained MCF7 (American) cells were incubated with primary antibody
(anti-AGR2 monoclonal) and Alexa secondary antibody to allow visualisation
of the endogenous protein. Although it is encouraging that AGR2 is seen at
the plasma membrane in secretory vesicles in a similar way to MKS3, it is
not possible to colocalise the signals using TIRF-M, and therefore no specific
conclusions can be drawn about whether AGR2 and MKS3 are directly binding




In this chapter evidence has been presented to support a possible interaction
between a linear peptide motif-containing protein, identified through phage-
display proteomics, and its binding partner. Specifically, we have shown that
AGR2 partially co-localises with a linear peptide in vivo (supporting previous
data showing that the linear peptide and AGR2 bind in vitro), and that this
linear peptide is found in a number of membrane and secretory proteins in the
human genome. In addition, we have shown that AGR2 and overexpressed
MKS3 can be co-immunoprecipitated from cell lines, and that overexpression
of MKS3 alters the balance of subcellular localisation of AGR2, concentrating
it into the membranes and organelles. We have also shown that mutating the
linear peptide motif, identified from the phage display proteomics, in MKS3,
affects both the degree of colocalisation of MKS3 and AGR2, and the cellular
localisation of MKS3 as seen by TIRF-microscopy. The evidence presented in
this chapter does not conclusively demonstrate an interaction between MKS3
and AGR2, however, it does support a possible interaction between these two
proteins. Further indirect evidence of a possible interaction between AGR2 and
MKS3 will be presented in Chapter 6, and future work will be required to show
a functional interaction between the two proteins. This will include siRNA-
mediated depletion of AGR2 to investigate the effect on MKS3 localisation by
TIRF-M (although this would only support a functional interaction rather than
direct binding). FRET studies to evaluate the binding of AGR2 to MKS3 wild
type and mutants at the plasma membrane is also planned, as is depletion of
AGR2 in epithelial, ciliated cell lines such as IMCD3 cells (discussed later), and
analysis of cilia phenotype. The idea of AGR2 as a molecular chaperone has
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been suggested before [Park et al., 2009], although this has not been proven.
These data lend support to the model of full-length AGR2 as a chaperone
protein resident in the ER and involved in the processing and maturation of
large, cysteine-rich membrane or secretory proteins.
The discovery of a putative novel interacting partner for the disease pro-
tein AGR2 is potentially important both for helping us to understand the
function of AGR2 and for providing a model system for investigating AGR2-
linked pathways. The discovery is potentially all the more important in that
it provides validation that phage-display proteomics could be harnessed to
identify interacting partners and networks on a larger scale. Furthermore, it
may add to the growing field of interactomics in which protein-protein interac-
tions are increasingly seen to be mediated by linear peptides binding to larger
globular domains.
In the process of investigating the interaction between AGR2 and MKS3
we discovered that commercially available anti-Meckelin antibodies did not
perform well, at least when used in our assays. Indeed, it is for this reason
that much of the work described in this chapter was carried out using tagged,
overexpressed Meckelin. We felt that having a reliable antibody made would
be useful for our studies, and therefore designed a strategy to have a new
polyclonal antibody made by a commercial group. The next chapter describes




Design and Characterisation of
Novel Anti-MK3 Antibody
5.1 Introduction
Antibodies are small multi-subunit protein complexes that are produced by
both higher and lower vertebrates [Marchalonis and Edelman, 1965] as part
of the immune system. They are also known as immunoglobulins, and are
Y-shaped glycoproteins produced by B-cells [Janeway et al., 2001]. Their ba-
sic structure is composed of four polypeptide chains, with two heavy chains
and two identical light chains held together by disulphide bonds [Tonegawa,
1983]. In mammals, there are five different types of heavy chain, and these
define the class of antibody (IgA, IgD, IgE, IgG, IgM). IgG is the main class of
antibodies responsible for detecting and binding to invading pathogens [Burry,
2010]. The variable region on the tips of the “Y” shape represents the antigen-
binding domain [Hilschmann and Craig, 1965]. This region is made by somatic
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recombination events in B-cells (cells of the immune system in vertebrates),
also called VJD recombination [Tonegawa, 1983], and the variable region may
recognise and bind a peptide from the target protein, or several disjointed
sequences from a folded protein forming a single epitope [Burry, 2010]. Ran-
domly produced antibodies made by VJD recombination in the B cells of the
bone marrow circulate in the body at low concentrations. When a pathogen
such as a bacterium or virus is present at high enough levels in the body, an
antibody containing a variable region that specifically recognises a part of that
antigen (the epitope) binds the antigen and begins a chain of events that may
include clonal expansion, where the B-cells begin to manufacture high levels of
that particular antibody containing that specific variable region. In this way
the circulating concentration (or titre) of the antibody is increased [Janeway
et al., 2001]. Vaccination works in this way, exposing the body to a particular
foreign antigen to increase the circulating titre of its corresponding antibody
so that the body is pre-primed for defense in the event of exposure.
In the last few decades, it has become possible to harness the ability of
vertebrates to produce specific antibodies in response to antigen exposure, in
order to make both polyclonal and monoclonal antibodies as a tool for use
in research [Kennett, 1979] [Kohler and Milstein, 1975]. When an antigen is
circulating, more than one variable region antibody may bind several different
epitopes on the same antigen. If these are purified as a single pool, the result
is a “polyclonal” antibody, one preparation that contains more than one anti-
body to the same antigen. If, however, each antibody that binds is individually
purified such that each preparation contains antibodies all with the same vari-
able region, then this is known as a “monoclonal” antibody. Monoclonal and
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polyclonal antibodies are useful tools in research in that they bind an epitope
strongly. Numerous downstream applications have been designed including
their use in immunofluorescence, immunohistochemistry and biochemical tech-
niques such as co-immunoprecipitation. In order to make an antibody towards
a particular antigen, usually a protein, either the entire protein or a peptide
from that protein can be used. The latter is especially useful when purifying
a protein in its entirety is not possible. A purified protein or a polypeptide
chain from the protein is used to immunise animals, often rabbits or mice. The
protein or polypeptide is injected into the rabbit or mouse and this is repeated
two, three or four times over a period of time to increase the exposure of the
animal to the antigen and increase the antibody titre, much the same way
as repeated vaccination. In the case of making a polyclonal antibody, serum
from the immunised animal is tested for immune response and may then be
affinity purified to remove any other contaminating immunoglobulins (Ig) that
are present in the serum of the animal [Harlow and Lane, 1988].
We decided to make a polyclonal antibody against murine MKS3 (meck-
elin) for use in our research. When commercially available antibodies as well
as two custom antibodies (Prof C Johnson, Leeds University), were tested by
western blot in various cell lines, we found that all tested demonstrated poor
specificity in our hands (Figure 5.1A,B,C). MCF7 (American) cells (Figure
5.1A,B) or a panel of cell lines including ciliated cell lines (Figure 5.1C) were
transfected with HA-tagged MKS3 or not transfected, and then lysed in urea
lysis buffer. Lysates were loaded onto a 10% reducing polyacrylamide gel and
separated by SDS-PAGE before being transferred to nitrocellulose membrane
and probed with various antibodies. The anti-MKS3 N-terminal polyclonal
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Figure 5.1: Specificity and sensitivity of commercial anti-MKS3 antibodies
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antibody from C Johnson did identify a band of appropriate size (Figure 5.1A),
however, a stronger band was also detected at 72KDa. It is possible that
this band corresponds to a processed form of meckelin, however, published
and predicted band sizes by western blot for MKS3 are 110-130KDa in size
as described in chapter 4. The affinity-purified C-terminal antibody did not
detect any band at all by western blot (although see Figure 4.11 for an example
of its use in immunofluorescence studies). Many antibodies are suitable for one
application but not others, such as is the case for this C-terminal antibody, and
this may be due to differences in pH associated with different techniques, or
accessibility of an epitope after denaturing the target protein or fixation with
cross-linking agents. Both the commercial antibodies tested were similarly
lacking in specificity (Abcam and Santa Cruz), and whilst it is possible to
detect bands at appropriate sizes, the numerous other bands did not make
these antibodies useful in our assays.
5.2 Strategy for design of polyclonal antibody
to MKS3 (meckelin)
The mouse Meckelin gene spans 29 exons across approximately 50 kilobases.
It encodes several transcripts, two of which are predicted to be protein coding.
The shortest of these encodes a 995 amino acid protein from 28 exons, and the
longer one encodes a predicted 1061 amino acid protein from 29 exons, with
an extra exon at the 5’ end and the protein differing only at its N-terminal
(www.ensembl.org Mouse). The significance of the longer protein in mouse
has not been reported, and the longest human transcript for Meckelin encodes
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a 995 residue protein (www.ensembl.org Human). This human protein shares
close homology to the mouse 995 residue protein (85% identity, 93% similarity)
and for this reason we decided to make antibodies to this isoform of MKS3.
Mouse and human Meckelin have three to seven predicted transmembrane
domains and contain 26 cysteines in the predicted extracellular and membrane
spanning domains, as well a signal peptide at the far N-terminal domain that
may target it to the ER and secretory pathway (Figure 5.2A). As mentioned
above, antibodies can be made to an entire protein, or to polypeptides from the
N-terminal, C-terminal or intra-protein regions. In our earlier investigations
into the interaction between MKS3 and AGR2 we attempted to purify MKS3
however, it was not possible to purify the protein in its entirety for technical
reasons despite repeated attempts. Large, cysteine-rich eukaryotic membrane
proteins are notoriously difficult to purify in bacterial cells due to the lack
of specialised folding machinery, and the reducing conditions of the cytoplasm
[Schwarz et al., 2008]. This can sometimes be overcome in insect cells, however,
we were ultimately unsuccessful in expressing MKS3 in either bacterial or
insect cells (in fact, the overexpression of MKS3 appeared toxic to E. Coli
as the cells did not grow well; data not shown). In order to overcome this,
we decided to use peptides from the N-terminal and far C-terminal of MKS3
as antigens for immunisation and antibody production, as shown in Figure
5.2A. The N-terminal peptide chosen was outwith the predicted signal peptide
region, encompassing residues 52-62 in the 995 amino acid isoform of MKS3.
The C-terminal peptide we used for antibody production comprised the final
10 residues of the protein, amino acids 986-995. These residues were chosen in
part for their location (more likely to be accessible in the native protein),
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Figure 5.2: Design Strategy for production of antibodies to mouse MKS3
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and also in part due to their homology with the human protein (Figure 5.2D),
in order to increase the chance of cross-reactivity of any antibodies to both
human and mouse meckelin. In the case of the N-terminal peptide, a cysteine
residue was already present at the C-terminal end of the peptide, whereas
for the C-terminal peptide, a cysteine was added to the N-terminal end of
the peptide. The sulfhydryl group on these cysteines were used to link an
immunogenic carrier via a disulphide bond.
Short peptide antigens that are used for immunisation are often linked to
another moiety to increase the immunogenicity of the antigen - in other words,
to increase the level of immune response. Keyhole limpet hemocyanin, or KLH,
is a copper-containing polypeptide from the species Megathura crenulata of
the monotypic genus Megathura, that can be linked by a disulphide bond to
a peptide antigen to increase immunogenicity [Helling et al., 1994]. It can be
used as a vaccine carrier, and is highly immunogenic due to its large size and
complex structure. It is composed of two subunits of 350KDa and 390KDa
each, but forms aggregates of 0.5 - 8 million KDa [Coligan et al., 1996]. The
KLH protein was linked to each of our MKS3 peptides as shown in Figure
5.2B, and this was used for immunisation of rabbits by a commercial company,
Moravian Biotech. In order to aid in screening the serum of the rabbits for
immune response to the immunised peptides, our peptides were also linked
to Bovine Serum Alubumin (BSA) (Figure 5.2C). BSA can be used as an
immunogenic carrier in its own right, however it is often used for screening
purposes. Short peptides do not adsorb as well as larger proteins to microtitre
plates, however, using KLH-linked peptide in our case was not appropriate for
screening serum since antibodies to the carrier (or hapten) will also be present
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in the serum of the immunised animal. BSA can be used as an irrelevant
carrier to aid the adsorption of peptides to a plate, but without binding to
antibodies present in the serum [Coligan et al., 1996]. In this way, specific
immune responses to the short polypeptides rather than to the KLH carrier
can be discerned.
5.3 Serum testing and affinity purification
After three rounds of immunisation to increase the titre of any antibodies to
the peptides, serum was tested by Moravian Biotech for immune response to
the peptides using a dot-blot (Figure 5.3A). This involves spotting peptide
onto a membrane and letting it adsorb, and then testing the serum from im-
munised animals for specific binding to the membrane. Serum from reactive
animals was isolated and used for further initial screening (Figure 5.3B,C).
MCF7 (American) cells were transfected with HA-tagged MKS3 and lysed in
urea lysis buffer. Lysates were analysed by western blot and serum from an
animal that had been immunised with either the C-terminal or N-terminal
peptides linked to KLH were used to probe the membranes. The potential
antibodies were designated CKT (for the C-terminal antibody) or NQY (for
the N-terminal antibody), and these were tested at dilutions of 1:100 or 1:500.
As controls, blots were also probed using the pre-immune sera (serum from the
same animal, before immunisation with the peptide), and also with commer-
cial anti-MKS3 (Abcam). In the case of both CKT (Figure 5.3B) and NQY
(Figure 5.3C) antibody-containing sera there was evidence of bands at the
approximate height expected that were not present in the pre-immune sera.
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Figure 5.3: Immune response to injected peptides and serum testing
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As there were many other bands also present, we decided to have the antibodies
affinity purified from the sera to increase specificity to MKS3.
Affinity purification is a process whereby a protein is concentrated from a
preparation by taking advantage of the binding properties to another molecule,
often another protein. In the case of antibody purification, the antigen may
be immobilised onto a column such as resin using a variety of immobilisation
techniques, and the serum containing the specific antibody washed through
the column. Any antibodies specific to the antigen are bound and remain
in the column, whilst all other proteins and antibodies present in the serum
do not bind and wash through. The bound antibodies are then eluted in
fractions, for example by decreasing the pH until a range is found that inhibits
binding of the antibody to the antigen, allowing the antibody-antigen complex
to dissociate. Affinity purification was carried out in this way by Moravian
Biotech. The peptide antigens were covalently coupled to a CDI-activated resin
via the free amine group at the N-terminal (Reactigel, Pierce). Serum from
the immunised and selected rabbits was run through the column, allowing the
antibody to the peptide to bind the column. Elution of the IgG (antibody)
was carried out by reducing the pH (0.1M Glycine, pH 2.2) and preparation
was then neutralised with 1M Tris buffer (pH 8.8). Fractions were analysed
by SDS-PAGE for immunoglobulin heavy and light chains, and two fractions
were chosen for further analysis based on the results (Figure 5.4A); fractions
1.5 and 2.4 for antibody CKT, and fractions 1.4 and 2.3 for antibody NQY.
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Figure 5.4: Optimisation of affinity purifed polyclonal antibodies to mouse
MKS3 by western blot - Part I
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5.4 Optimisation of affinity purified antibodies
by western blot
Initially, the affinity purified antibodies for the C-terminal (CKT) and N-
terminal (NQY) regions of MKS3 were assayed by western blot at low dilutions
(1:100-1:500) and using TBS-Tween20 for the washes (Figure 5.4B). 2% BSA
in TBS was used for blocking and for diluting antibody. These conditions al-
lowed both antibodies to detect bands at the appropriate height (110-130KDa)
and matching bands detected with the commercial anti-MKS3 antibody (Ab-
cam) that were not present in the pre-immune sera. Due to the non-specific
bands present, optimisation of these conditions was required, and this included
varying dilutions (1:100 - 1:5000), blocking conditions (milk or BSA, 2% - 5%),
wash conditions (TBS or PBS), and detergents used for washing (TritonX100
or Tween20, 0.05% - 0.1%). For both antibodies, the optimal conditions were
found to be as follows: antibody dilution of 1:1000 in 2% milk and PBS washes
with 0.1% TritonX100. Conditions were tested for lysates from both MCF7
(American) and ciliated cell line IMCD3 as summarised in Figure 5.5 A (anti-
body CKT, fractions 1.5 and 2.4), and Figure 5.5 B (antibody NQY, fractions
1.4 and 2.3). In particular, antibody CKT fraction 1.5 was found to detect
MKS3 in both MCF7 (American) cells and IMCD3s well with little unspecific
reactivity. The identity of the larger bands detected by this antibody is not
known, however, these bands are detected by both antibodies and in both cell
types, despite their distinct epitopes, perhaps suggesting a modified form of
MKS3 or aggregates due to boiling that causes many membrane proteins to
aggregate.
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Figure 5.5: Optimisation of affinity purified polyclonal antibodies to mouse
MKS3 by western blot - Part II
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In summary, the antibody produced to the C-terminal of meckelin was
optimised and found to be appropriate for use in assays involving detection
by western blot. The antibody produced to the N-terminal of meckelin was
also optimised, and one fraction, from the affinity purification column, fraction
1.4, was found to be suitable for analysis by western blot although with some
degree of background detection present. The other N-terminal fraction tested,
fraction 2.3, was not seen to detect MKS3 (or any other protein) by western
blot, making it unsuitable for use in these assays.
5.5 Optimisation and assay of anti-MKS3 anti-
bodies for immunofluoresence
We next decided to characterise the anti-MKS3 antibodies to the N-terminal
and C-terminal of meckelin for use in immunofluorescence studies. As discussed
in chapter 4, known intracellular locations for meckelin include the plasma
membrane, ER and Golgi, and the primary cilium [Dawe et al., 2007b] [Dawe
et al., 2009]. In particular, the ciliary basal body [Adams et al., 2012] and
transition zone [Williams et al., 2011] have been described as a known location
for meckelin. This provided us with a specific and readily-identifiable intra-
cellular location to test the specificity of our antibodies by immunofluorescence.
Primary cilia are long projections from the cellular plasma membrane with a
variety of functions including cell signalling and development [Goetz et al.,
2009] [Berbari et al., 2009], regulation of cell cycle [Alaiwi et al., 2009], and
mechano-sensory roles [Praetorius and Spring, 2001]. All mammalian cells are
believed to be able to form cilia, and in the case of primary cilia, only one cilia
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exists per cell at any one time under normal circumstances. One ciliated cell
line frequently used for cilia studies is a cell line derived from the mouse kidney
known as IMCD3 cells (inner medullary collecting duct cells) [Rauchman et al.,
1993]. These cells, when plated at high confluence, project long primary cilia
that are easily visualised using antibodies. We used this cell line to visualise
primary cilia and look for co-localisation of MKS3 at the cilium or basal body
to confirm that the antibodies were suitable for immunofluoresence assays.
Each of the two fractions for each antibody assayed by western blot (an-
tibody CKT fractions 1.5 and 2.4, antibody NQY fractions 1.4 and 2.3) were
tested for suitability by immunofluorescence, using four different fixation and
permeabilisation protocols and three different andtibody dilutions. The results
are summarised in Figure 5.6, with one asterisk referring to some incidences
of co-localisation of the antibody at the basal body, three asterisks referring
to most or all ciliary basal bodies visualised co-localising with the antibody,
and no asterisk depicting no co-localisation. All protocols included fixing in
3-4% paraformaldehyde (PFA), either with or without methanol. Permeabil-
isation was with either TritonX100 0.1% (fixation protocol 1), Triton X100
0.5% (fixation protocol 4), methanol and TritonX100 0.5% (fixation protocol
2) or glycine and saponin (fixation protocol 3) (see Materials and Methods Ta-
ble 2.13). Anti-acetylated alpha tubulin allows detection of the cilia axoneme
(the projection from the cell body), whereas anti-gamma tubulin identifies the
basal body of the cilia. The purpose of this screen was to identify MKS3 in
one of the known cellular locations as a means of validating the polyclonal
antibodies for use in immunofluorescence assays. For this reason, only clear
visualisation of the ciliary axoneme was required, with the basal body located
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directly adjacent to the proximal end of the axoneme [Marshall, 2008].
All fixation protocols were found to be compatible with the mouse anti-
acetylated alpha tubulin antibody used (Figures 5.7, 5.8, 5.9, 5.10). Affinity
purified antibody CKT (fraction 1.5) to the C-terminal peptide of meckelin was
found to clearly co-localise with the base of the cilia but only using fixation pro-
tocols 1 and 2, which involved fixation in PFA with or without methanol and
followed by permeabilisation in TritonX100 (0.1%) (Figure 5.7A,D,G,J). By
contrast, fix protocols 3 (PFA fixation followed by glycine/saponin permeabil-
isation) and 4 (PFA fixation followed by permeabilisation in high concentration
of TritonX100 0.5%) did not allow detection of MKS3 using this antibody (Fig-
ure 5.8 A,D,G J). Interestingly, another fraction from the purification column
of the same antibody (CKT, fraction 2.4) did not detect meckelin using any
of the fixing protocols (data not shown), indicating that this fraction of the
affinity purified serum is not suitable for immunofluorescence studies.
Affinity purified antibody NQY (fraction 2.3) to the N-terminal peptide
of meckelin was also found to co-localise with the base of cilia, although this
time only with fixation protocol 4 (PFA fixation followed by permeabilisation in
0.5% TritonX100) (Figure 5.9 G,J). Fixation protocols 1, 2 and 3 as described
above did not allow detection of meckelin at the base of the ciliary axoneme
(Figure 5.9 A, D and Figure 5.10 A, D, G, J). In addition, no antibody signal
at the basal body was detected for affinity purified fraction 1.4 of the antibody
to the N-terminal of meckelin using any of these fixation protocols or at any
of the antibody dilutions assayed (data not shown).
We had shown that both antibodies detected a protein at the base of
the ciliary body, however, there are numerous proteins at the base of the
187
5.5. OPTIMISATION AND ASSAY OF ANTI-MKS3 ANTIBODIES FOR
IMMUNOFLUORESENCE
Figure 5.6: Optimisation screening of affinity purified polyclonal antibodies to
mouse MKS3 for immunofluorescence
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Figure 5.7: Affinity purified anti-MKS3 polyclonal antibody CKT (Fraction
1.5) localises to the ciliary basal body using PFA or PFA-methanol fixation
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Figure 5.8: Affinity purified anti-MKS3 polyclonal antibody CKT (Fraction
1.5) does not localise to the ciliary base or axoneme using Glycine-Saponin or
0.5% Triton permeabilisation
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Figure 5.9: Affinity purified anti-MKS3 polyclonal antibody NQY (Fraction
2.3) localises to the ciliary base or axoneme using PFA fixation with 0.5%
Triton permebilisation, but not with Glycine-Saponin permeabilisation
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Figure 5.10: Affinity purified anti-MKS3 polyclonal antibody NQY (Fraction
2.3) does not localise to the ciliary base or axoneme using PFA or PFA-
methanol fixation
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cilia [Marshall, 2008], and the centrosomes which also localise to the base of
the cilia are known to be “sticky" to some rabbit polyclonal antibodies (per-
sonal communication, P Mill). Nevertheless, detection by these antibodies of
the appropriate band size when assayed by western blot does indicate that they
are capable of detecting meckelin. In order to further verify that the antibodies
were able to detect meckelin by immunofluorescence, we transfected IMCD3
cells with HA-tagged Meckelin, overexpressing the HA-tagged protein. Cells
were fixed using PFA (3.7%) and permeabilised with Triton X100 (0.1%), and
blocked in PBS containing TritonX100 and 2% BSA. Transfected cells were
then incubated overnight at 4◦C with anti-HA antibody raised in mouse (as
described previously, abcam) and affinity-purified anti-MKS3 antibody CKT
(fraction 1.5) raised in rabbit at a dilution of 1 in 1000. Cells were washed
and incubated with secondary antibodies (Alexa fluorophore-conjugated don-
key anti-rabbit 488, Alexa fluorophore-conjugated goat anti-mouse 594) before
mounting with mounting fluid containing DAPI. Analysis showed that there
was co-localisation of the two antibody signals in the peri-nuclear region of
these IMCD3 cells (Figure 5.11A), as seen in previous immunofluoresence as-
says in a different cell types (Chapter 4, Figure 4.9, 4.10). Untransfected
controls confirmed that the anti-HA antibody was specific (Figure 5.11B), and
secondary antibody only controls also demonstrated specificity of the Alexa
secondaries in this cell type (Figure 5.11 C).
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Figure 5.11: Affinity purified anti-MKS3 antibody CKT partially co-localises




One way of testing the validity of an antibody is to remove the antigen either
with gene knockout animal tissue or using siRNA to knock down the gene.
In order to verify the antibody for immunofluorescence by loss of signal, the
gene must be fully or at least very substantially depleted by siRNA. In the
case of Meckelin, the gene has been shown to be essential for the formation
of cilia in ciliated cell lines such as IMCD3s, making our assay for antibody
detection at the cilia body or base redundant when Meckelin is depleted. For
this reason, we used transfected HA-tagged Meckelin, overexpressing the HA-
tagged protein to verify that the C-terminal antibody, affinity purified fraction
1.5, was detecting Meckelin and not some other basal-body or transition zone-
associated protein. As previously discussed, Meckelin knockout animals retain
the formation of cilia, although they are abnormal in length; this could po-
tentially serve as a mechanism for further verifying the antibody specificity
although the antibodies have not to date been tested for use on tissue using
immunohistochemistry.
Differences exist between the two antibodies, and even between affinity-
purified fractions of each antibody. For example, a later fraction from the
purification column of the antibody to the C-terminal (CKT fraction 2.4) did
not detect MKS3 whereas an earlier fraction did. This may be due to differ-
ences in the concentration or purity of the fractions collected. Both of these
fractions were able to detect MKS3 by western blot, suggesting a possible
difference in the affinity of the interaction when binding to fully denatured
(western blot) or fixed proteins in immunofluorescence assays.
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It is noteworthy that fraction 2.3 of the N-terminal antibody did not
detect MKS3 by western blot, although it did detect MKS3 at the base of the
cilia using fixation protocol 4 (PFA fixation with 0.5% TritonX100 permeabili-
sation). The number of antibody signals seen to co-localise with the cilia were
much fewer than that seen with the C-terminal antibody, perhaps reflecting a
reduced affinity of the interaction. Both antibodies were made using peptides,
however, the C-terminal peptide is at the very far end of the protein, whereas
the N-terminal peptide is further into the protein, partly to avoid the signal
peptide. This might reflect a degree of accessibility of the antigen in the native
protein. Furthermore, a naked peptide may not carry the same conformation
as a polypeptide within the context of a native protein.
In this chapter, we demonstrated a need for a reliable anti-MKS3 anti-
body for use in our assays, and described a strategy for producing our own
antibodies to the C-terminal and N-terminal of the protein. We then char-
acterised some of the resulting affinity-purified fractions for use in two com-
mon assays, detection by western blot and immunofluorescence. We used a
known cellular location for MKS3 that is convenient and easy to identify as a
means of verifying its usefulness in immunofluorescence assays, and validated
its specificity using a transfected, tagged version of the same protein. We have
demonstrated that the two antibodies are compatible with differing fixation
and permeabilisation protocols, and characterised which conditions are suit-




Agr2 Expression in a Ciliated Cell
Line and in cultured Embryonic
Kidneys
6.1 Introduction
The usefulness of analysis of a gene’s expression pattern was discussed in Chap-
ter 3, where we made an expression vector for ectopic expression of a reporter
driven by the Agr2 promoter. Although we were not to date able to produce
detectable reporter gene expression in mice from this Agr2 line, the benefit
of gene expression pattern analysis for investigating the biological function of
AGR2 is still valid. Endogenous expression of a reporter from a gene’s own
promoter in vivo is an excellent and reliable way to analyse expression pat-
terns. However, expression analysis using antibodies can also be very useful
in determining the expression patterns of a gene. A promoter reporter such as
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the one we made for AGR2 will determine which cells are expressing the gene
of interest, however, the reporter is not tagged to the protein and remains dif-
fuse in the cytoplasm or nucleus of the cell. Since antibodies bind to proteins,
expression analysis using antibodies may provide intracellular information as
well as more global expression data.
As discussed in Chapter 4, a novel putative interaction between AGR2
and MKS3 was discovered as a result of a phage-peptide interactomics screen.
Biochemical techniques were employed to help validate the potential interac-
tion, however, we wished to investigate this interaction in vivo. As mentioned
previously, Meckelin (MKS3) is required for ciliogenesis and localises to the ER,
Golgi network, plasma membrane and cilia in mammalian cells [Dawe et al.,
2007b] [Dawe et al., 2009] [Adams et al., 2012]. If AGR2 and MKS3 were inter-
acting in vivo, we hypothesised that AGR2 might also be localised to the cilia, a
highly specialised organelle found in nearly all mammalian cells [Berbari et al.,
2009]. We decided to test whether AGR2 localised to this cellular compartment
using both monoclonal and polyclonal antibodies to AGR2. In addition, we
decided to identify the expression pattern of AGR2 in the developing embry-
onic kidney. Disease-causing mutations in Meckelin cause polycystic kidneys,
among other phenotypes, brought about by abnormal or absent primary cilia
during embryogenesis and postnatally [Chen, 2007]. Given the possible inter-
action between AGR2 and MKS3 described in Chapter 4, we were interested in
the expression pattern of Agr2 in the developing kidney and any overlap with
ciliated cells expressing Meckelin. Furthermore, a consortium that provides ex-
pression data for the mouse genito-urinary tract based on in situ hybridisation
techniques, immunohistochemistry, transgenic reporters and microarray data
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(GUDMAP), has suggested that Agr2 is expressed in the embryonic kidney in
specific compartments [Harding et al., 2011] [Davies et al., 2012].
Apart from being able to be cultured for up to 6 days with relative ease
once dissected from the embryo, the mouse embryonic kidney continues to
develop the specialised structures found in the mammalian kidney for some
time [Srinivas et al., 1999] [Giuliani et al., 2008]. Thus, kidneys dissected
at E12.5 will continue to undergo branching morphogenesis of the ureteric
bud, and go on to develop nephrons. These nephrons progress through several
stages and form comma shaped bodies, S-shaped bodies and early nephrons
that contain proximal, medial and distal tubules, as well as glomeruli and
associated podocytes. Many antibodies (though by no means all) penetrate
with depth into the embryonic kidney once fixed, as do commonly used nuclear
stains such as DAPI allowing distinct structures to be imaged [Barak and
Boyle, 2011].
6.2 AGR2 localisation at the base of the cilium
Cilia are a specialised organelle that are thought to be potentially found on all
mammalian cells. They are tubulin-based projections from the plasma mem-
brane, that grow and recede in a cell-cycle dependent manner. Initiation of
ciliogenesis for primary cilia is brought about by rearrangement of the centri-
oles and docking at the apical cell surface to form a basal body from which
the cilium elongates [Dawe et al., 2007a]. Meckelin (MKS3) together with
MKS1 were previously shown to be essential for faithful rearrangement of the
centrosomes and the initiation of ciliogenesis for primary cilia [Dawe et al.,
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2007b]. Primary cilia differ in structure and function from motile cilia [Satir
and Christensen, 2008], and unlike motile cilia, only one primary cilia is found
per cell under normal conditions. Models to study cilia and the genetics of
ciliogenesis include cell lines that readily produce cilia under the appropriate
conditions. IMCD3 cells are an SV40-transformed cell line derived from the
inner medullary collecting duct (terminal tubule) of a mouse kidney [Rauch-
man et al., 1993]. IMCD3 cells are ciliated when grown at high confluence,
and put out long primary cilia that are easily visualised using antibodies to a
number of ciliary proteins. Antibodies against acetylated α-tubulin (marker
of stabilised tubulin in the ciliary axoneme) and γ tubulin (ciliary basal body)
are commonly used to visualise the cilium by immunofluorescence as seen in
Chapter 5. Another commonly used cilia marker is Arl13B, a member of the
Ras superfamily of small GTPases that localises to the primary cilia axoneme
in diverse organs including kidney, retina and cerebellum [Cantagrel et al.,
2008]. In order to avoid possible issues with antibody staining or compatibility,
we used IMCD3 cells that had been adapted to stably express fluorescently-
tagged Arl13B (generously donated by E Hall, IGMM, Prof I Jackson group).
These IMCD3 cells express mKate2-Arl13B, a fluorescent marker in the far red
spectrum (excitation/emission maxima 588nm and 633nm respectively). This
fluorescent marker is a monomeric protein with high pH stability and photo-
stability, and also exhibits low cytotoxicity [Shcherbo et al., 2007], making it
a useful tag for a variety of cell-based assays.
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6.2.1 Ciliary localisation of Agr2 in IMCD3 kidney ep-
ithelial cells
IMCD3(mKate2-Arl13B) cells were plated at high confluence and incubated
overnight at 37◦C on coverslips. Cells were fixed and incubated with anti-
AGR2 mouse monoclonal antibody (Abnova). Fixed, stained and mounted
coverslips were analysed by confocal microscopy. In cells stained with Agr2
monoclonal antibody, cilia projections were readily visualised in the far red
spectrum, and Agr2 was seen to localise to the base of the cilium in each cell as
well as in punctuated regions along the cilium axoneme (Figure 6.1 A-I). Cells
incubated with anti-AGR2 polyclonal antibody also demonstrated localisation
of AGR2 at the cilium base, and also along the cilium (data not shown). This
localisation is in agreement with known intracellular localisations for MKS3
at the ciliary basal body, transition zone and ciliary axoneme [Dawe et al.,
2007b], [Garcia-Gonzalo et al., 2011] [Williams et al., 2011], further lending
support to a possible interaction between the two proteins.
Whilst encouraging that Agr2 localised to the same intracellular com-
partment as MKS3 in cell-based assays, we wished to investigate whether Agr2
localised to the cilia and basal body in vivo. As mentioned above, murine em-
bryonic kidneys can be dissected from embryos from embryonic day 11.5-13.5
(E11.5-E13.5) and cultured for up to 6 days, and many antibodies can pen-
etrate into the organ after fixation allowing imaging of specialised structures
including cilia. This provided a model system to investigate AGR2 localisation
at the cilium in vivo.
201
6.2. AGR2 LOCALISATION AT THE BASE OF THE CILIUM
Figure 6.1: AGR2 localises to the ciliary base and segments of the axoneme in
IMCD3 kidney epithelial cells stably expressing mKate-Arl13B
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6.2.2 Ciliary localisation of Agr2 in cultured mouse em-
bryonic kidney
Embryonic mouse kidneys were dissected from wild type CD1 mouse embryos
at embryonic day 12.5 (E12.5) and cultured for 48h on porous membranes
according to published protocols [Barak and Boyle, 2011]. Cilia were stained
with mouse monoclonal anti-aceylated α tubulin (Sigma, T6793) and Agr2 was
visualised with anti-AGR2 rabbit polyclonal antibody (Moravian Biotech).
Fixed, stained and mounted kidneys were analysed by confocal microscopy
with a 60x oil immersion lens. Cilia were clearly visible on many cells in
the developing embryonic kidney on both mesenchymal and epithelial cells,
and Agr2 was seen to localise at and around the base of the cilium (Figure
6.2). Clustering of proteins at the cilia base has been reported for proteins
known to localise to the axoneme, basal body or transition zone such as IFT
proteins [Sedmak and Wolfrum, 2010] [Wang et al., 2009]. This clustering was
not seen in the IMCD3 cells described above, however, mKate2-Arl13B stable
IMCD3 cells have been seen to project very elongated cilia, indicating that
the biology of these cells and cilia may be altered due to the tagged Arl13B
protein (personal communication, Dr P Mill, Dr E Hall, Jackson group, MRC
Human Genetics Unit). Nevertheless, clear localisation of Agr2 at the base of
the cilia both in cell culture and in embryonic renal organ culture supports a
role for Agr2 in the biology of cilia.
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Figure 6.2: AGR2 protein localises to the base of the cilia in cultured embryonic
mouse kidneys
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6.3 AGR2 expression patterns in developing em-
bryonic kidney
6.3.1 Embryonic kidney development in mice and asso-
ciated markers of renal structures in vivo
Organogenesis of the embryonic kidney is a dynamic process that progresses in
a very specific temporal and spatial manner. In the mouse embryo, cells from
the intermediate mesoderm (IM) give rise to the embryonic kidney starting
from about embryonic day 9.5 (E9.5) [Saxen and Lehtonen, 1987]. Dorsal
intermediate mesoderm cells come together to form the nephric duct (ND),
also known as the Wolffian duct, whilst ventral IM mesenchymal cells remain
undifferentiated. This population of cells is called the nephrogenic cord (NC)
[Costantini and Kopan, 2010] [Saxen and Lehtonen, 1987]. Later, the IM, now
divided into nephric duct (ND) and nephrogenic cord (NC), aligns along a
rostro-caudal axis of the embryo (along the length of the body), forming an
epithelialised tubule in the ND and a group of cells at the caudal end called
the metanephric mesenchyme (MM) (Figure 6.3) [Costantini and Kopan, 2010].
At around embryonic day 10.5 (E10.5), the metanephric mesenchyme (MM)
signals to the nephric duct epithelia to evaginate, forming the ureteric bud
(UB). This then branches repeatedly in response to bi-directional signalling
between the ureteric bud tips and metanephric mesenchyme, an example of
epithelial branching morphogenesis [Costantini, 2006] [Costantini and Shakya,
2006] [Dressler, 2006]. These branched structures will contribute to the future
collecting ducts of the mature kidney.
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Figure 6.3: Mammalian Embryonic Kidney Development
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Meanwhile, cells from the MM form a cap around the ureteric bud tips,
leading to the formation of the cap mesenchyme (CM) cells [Mugford et al.,
2009]. These cap mesenchyme cells contain the progenitor cells that have the
potential to form nephrons [Boyle et al., 2008] [Kobayashi et al., 2008]. Bi-
directional signalling between the ureteric buds and cap mesenchyme leads to
maintenance of the stem cell population, and signals from the ureteric bud
induce cap mesenchymal cells to undergo mesenchymal-to-epithelial transition
(MET) and generate nephron epithelia [Saxen and Lehtonen, 1987]. The ini-
tial epithelial nephrogenic structure to be formed is the renal vesicle (RV), and
these epithelial cyst-like structures appear beneath the ureteric bud tips [Saxen
and Lehtonen, 1987]. Cells at the distal end of the renal vesicle (at the end clos-
est to the ureteric bud) fuse with the UB to form a connecting segment [Georgas
et al., 2009], whilst the renal vesicle continues to mature, elongating to form a
“comma-shaped body”, and then an “S-shaped body”. These bodies continue to
lengthen and become more complex in a poorly-understood process, eventually
developing into the embryonic nephron and glomerulus. The precursors of the
mature nephron are segmented into proximal, medial and distal tubules, and
podocyte precursors are present at the most proximal part of the developing
nephron. The glomerulus forms at the proximal end of the nephron, and is
the main filtering unit of the mature kidney comprising a capillary network
enveloped in podocytes and enclosed in a capsule (Bowman’s capsule) [Saxen
and Lehtonen, 1987]. The entire process is summarised in Figure 6.3.
There are numerous antibodies that can be used to selectively mark the
specialised structures found in the developing kidney. Among these, are anti-
bodies against markers of the CM and early nephrons such as NCAM (Neu-
207
6.3. AGR2 EXPRESSION PATTERNS IN DEVELOPING EMBRYONIC
KIDNEY
ral cell adhesion molecule), antibodies against markers of podocytes such as
podocalyxin, and antibodies against the Notch ligand, Jagged1, which selec-
tively marks the proximal/medial tubule of the developing nephron. Con-
versely, antibodies against E-cadherin (CDH1) can be used as a specific marker
of the distal cell population in developing nephrons as well as other epithelial
structures such as the ureteric bud. The antibodies used are summarised in
Materials and Methods Table 2.16. Using these antibodies in combination
with an anti-AGR2 antibody, expression patterns of AGR2 in the developing
embryonic mouse kidney were analysed.
6.3.2 AGR2 expression in embryonic mouse kidney
We wanted to investigate the expression of Agr2 in different segments of the
embryonic mouse kidneys, using a previously-validated polyclonal antibody
to AGR2. As mentioned above, MKS3 is a cilia-associated protein that is
essential for ciliogenesis, and localises to the primary cilium in mammalian
cells. Primary cilia are found in many structures of the developing mammalian
kidney, including at the apical side of some renal epithelial cells [Mirna Saraga-
Babic et al., 2012], and in the case of the ureteric bud this corresponds to
the lumen. Embryonic kidneys were dissected from embryos at E12.5 and
cultured for 24 hours according to established protocols as described above.
Kidneys were fixed as described in section 2.7 and incubated with anti-Agr2
rabbit polyclonal antibody (Moravian Biotech) overnight also as described in
section 2.7. Fixed, stained and mounted kidneys were analysed using confocal
microscopy.
In the early (E12.5 plus one day) cultured embryonic kidney, Agr2 lo-
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calised to the apical side of the ureteric bud, in agreement with reported lo-
calisation of primary cilia in mammals [Trapp et al., 2008]. Agr2 was also
seen to localise to the cap mesenchyme (CM) in a polarised manner in these
early developing kidneys. This is in agreement with GUDMAP data showing
expression of Agr2 in the CM. In addition, the staining pattern of Agr2 in
the CM was also apical, with the apical side facing away from the ureteric
bud basolateral membrane (Figure 6.4 A,B). The metanephric mesenchyme
has previously been shown to have primary cilia, as seen in Figure 6.2 and in
human embryonic kidneys [Mirna Saraga-Babic et al., 2012].
In order to confirm that the localisation of AGR2 in the ureteric bud was
apical, we used a marker of apical-basal polarity that is only present at the
apical side of epithelial cells. ZO-1 (Zona Occludens-1) protein binds occludins
directly and is a marker of tight junctions and apical (luminal) polarity [Fan-
ning et al., 1998]. Kidneys were harvested at E12.5 and cultured for 24h
before fixing, washing and staining. Kidneys were incubated overnight with
anti-Agr2 rabbit polyclonal antibody (Moravian Biotech) and anti-ZO-1 rat
polyclonal antibody (DSHB). Kidneys were analysed by confocal microscopy.
ZO-1 expression, used to mark the apical side of the ureteric bud, indicated
that polarised Agr2 staining was detected at the luminal, apical side of the
ureteric buds as shown in Figure 6.5.
Having observed that Agr2 was localised to the CM and UB in early stage
developing embryonic kidneys, we wished to assess the expression pattern of
Agr2 in nephron development. NCAM is a marker of CM and early nephrons
[Klein et al., 1988] but not of the ureteric bud. Kidneys were dissected at
E12.5 and cultured as described above.
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Figure 6.4: Agr2 protein localises to the apical side of the ureteric bud and to
focal points in the mesenchyme of cultured E12.5 developing mouse kidney
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Figure 6.5: AGR2 localises to the apical side of the ureteric bud with apical
marker ZO-1
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Kidneys were fixed and incubated with anti-Agr2 rabbit polyclonal anti-
body (Moravian Biotech) and anti-NCAMmouse monoclonal antibody (Sigma),
and fixed, stained and mounted embryonic kidneys were analysed as described
above. Agr2 was co-expressed with NCAM in early stage nephrons and renal
vesicles (Figure 6.6). We also wished to assess the expression pattern of Agr2
in later stages of nephron development. After the renal vesicle stage, in which
the nascent nephron is already divided into proximal and distal regions, the
developing nephron in mammalian kidneys becomes segmented into the prox-
imal, medial and distal tubules, with the distal-most segment connecting to
the ureteric bud. One of the components that helps to create proximal-distal
identity is the family of Notch signalling proteins [Costantini and Kopan, 2010].
The Notch signalling pathway is highly conserved and has been shown
to control differentiation, growth, and patterning processes [Benedito et al.,
2009]. Although studies have revealed that Notch2 is most important for this
process, both Notch1 and Notch2 are involved in patterning proximal fate in
the nephron [Cheng et al., 2007]. Jagged1 (JAG1) is a ligand for the Notch1
receptor, and as such has been used effectively as a marker of medial/proximal
tubule in nephrons. Conversely, E-cadherin (CDH1) is a calcium-dependent
cell adhesion protein that has been shown to be expressed mainly in the distal
tubules of developing kidneys, and only at very low levels in the proximal
tubule [Prozialeck et al., 2004]. Initially, kidneys were dissected at E12.5 and
cultured for four to five days before fixing and staining as described above.
To begin with, kidneys were incubated with anti-AGR2 rabbit polyclonal
antibody (Moravian Biotech) and mouse monoclonal anti-acetylated α-tubulin
(Sigma, T6793). As well as labelling the ciliary axoneme, anti-acetylated α-
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Figure 6.6: Agr2 is co-expressed with a marker of CM, renal vesicles and early
nephrons, NCAM, in cultured E12.5 developing mouse kidney
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tubulin also labels acetylated tubulin filaments within the cell, helping to
visualise various specialised structures (Figure 6.7). After incubation with
primary antibodies, kidneys were incubated with secondary antibodies and
mounted using DAPI-containing mounting fluid. Kidneys dissected at E12.5
and cultured for several days continue to develop, and at this stage segmented
nephrons and glomeruli with podocytes can be observed. Agr2 staining was
again clearly seen in the ureteric bud and metenephric mesenchyme as pre-
viously described. In addition, Agr2 was expressed in the proximal tubule
in these kidneys, but was absent in the centre of the glomeruli (Figure 6.7).
In order to further probe the segement-specificity of Agr2 expression in the
nephron, we also stained E12.5 kidneys that had been cultured for 4 days
with markers of proximal and distal tubules. Kidneys were incubated with
anti-AGR2 rabbit polyclonal antibody, anti-JAG1(Jagged1) goat polyclonal
antibody and anti-CDH1(E-cadherin) monoclonal antibody. Fixed, stained
and mounted kidneys were analysed by confocal microscopy. Figure 6.8 shows
images from separate stacks through a single nephron, with distal tubule (DT),
medial tubule (MT) and proximal tubules (PT) labelled. Agr2 is seen to be ex-
pressed in the proximal and medial tubule, with much lower expression in the
distal tubule, and expression of Agr2 increases the more proximal the tubule
becomes. The proximal tubule is also the site of primary cilia in the embry-
onic kidney in humans [Mirna Saraga-Babic et al., 2012], and MKS3 has also
been shown to be expressed in the proximal renal tubules of early human em-
bryos [Dawe et al., 2007b]. In addition, Agr2 staining in the proximal section
of the nephron appeared to stain the visceral and parietal epithelia, although
it is not possible to state this definitively without appropriate markers.
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Figure 6.7: AGR2 localises to the apical side of the ureteric bud and proxi-
mal tubule of the developing nephron but not the centre of the glomerulus in
cultured embryonic kidneys
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Figure 6.8: AGR2 is expressed in a gradient in the proximal and medial tubule
of the developing mouse embryonic kidney
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This would be in agreement with expression data from GUDMAP which also
reports expression of Agr2 in the visceral epithelia of the embryonic kidney.
The observation that Agr2 was expressed in segments of the nephron
but appeared to stain glomeruli to a lesser degree (Figure 6.7), together with
GUDMAP expression data showing high levels of AGR2 in podocytes, led us
to investigate the expression pattern of Agr2 in the glomeruli using a podocyte-
specific marker. We dissected kidneys from E12.5 embryos and cultured them
for 4 days. Kidneys were fixed and incubated with anti-AGR2 rabbit poly-
clonal antibody and anti-podocalyxin goat polyclonal antibody. Podocytes
are polarised epithelial cells with a specialised structure that wrap around the
glomerular capillaries. Adjacent podocytes interdigitate like entwined fingers
creating filtration slits that are bridged by specialized cell junctions known as
slit diaphragms [Dryer and Reiser, 2010]. They are rich in cell surface pro-
teins that restrict the uptake of proteins in the bloodstream whilst allowing
smaller molecules and ions to pass [Rodewald and Karnovsky, 1974]. One such
abundant cell-surface protein found in podocytes is podocalyxin, making it a
useful podocyte marker. Fixed, stained and mounted kidneys were analysed as
described above. Agr2 was seen to be expressed in the ureteric buds (UB) as
previously observed, and also in the surface of the podocytes (P) (Figure 6.9).
By contrast, Agr2 expression appeared absent inside the glomeruli, contain-
ing the vasculature (G), in agreement with previous observations (Figure 6.7).
Again, this supports the possibility that AGR2 and MKS3 may be interacting
and localised to the cilia, since podocytes, but not the rest of the glomeruli,
have been shown to have primary cilia in human embryos [Mirna Saraga-Babic
et al., 2012]. The specific expression of Agr2 in podocytes is noteworthy, since
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Figure 6.9: Agr2 localises to the podocytes and parietal epithelium but not to
the centre of the glomerulus in cultured developing mouse embryonic kidneys
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podocytes are rich in transmembrane proteins such as solute channels, mem-
brane proteins [Greka and Mundel, 2012] and some active protein-transport
channels [Akilesh et al., 2008]. If Agr2 is indeed, as the phage-display inter-
actomics screen would suggest, a chaperone for a family of large, modified,
transmembrane proteins, then this would agree with expression of Agr2 in the
podocytes of the embryonic kidney.
6.4 Discussion
Analysis of Agr2 expression first in a murine ciliated cell line and then in
cultured embryonic mouse kidneys have revealed a localisation at the primary
cilium and in and around the base of the cilium. Further expression analysis
using a panel of specific markers to specialised renal structures have revealed
a pattern of expression that is in agreement with reported expression data
from Gudmap, and with published locations of primary cilia and MKS3 in the
kidney. Specifically, Agr2 is expressed in the proximal tubule, ureteric bud,
podocytes and metanephric mesenchyme in murine embryonic kidneys, but
not in the glomeruli or distal tubules (Figure 6.10). This is also in agreement
with tissue expression of the linear-peptide containing gene set, in which the
expression of many of the genes is enriched in the proximal tubule, ureteric
bud, podocytes and cap mesenchyme.
Primary cilia and MKS3 are known to be involved in epithelial branching
morphogenesis [McDermott et al., 2010] [Dawe et al., 2007b]. In developing
kidneys, signals between the metanephric mesenchyme and ureteric bud lead
to repeated branching of the ureteric buds [Davies and Bard, 1998], and it
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is of note that both these structures have primary cilia and thus presumably
MKS3, and that both cell types also express Agr2. In addition, the obser-
vation that Agr2 is expressed in a polarised manner in the mesenchyme, and
particularly in the cap mesenchyme, of early embryonic kidneys is of inter-
est. Recent studies point to the cap mesenchyme as the likely provenance of
Wilms tumours [Pode-Shakked et al., 2013] [Metsuyanim et al., 2009], and a
study pointed to the region encompassing the Agr2 gene as the site of loss-of-
heterozygosity linked to Wilms tumours [Sossey-Alaoui et al., 2003]. Polari-
sation of the metanephric mesenchyme in the developing kidney has not been
reported previously, and polarity is generally thought to be a marker of epithe-
lial cells [Bryant and Mostov, 2008]. Early polarisation of cells in response to
epithelialisation signals may include asymmetrical rearrangement of cytoskele-
tal and membrane-trafficking systems [Goldstein and Macara, 2007] [Bryant
and Mostov, 2008]. If so, the metanephric mesenchyme at E12.5 in mouse em-
bryonic kidneys may be displaying early signs of polarisation, perhaps the first
step in epithelialisation of the CM as it is induced to form nephron precursors.
At first glance, the most recent murine Agr2 knockout mouse does not appear
to support an essential role for Agr2 in early polarisation of the mesenchyme
and subsequent epithelialisation. However, mice with reduced MET could still
potentially be viable. As a putative chaperone protein involved in trafficking
and folding of membrane and secretory proteins, Agr2 might play a role, even
if some redundancy exists, in the early stage of mesenchymal to epithelial tran-
sition, as the cytoskeleton and membrane-trafficking systems redistribute in a





The importance of AGR2 as a factor in disease onset and progression has
become clearer during the last few years. In the last year alone some twenty
published articles have highlighted the role of AGR2 in both hormonal and non-
hormonal cancers, as well as in the pathology of inflammatory bowel disease
and asthma. AGR2 was also shown in studies to be associated with poor prog-
nosis and drug resistance in hormone-related cancers, and was more recently
shown to be responsive to ERα (estrogen-receptor alpha) and also induced
by tamoxifen [Hrstka et al., 2010]. In addition, several studies have begun
to investigate the biology of AGR2, with the most recent mouse gene knock-
out implicating AGR2 in terminal differentiation of gastric cell types [Gupta
et al., 2012b], although no functional mechanism has yet been established. We
wanted to investigate the biology of AGR2 using a combination of interac-
tomics to identify functionally-relevant binding partners, and mouse genetics
to determine the expression pattern of AGR2 both in development and in
adult mice. In addition, we wanted to create an AGR2-promoter driven Cre
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recombinase mouse for use in functional genetics mouse models.
7.1 Linear Domain Interactome of AGR2
AGR2 can form a homodimer, and dimerisation of AGR2 has been shown to
be involved in mediating the ER stress response [Ryu et al., 2012]. Using
phage-peptide display proteomics, we identified a core peptide that bound
AGR2 with high specificity (Figure 4.1) [Murray et al., 2007]. Recent work has
identified the structure of the dimer and the dimer interface [Patel et al., 2013],
and has identified a region that is thought to stabilise the homodimer (Figure
7.1). In addition, unpublished work from collaborators has identified the likely
peptide binding site, corresponding to amino acids 131-135 (Figure 7.1). This
region is highly conserved (see Figure 1.6), indicating the likely importance
of binding to this interface for protein function. It is thought that binding to
the peptide interface on AGR2 stabilises and regulates the formation of the
homodimer drawing a possible link between binding to this site and the ER
stress response (unpublished, personal communication, T Hupp). Further work
identified the linear motif and allowable substitutions that continued to bind
AGR2 [Fourtouna et al., 2009], and using this motif we searched the human
genome for potential AGR2 binding partners. Many potential interactors were
identified, and we analysed the characteristics of this set of genes using a
web-based informatics approach. Several classes of proteins with specialised
functions or cellular compartments were identified, and more, a pattern in
the hits was identified that pointed toward a biological role for AGR2 as a
chaperone for a subset of client proteins in the secretory pathway.
223
7.1. LINEAR DOMAIN INTERACTOME OF AGR2
Figure 7.1: AGR2 Dimer Structure with Linear Peptide Binding Region
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Since beginning this project, several studies have also identified a role
for AGR2 as a molecular chaperone [Park et al., 2009] [Ryu et al., 2012] [Higa
et al., 2011], and also as a secreted protein that increases the levels of another
secreted protein, Cathepsin D [Dumartin et al., 2011]. These and other studies,
together with the data from the database mining, strongly suggest a biologi-
cal role for AGR2 in the secretory pathway (Figure 7.2). Many of the genes
identified by the phage-display / database mining analysis have functions as-
sociated with cell growth, metastasis, and ER-stress responses. As mentioned
in the Introduction, however, there are likely to be other cellular localisa-
tions and thus functions for AGR2 in the cytoplasm and nucleus of some cell
types, indicating that the contribution of AGR2 to cell proliferation, survival,
metastasis and drug resistance may be complex and mutli-faceted. By far the
most common characteristic of the proteins identified by the phage-display /
database mining analysis was membrane association. Agr2 contains a putative
PDZ-interacting domain [Xia et al., 2009] in addition to the thioredoxin-like
PDI motif (CXXS), the ER retention motif (KDEL) and the N-terminal signal
sequence. PDZ proteins mediate the clustering of ion channels through their
C-terminal domains [Doyle et al., 1996], by interacting with a short linear pep-
tide on target proteins. This is in agreement with the large number of ion and
solute channels identified by the linear motif-based database mining. Most
of the membrane or transmembrane proteins identified are known to be post-
translationally modified (in particular, glycosylation), and most contained a
large number of cysteines. Enrichment analysis for this gene set also showed
that many of these genes are expressed in the developing kidney.
We therefore chose Meckelin (MKS3), a glycosylated, transmembrane,
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Figure 7.2: Model of AGR2 as a PDI family chaperone
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cysteine-rich disease protein, mutations in which cause polycystic kidneys
among other defects, to validate as a client protein for AGR2.
Using a number of biochemical approaches, we determined that MKS3
and AGR2 associate in cell lines, when MKS3 is overexpressed. Mutating
the linear peptide motif changed the localisation of MKS3 as determined by
widefield and TIRF microscopy, with the peptide “loss-of-function” mutated
form accumulating in aggregates in the endoplasmic reticulum (ER) and at
the plasma membrane. In addition, AGR2 localised to the cilium (and other
compartments) in IMCD3 renal epithelial cells, and also localised to the cilium
in the developing embryonic mouse kidney. These data support an interaction,
either direct or indirect, between AGR2 and MKS3, although further work is
being carried out to analyse and verify the interaction in vivo and using endoge-
nous MKS3 in cell lines. This task will be aided by the design, optimisation
and characterisation of a new anti-MKS3 antibody as described in Chapter 5.
If AGR2 is a member of the PDI chaperone family, helping to isomerise
and fold a subset of client proteins into their mature forms while they are
trafficked through the secretory pathway, then we would expect a phenotype
in mice when Agr2 is functionally deleted. The first published AGR2 mouse
knockout paper [Park et al., 2009] did not report major phenotypes such as em-
bryonic lethality or perinatal lethality. In fact, the mice seemed viable and were
only susceptible to inflammatory bowel disease in response to dextran sulphate
sodium (DSS). In contrast, the second [Zhao et al., 2010] and third [Gupta
et al., 2012b] AGR2 mouse knockout papers identified more severe phenotypes
both in the gut and in the stomach. The second mouse knockout paper con-
sisted of two knockout lines, one germline and one tamoxifen-inducible, both
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with the deletion of exons 2, 3 and 4. They identifed a severe intestinal phe-
notype upon loss of Agr2, independent of administration of DSS in both lines.
They also described a marked increase in Paneth cells, increase in the expres-
sion of Paneth cell and stem-cell marker gene Sox9, and a loss of Mucin 2. The
loss of Mucin 2 did not include loss of the goblet cell lineage, however, and
the inducible mouse line showed that expansion of the Paneth cell population
preceded loss of Mucin 2 and intestinal inflammation, suggesting independent
pathways. Interestingly, the acute loss of AGR2 in the inducible mouse line
caused severe ER stress pathway induction, including increases in apoptosis
as monitored by caspase-3 activity as well as decreases in proliferation. The
same was not seen in the Agr2 germline knockout mouse line, and the authors
hypothesise that this is caused by a gradual upregulation in alternate chaper-
one / PDI activity that is not possible with the acute deletion of AGR2 seen
in the inducible knockout (redundancy). This may explain how AGR2 could
function as a chaperone protein for many different proteins including MKS3,
(as suggested by the linear motif / database mining analysis, the homology
to other PDIs and thioredoxin, and published chaperone-like activity), and
yet not prove embryonic or peri-natal lethal when deleted in the germline, in-
stead causing phenotypes that are only related to client proteins for which no
alternate PDI is available.
The third mouse knockout paper also removed exons 2, 3 and 4, yet the
reported phenotype in these mice was even more severe. The females were in-
fertile and thus necessitated heterozygous breeding to produce Agr2 null mice.
These mice were viable at birth, however, by 12 weeks of age most were eu-
thanised due to enlarged stomachs and intestines. Analysis of the stomachs
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of these mice showed drastic gastric phenotypes including loss of gastric cell
lineages and proliferation of stem-cell like populations, suggesting again that
Agr2 may be involved in differentiation of certain cell types, which could pos-
sibly include differentiation of nephron progenitors. Although these knockout
papers do not report kidney defects, the pronounced intestinal and gastric phe-
notypes observed may have precluded in-depth analysis of the kidney, however,
it is not possible to comment without further analysis of these knockouts.
Although the first reported Agr2 knockout mouse did not appear to have
a strong phenotype, this study deleted exon 2 alone to create their germline
null mice, and only reported using antibody analysis on tissue by western blot
to confirm that the animals were Agr2−/− (null). This commercial antibody
was made from a peptide found in exon 2, and would therefore not detect a po-
tential N-terminally truncated protein. In addition, a putative alternate start
site that is in frame with the endogenous protein exists near the start of exon 3
of the Agr2 gene. This means that a putative N-terminally truncated protein
would retain the original sequence of the Agr2 protein from the new start site
onwards. Inspection of this sequence shows that the PDI CXXS motif would
be retained, as would the peptide binding interface, the ER-retention sequence
at the C-terminus, and the PDI-like loop motif, although the N-terminal leader
sequence would be removed. To test this, tissue from this knockout line was
obtained, however, the tissue integrity was damaged during transport and thus
it was not possible to determine whether an N-terminally truncated protein
has been created in this mouse line. It is tempting to hypothesise that such a
protein would mimic the mature form of Agr2 (without the leader sequence),
although it would not likely be targeted to the ER lumen or secretory pathway,
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and the cytoplasmic / nuclear pools that bind p53 may be enriched. If so, it
would explain why the first mouse knockout study did not report increased
apoptosis in their mice in response to DSS treatment.
Deletion of Meckelin in mice leads to embryonic death or perinatal lethal-
ity [Cook et al., 2009], and in humans, truncating mutations also lead to early
lethality [Iannicelli et al., 2010]. Some mutations in Meckelin have been iden-
tified that lead to a less severe syndrome, however all of these are missense
mutations and never truncating mutations [Iannicelli et al., 2010]. In addition
to the possibility of redundancy of PDIs in chaperoning membrane proteins
that are being trafficked through the secretory pathway, it is possible that the
absence of Agr2 in mice does not lead to a complete loss of Meckelin, but rather
to a misfolded or partially folded isoform. The TIRF microscopy data support
this assertion, with a mutation in the putative linear peptide domain leading
to accumulation of MKS3 aggregates. Just as a missense mutation may lead
to a less severe phenotype in humans, deletion of Agr2 in mice may lead to a
reduced pool of functional Meckelin rather than an absence of the protein, or
a pool of partially folded Meckelin retaining some biological function. If true,
this could rationalise the findings of an interaction between MKS3 and AGR2
and viability of the Agr2 knockout mouse.
7.2 In vivo Expression Pattern of AGR2 in Em-
bryonic Murine Kidney
The expression pattern of Agr2 in the developing kidney was investigated
using an antibody-based approach. The putative interaction between Agr2
230
7.3. AGR2 GFP-CRE DRIVER MOUSE LINE
and MKS3 together with the gene set enrichment data mentioned above, and
Gudmap array data showing expression of Agr2 in the developing kidney, sug-
gested that this organ would be rich in AGR2. Using a characterised antibody
to AGR2 we analysed the cell-specific localisation of Agr2 in the developing
embryonic kidney, using organ culture. The observed expression pattern of
Agr2 (in a polarised manner in the cap mesenchyme, in the lumen (apical
side) of the ureteric bud, in the apical side of the podocytes and at the prox-
imal end of the developing nephron in a proximo-distal gradient), supports a
role for Agr2 in chaperoning membrane proteins. All these renal structures,
and in particular the apical side, are rich in ion and solute transporters as well
as many signalling proteins such as G-protein coupled receptors. Furthermore,
the lumen (apical side) of the ureteric bud, the metanephric mesenchyme and
the podocytes have all been shown to have primary cilia, supporting a role for
AGR2 in the biology of primary cilia, although this will need to be verified
with functional genetic studies in vivo or in cell culture.
7.3 Agr2 GFP-Cre driver mouse line
A modular, adaptable expression vector was created for use with BAC trans-
genics, as described in Chapter 3. This vector was modified via the 5’ and
3’ multiple cloning sites to be compatible with the murine Agr2 BAC, and
recombineering was used to replace the start codon on the Agr2 BAC with the
expression cassettes as detailed in Figure 3.7. The resulting GFP-Cre fusion
protein-puroR-pA-Neo/Kan expression cassettes integrated near the start of
exon 2 (start codon) on the Agr2 BAC was introduced into the mouse genome
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by oocyte microinjection. BAC transgenics have several advantages in that
they are usually integrated as a single copy due to their large size, and con-
tain much of the upstream and downstream sequences together with intronic
sequences that may be important for the expression of a gene. However, we
chose to integrate the modified BAC randomly rather than targeting to a par-
ticular locus or to the endogenous locus (a knock-in). It is likely that the low
or possibly absent expression of GFP seen in the mice and embryos analysed
from this transgenic line is due to sub-optimal localisation of the BAC in the
genome, at a region that is silenced or inaccessible to transcription machinery.
The plethora of recent publications on AGR2 and first mouse knockout
papers highlight the growing community of researchers investigating AGR2
from several different perspectives - cancer research, pathology of GI disor-
ders, asthma, ER homeostasis, and differentiation cell types. There is there-
fore an increasing need for tools to study AGR2 in vivo, and a Cre-driver
mouse would be valuable for such purposes. In addition, a thorough charac-
terisation of AGR2 expression patterns in the tissues of both embryonic and
adult mice would provide important background data for researchers looking
to investigate the mechanisms of AGR2, and looking to design treatments for
AGR2-mediated drug resistance. Retrieval of the AGR2 targeting cassette into
a targeting vector as described in Figure 3.5 and creation of an Agr2 GFP-Cre
knock-in mouse is a current consideration for future work.
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7.4 Ongoing work arising from this project and
future outlook
In addition to the research described in this thesis, ongoing work has been
undertaken. A GFP-miRNA construct to knockdown Agr2 in mouse cells has
been cloned, and testing is underway with the intention to knock down Agr2
in murine IMCD3 cells. This would allow us to carry out phenotypic analysis
of cilia both in morphology and in number. In addition, a series of TALENs
pairs to cut in the first coding exon of Agr2 have been generated. These
are currently being used to generate a frameshift mutation in IMCD3 cells to
create a mouse knockout cell line. The TALENs pairs may also be used to
generate an in-house Agr2 mouse knockout line, although work on this has not
yet begun, and these TALENs may also be used to make the generation of the
promoter reporter model at the endogenous locus more efficient.
As well as the pMULITrec with GFP-Cre expression cassette described in
Chapter 3, an mCherry version was also constructed (Figure 3.3). Homologous
arms to the start codon of the Meckelin gene have been cloned into the multiple
cloning sites at the 5’ and 3’ ends of the mCherry construct, and work has
begun to recombine this construct into a Meckelin BAC. If successful, this
would provide a Meckelin promoter reporter for analysis of Meckelin protein
expression in vivo, and a mouse line that could be crossed to an Agr2 promoter
reporter such as a GFP-Cre endogenous knock-in for co-expression analysis.
The list of potential interacting partners for AGR2 identified by database
mining with the linear peptide motif provides a unique avenue to probe the
interactome of AGR2. In this project one “hit” from the list was chosen for
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in-depth validation. Further work remains to be carried out including analysis
of cilia phenotype and localisation patterns after knockdown or knockout of
Agr2 in IMCD3 cells or AGR2 in human MCF7 cells. The new anti-MKS3
antibodies should also be used with AGR2 antibodies to analyse endogenous
co-localisation and co-immunoprecipitation of the two proteins. The discovery
and further validation of an interaction between the disease-associated MKS3
and AGR2 might provide a functional assay for AGR2 activity and be impor-
tant in research into the pathophysiology of Meckelin-associated syndromes.
However, the entire putative client set for AGR2 as a PDI chaperone is po-
tentially just as useful, and screening the client set for changes in response
to reduced or absent AGR2 could give insights into the specificity or level of
redundancy of AGR2. Probing this client set further may thus provide a novel
biological model to dissect the role of AGR2 in ER-trafficking, and validation
of the linear peptide motif as an important part of its action as a chaperone
protein could provide a new target for disrupting these interactions with small
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